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5Abstract
Increasing numbers of drugs are being developed for the treatment of multiple
sclerosis. Measuring outcomes is key to assessing the efficacy of drugs in clinical trials
and monitoring response to disease-modifying drugs in individual patients treated
upon registration. In both clinical trials and the clinical setting, most outcomes reflect
relevant aspects of the disease, from clinical or neuroimaging perspectives, such as
the presence of clinical relapses and accrual of disability, or the presence of visible
inflammation and brain tissue loss, respectively. However, most of the measures
employed in clinical trials to assess treatment effects on these relevant outcomes (i.e.
outcome measures) are not used in routine practice. In the trial setting, the choice of
outcome measures is crucial because they determine whether a drug is considered
effective and can move to the next step of development; in the clinic, such outcome
measures may be used for individual decision-making, such as choosing a first-line
disease-modifying drug or escalating to a second-line treatment. This review discusses
the clinical, neuroimaging, and combined outcome measures, including patient-
reported ones, that are used in both trials and the clinical setting, to help clinicians
and researchers to navigate through the multiple options when choosing an outcome
measure. The barriers and limitations that need to be overcome to translate outcome
measures from trials to a clinical setting are also discussed.
Introduction
6Multiple sclerosis (MS) is a major cause of irreversible disability in young adults.
Neurological disability in MS may occur as a consequence of acute relapses with
incomplete recovery, or as a result of a clinical progression that occurs independently
of the presence of relapses1. The pathological processes that lead to the development
of acute disability are different from those that contribute to clinical progression.
Acute inflammatory demyelination is responsible for the development of relapses,
whilst neurodegeneration is the main determinant of progressive disability2. There are
no few licensed treatments to slow progressiveion in MS, whilst numerous disease-
modifying treatments (DMT), which reduce the frequency of relapses in relapsing-
remitting (RR) MS, are available. Current efforts are shifting towards progressive MS3,
and the number of trials has increased steadily over the last five years.
Measuring appropriate outcomes is central to assessing the efficacy of novel drugs,
determining whether a drug can be moved to the next step of a drug development
programme, and its regulatory approval. The efficacy of an experimental therapy
cannot be demonstrated if the selected measure is unable to capture it, and no trial
designs can compensate for inappropriate and poor measures. Outcome measures in
RRMS trials focus on clinical (relapse) and radiological (lesion count) disease markers
of inflammation, whilst in progressive MS the emphasis is on measures of clinical
progression and (brain) atrophy as markers of neurodegeneration. Ideally DMTs
would prevent both inflammation and neurodegeneration4.
In the clinical setting, similar measures are used to monitor the response to DMTs in
the individual patient, and, consequently, for decision-making, such as choosing a
7specific initial DMT or escalating to second-line treatment. Although Mmost of the
outcome measures used in clinical trials are not used in routine practice, the level of
standardization and the quality control are lower in the clinic than in trials, because of
technical, financial and logistic barriers. However, important efforts have been made
to standardise outcome measures in the clinic, especially in relation to monitoring
treatment efficacy, in order to allow comparisons across centres5,6.
The answer to the question what makes an outcome measure appropriate is a
complex one. The psychometric properties of the measure must be appropriate for
the study, and the chosen measure should be reliable and valid. Reliability indicates
that the data collected are accurate and reproducible, while validity refers to the
ability of the tool to measure what it is supposed to measure. In addition, the outcome
measure must be responsive, i.e., detect changes in the specific functions and areas
that are expected to occur as a consequence of the intervention/therapy7. The degree
of the predicted changes in the outcome measure and the period over which they are
expected to happen are also factors that need to be considered8. Well-known,
traditional endpoints used in MS trials have the advantage that are immediately
understood by clinicians, whereas novel outcomes may provide insights into more
subtle, but relevant, treatment effects that would have been overlooked when using
traditional endpoints. In the clinical setting, the choice of a response measure needs
to consider whether the administration of the tool is easy, the data collected are
clinically useful, and the interpretation of the test results is straightforward.
8This review discusses the clinical and imaging outcomes used in clinical trials, stressing
their advantages and limitations, which need to be considered when interpreting the
results of clinical trials or designing new studies, with a particular focus on combined
outcomes, as recently employed in progressive MS trials. The response measures used
in routine clinical practice are also reviewed, and attention is given to their value and
practicality. Clinically meaningful outcomes from the perspectives of patients and
healthcare professionals are also discussed, with a view on their complementary role
to more classical (objective) outcomes to detect treatment effects.
Outcomes in clinical trials
In this section, we first describe the clinical, neuroimaging and the other outcome
measures that have been used in clinical trials, especially in phase III trials, and then
the combined clinical and MRI measures.
Clinical outcomes
We have divided the clinical outcomes used in clinical trials into: clinical relapses,
measures of disability progression, and patient reported outcome measures (PROMs).
Relapse-based outcomes are prevailing in trials with RRMS patients, whereas
progression-related outcomes are prominent in progressive MS trials. PROMs can be
observed in all types of trials. , but may be particularly relevant in trials with
progressive MS patients, who are more likely to present with symptoms such as
fatigue, pain or depression, than RRMS9.10Regulatory agencies have therefore shown
9a growing interest in the use of PROMs for trials in MS over recent years9,10, to
measure common and disabling symptoms such as pain, fatigue and depression.
Clinical relapses
The majority of phase III trials have been carried out in patients with RRMS, and, to a
lesser extent, with the clinically isolated syndrome (CIS) (Figure 1). Since these trials
aim to reduce (or suppress) the inflammatory activity responsible of acute relapses,
their main outcome measure is relapse counting (Tables 1 and Supplementary Tables
1 and 2).
These relapse-centred outcome measures can be classified into four groups
(Supplementary Tables 1 and 2): (i) quantification of the number of relapses in a
discrete fashion (which are the most widely used) (ii) those that quantify the number
of relapses as a binary phenomenon, such as the proportion of patients without
relapses (relapse-free population) –or its opposite - the proportion of patients with at
least one relapse (non-relapse-free population)–, (iii) metrics that quantify the time
to the first relapse while on treatment (which are common in trials in CIS patients),
and (iv) composite outcome measures.
An additional group that could be considered is based on the severity of the relapses,
such as those associated with hospital admissions and intravenous steroids.
A relapse is generally defined as new or recurrent neurological abnormalities that are
separated by at least 30 days from the onset of the preceding event. It lasts at least
10
24h, and occurs without fever or infection11. The definition of a relapse has changed
over time and has become more stringent in recent trials compared with early
trials12,13. For example, in the phase III ALLEGRO trial, which compared laquinimod
with placebo in RRMS, neurological symptoms had to last at least 48h to be considered
relapses13. The vast majority of Some trials demand an objective assessment by the
examining neurologist16, and request a specific increase in the Expanded Disability
Status Scale (EDSS) score and associated Functional System sub-scores14-16.
The most widely used outcome measure is the annualised relapse rate (ARR: number
of relapses during the treatment period per patient-year), which belongs to the first
abovementioned group (i) above and has been used so far in more than 40 phase III
trials, most of which are in RRMS (Table 1 and Supplementary Table 1). In more than
half of these trials, and in all trials with RRMS, the ARR has been used as the primary
trial endpoint (Table 1). The ARR is easy to understand and compute, and it is thought
to reflect well the extent of inflammatory activity of the disease. However, it may lack
specificity in respect to MS course severity, since the background level of disability
and the severity of the attack are not captured. This limitation has prompted the
development of the annualised rate of severe relapses, which are those relapses that
require intravenous steroid treatment and/or hospitalisation13, or those that entail a
high-level of disability17, which has been used since 1993 as a secondary endpoint
(Table 1). However, the lack of standard guidelines to treat MS relapses implies there
is an enormous inter-site variability in terms of management of relapses and it might
not be appropriate to consider these measures as potentially eligible clinical outcomes
in trials.
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The second group of relapse-centred outcome measures includes the relapse-derived
binary outcome measures, which have been used since the very beginning of the trials
in MS, but have become more popular over recent years with the testing of highly
effective drugs that may lead to a relapse-free status. The percentage of relapse-free
patients and the percentage of patients with at least one relapse may depend on the
length of the study, as the risk of getting a relapse may increase with time; therefore,
the design of the study needs to be considered when comparing these outcome
measures among trials. For example, the GATE study, a 9-month placebo-controlled
phase III trial, where generic glatiramer acetate (GA) was compared to brand GA and
placebo in RRMS patients, the percentage of relapse-free patients in the placebo
group was 79.3%. Instead, in RRMS trials with longer durations, usually 24 months,
such as the FREEDOMS14 or the ALLEGRO13 studies, that percentage is around 50-60%.
This has immediate consequences from a statistical point of view: to be able to detect
a given difference in relapse-free patients between placebo and active arms, we will
need much greater sample sizes if the percentages in both groups are around 50%
than if they are closer to 0% or 100%.
The most relevant measure within the third group is time-to-relapse, often used in CIS
studies, where the occurrence of the first relapse since study entry indicates
conversion to clinically definite MS (CDMS)18-20; therefore, time to CDMS is often the
primary trial endpoint (Table 1 and Supplementary Table 1). Since the development
of a new lesion on MRI in patients with CIS can also confirm a diagnosis of MS
(assuming that the dissemination in space criteria are also fulfilled), according to the
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2001 McDonald criteria20, time to McDonald MS has also been used as trial endpoint
in CIS trials, although this measure requires a trial design with repeated MRI scans and
is heavily dependent on frequency of MRI assessments. At present, a few phase III
trials have used time to McDonald MS as trial endpoint: the BENEFIT study21, which
compared interferon beta-1b 250µg SC every other day versus placebo, the REFLEX
study22, comparing three-weekly and weekly INTERFERON beta-1a versus placebo,
and the TOPIC study23, comparing oral teriflunomide 7mg and 14mg versus placebo
(Table 1). In the both BENEFIT and REFLEX studies, where time to McDonald MS was
the primary outcome, this reached statistical significance well before time to first
relapse and allowed for a dose differentiation in REFLEX that was not apparent using
clinical outcomes22.
The most important outcome within the fourth group is “time to treatment failure”,
which is a primary composite endpoint, recently introduced in the TENERE study,
which compared oral teriflunomide 7mg and 14mg versus interferon beta-1a in
RRMS15. The time to treatment failure is defined as the occurrence of the first
confirmed relapse while on treatment, or permanent treatment discontinuation for
any cause15 (Table 1); this outcome is thought to account for all the factors that
determine the effectiveness of a therapy, such as efficacy, safety and tolerability, and,
therefore, may be applicable to the real-life clinical setting.
Measures of disability progression
Measures of disability progression are generally used as primary outcome measures
in phase III trials in progressive MS (Table 1 and Supplementary Table 3). Most pPhase
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III trials in progressive MS using these outcome measures have reported negative
results24,25, with the exception of the ORATORIO study, which compared IV
ocrelizumab versus placebo in primary progressive (PP) MS26 and the EXPAND trial,
which compared oral siponimod to placebo in secondary progressive (SP) MS27. Many
trials in RRMS (and CIS) patients have also included disability progression as a trial
endpoint (Table 1 and Supplementary Tables 1 and 2), either secondary or primary,
suggesting that targeting clinical progression is also a may be a priority even in the
relapsing forms of MS.
Similarly to the relapse-centred outcomes, dDisability progression-related outcomes
can be classified into four five groups: (i) those that quantify the amount of
progression in a continuous fashion, such as changes in the Expanded Disability Status
Scale (EDSS)28 scores, or the EDSS score at follow-up, (ii) metrics that quantify the
amount of progression as a binary phenomenon, such as the proportion of patients
with (or without) (confirmed) disability progression, (iii) quantification of the
(confirmed) improvement in disability progression also binary, (ivii) metrics those that
quantify the time to confirmed disability progression (CDP), and (iv) composite
outcome measures (see Table 1).
The most frequently used outcome measure in the first group is the absolute change
in the EDSS score from baseline to follow-up (Table 1 and Supplementary Table 3). Of
note, in some trials, such as the PRISMS17 and CARE-MS I29 and II30 trials, changes in
the EDSS raw scores are reported, but in other trials, such as the Copolymer-1 trial in
RRMS31, the EDSS-step methodology, instead of raw EDSS changes, is used. It consists
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of assigning new values to observed EDSS changes depending on the position of the
initial EDSS score in the whole scale. This approach was meant to overcome the non-
linear behaviour of the EDSS. The main limitations of the EDSS-based measures are
that a worsening in EDSS does not reflect which functional system changes and that a
relapse-associated transient deficit may lead to a (transient) change in the EDSS32.
Additionally, the EDSS may not be sensitive to deterioration of the upper limb motor
function, cognitive function or short-distance walking, which may occur in patients
with progressive MS and high EDSS scores33. Besides, the absolute change in EDSS,
especially when relying on a small number of visits, may be affected by noise due to
the low inter-rater and intra-rater reproducibility of the scale, namely in the lower end
of the scale34. The EDSS score does not reflect the whole patient’s functional
impairment, since it has a low ability to discriminate people with different levels of
disability according to the Barthel Index35, a measure of functional independence in
10 daily activities36. Therefore changes in scores other than EDSS, such as MS
Functional Composite (MSFC)37, and its subtests38,39, Regional Functional System
Score (RFSS), ambulation index, arm index, and cognitive tests40,41, from baseline to
follow-up, have been included into some trials to complement the EDSS (Table 1 and
Supplementary Table 3). Cognitive tests that have been used in phase III trials include
the: Paced Auditory Serial Addition Test (PASAT), which is one the subtests of the
MSFC37; Rao’s Brief Repeatable Battery (Rao’s BRB)42. With the PASAT, the changes in
the z-score over the trial period time was used43,44. For Rao’s BRB, different trials have
used different outcome measures: whereas in the phase III North American trial of SC
interferon beta-1b in SPMS the outcome measure was the change in a composite
neuropsychological score41, in the ARIANNA study (atorvastatin add-on vs. placebo
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add-on in RRMS patients on SC interferon beta-1b treatment), the outcome measure
was the change in the percentage of patients with mild or severe cognitive
impairment, defined as failure in one-two or three or more tests, respectively40.
With regard to the oOutcomes in the second and third and fourth groups , they vary
considerably between studies and are numerous (Table 1 and Supplementary Table
3). Confirmed disability progression (CDP) is defined as a worsening of the EDSS
(usually 1.5-step EDSS progression when starting EDSS is 0, 1-step EDSS progression
for EDSS≤5.5, or 0.5-step EDSS progression for EDSS>5.5) that persists for either three 
or six months. It has been demonstrated that 3-month and 6-month CDP overestimate
the long-term accumulation of irreversible disability by 30% and 26%, respectively45.
Longer disability confirmation periods (12 and 24 months), although not completely
free from such bias (overestimation of 20% and 11% respectively), would be
recommended to detect true, irreversible disability, with a possible little effect on the
sensitivity of the progression criteria45. However, so far, no trials have used such long
periods to confirm disability progression. Most trials have used both 3-month and 6-
month disability progression, although some recent studies, such as CARE-MS I29 and
II30, have used only the 6-month CDP outcome. If a trial uses the time to 3-month CDP
(or the percentage of patients with 3-month CDP) as primary endpoint, then the time
to 6-month CDP is a secondary endpoint.
The MSFC or its subtests, which are the 25-foot Timed Walk Test (TWT), the 9-Hole
Peg Test (9-HPT) (which reflects the motor impairment in the upper limbs), and the
Paced Auditory Serial Addition Test (PASAT) (which reflects the speed of (auditory)
16
information processing and calculation ability)39, can be used instead of the EDSS to
define the CDP. Although the training effects often seen on the PASAT could
theoretically be responsible for a lower responsiveness of the MSFC than the EDSS to
detect disability progression46, this is not supported by the results of the trials
published so far, where MSFC-derived outcomes seem to be more sensitive than those
derived from EDSS. For example, the CARE-MS II30 or the FREEDOMS II47 trials, carried
out in RRMS, or the IMPACT trial, in SPMS43, showed significant results in the MSFC
but not in the EDSS. Instead, trials that showed significant effects in the EDSS, such as
CARE-MS I29 and the FREEDOMS14, tended to show also significant results in the MSFC.
Further attempts have been made to improve the sensitivity of MSFC and its subtests
to disease progression, and therefore increase its sensitivity to treatment effects. For
instance, it was suggested that only increases of at least 20% in MSFC subtests were
clinically meaningful and had an acceptable signal-to-noise ratio, suggesting that
clinical trials should use outcomes based on these subtests as binary metrics48.
However, so far, only one phase III trial, the ARIANNA study, which compared oral
atorvastatin add-on to SC interferon beta-1b in RRMS, has used this 20% cut-off to
define the MSFC-related outcome measure40.
Among the outcome measures of the third group, the most widely used one is the
sustained improvement in the EDSS score, which was used as a secondary outcome in
the CARE-MS II trial30 and The Copolymer 1 Multiple Sclerosis study31 (Table 1). In
phase III trials, it has only been used when drugs were to be tested in patients with
RRMS, possibly reflecting the role of acute inflammation in the development of
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disability in these patients. Quite recently, a phase II study carried out in progressive
MS, the biotin study, also used the improvement of disability as an outcome measure
–in particular, as a primary outcome measure49. In this study, which showed positive
results, the improvement of disability was not only reflected by improvements in the
EDSS score, but also in the TWT score49. Improvement was considered if there was a
decrease in the EDSS of ≥0.5 or ≥1 points, if baseline score was between 6 and 7 or 
between 4.5 and 5.5, respectively, or if there was a decrease in the TWT of at least
20%. Sustained improvement of disability as outcome measure may therefore reflect
clinical changes secondary to not only remission of inflammation but also tissue
regeneration, which may be expected in the new era of drugs being tested in
progressive MS, such as the abovementioned biotin49, simvastatin (tested in the phase
II MS-STAT trial50) or oxcarbazepine (being currently tested in the phase II PROXIMUS
trial51).
Composite endpoints, which are in the fourth group of disability progression
measures, facilitate higher event rates and theoretically increase the sensitivity of the
progression parameters, thereby reducing the length of the trial and the sample size.
Besides, they theoretically reduce the risk of multiplicity and so the risk of type I error9.
However, composite endpoints should be pre-specified before starting the trial and
their individual components should only be tested when there is a statistically
significant treatment effect for the composite, unless the components have been pre-
specified as outcome measures too9. A recent reanalysis of a PPMS trial showed that
composite endpoints including different disability measures allows detection of larger
treatment effects, then reducing the sample size needed for clinical trials52. The
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highest efficiency and event rate estimates were obtained by using a sustained
disability progression endpoint confirmed by any two of the following: [EDSS and TWT]
or [EDSS and 9-HPT] or [TWT and 9-HPT]. This endpoint usefully combines the logical
“and” and “or” criteria, maximizing the likelihood to detect a clinical event. However,
composite endpoints are only valid when the composite includes outcomes that are
causally related to the treatment53.
A recent phase III trial in PPMS used as primary outcome measure the time to 3-month
CDP based on a composite endpoint, defined as the presence of at least one of the
following three changes: increase in EDSS (1 if EDSS<5.5 or 0.5 if EDSS ≥5.5), increase 
in ≥20% in 9-HPT, and increase ≥20% in TWT54. Post-hoc re-analyses of trial data have
suggested that this composite endpoint may separate MS patients with ongoing
progression from those who are stable54, thereby representing an improved endpoint
for disability progression trials. Another composite outcome used as secondary
endpoint in a progressive MS trial55 is the time to a 3-month CDP or to a confirmed
20% worsening in the 9HPT treatment failure (Supplementary Table 3).
Patient-reported outcome measures
Patient-reported outcome measures (PROMs) are self-completed questionnaires that
measure the impact of the disease on daily activities, social functioning and quality of
life. In 2009, the Food and Drug Administration (FDA) published a guidance on
PROMs9, which were defined as ‘any report of the status of a patient’s health
condition that comes directly from the patient, without interpretation of the patient’s
response by a clinician or anyone else’9. In 2016, the European Medicines Agency
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defined PROMs as any data directly reported by a patient that is based on his/her
perception of a disease and its treatment (www.ema.europa.eu), thereby further
developing the concept of “personal perspective”. The term PROM is an umbrella
term, which includes evaluations of health-related quality of life, health status, well-
being, satisfaction with treatment, adherence to treatment, and symptoms.
Therefore, PROMs complement and support the outcome measures based on clinical
assessments, and, as mentioned in the 2009 guidance of the FDA, they can be used in
clinical trials to measure the risks of a given treatment as well as its benefits9,56.
PROMs can be divided into two groups: condition-specific and generic PROMs. In the
first group, there are tools designed for MS, which cannot be extrapolated to the
general population and are sensitive to detect an MS-induced change. Examples of
MS-specific health-related quality of life PROMs are the 29-item MS impact scale
(MSIS-29)57, the patient-reported indices in MS (PRIMUS)58, and the MS quality of life-
5459. Thirteen fatigue-centred PROMs have been proposed in 20 years, and the most
popular are the fatigue severity scale (FSS)60 and the fatigue impact scale (FIS)61 (Table
2). The MS-specific PROMs that measure the impact of motor impairment on daily
activity, such as the Arm Index37 and the Multiple Sclerosis Walking Scale (MSWS-
12)62,63, have been frequently used as trial endpoints over the last 5 years54,64,65 (Table
2). It has been suggested that a reduction of 4-6 points on the MSWS-12 is clinically
meaningful66, although the MSWS-12 has also been used as a continuous measure,
without any thresholding, in a symptomatic trial (i.e. the Fampridine trial)67. Many
generic PROMs, such as those that focus on symptoms, such as pain, tremor, and
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spasticity, have been used in symptomatic trials in MS68,69, but a deep discussion of
these is outside the scope of this review.
PROMs that in future may be further studied and validated for use in clinical trials and
clinical practice are the patient-determined disease step (PDDS), which is a simple and
economical scale compared with the EDSS, but correlates with it and its functional
system scores70, and the subscales of both the MFIS and MSIS-29. A recent trial has
included the physical subscale of the MSIS-29 as a co-primary endpoint of the study
together with time to EDSS-based 6-month CDP65. This indicates that composite
endpoints may be obtained by combining objective scales (e.g., EDSS) and PROMs,
although the same limitations associated with the combined scores discussed above
apply to these combined endpoints.
Neuroimaging outcomes
We have divided the neuroimaging outcomes used in clinical trials into: focal brain
lesions, brain and spinal cord atrophy measures, and novel MR outcomes for
neurodegeneration and remyelination.
Focal brain lesions
MRI measures of focal brain lesions often serves as primary endpoints in phase II trials
and typically secondary outcomes in phase III trials. They are particularly relevant to
trials carried out in patients with RRMS and CIS, which test the efficacy of medications
targeting the inflammatory activity71 (Table 3 and Supplementary Tables 4 and 5),
although they are also used in trials in progressive MS (Table 3 and Supplementary
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Table 6). The most commonly used MRI measures are based on T1 gadolinium
enhancing and new T2 brain lesions, which reflect the occurrence of new
inflammatory activity. In particular, Gadolinium enhancement signifies breakdown of
the blood-brain barrier as a consequence of acute inflammation in the CNS. However,
there is a fundamental difference between T1 gadolinium enhancing and new T2 brain
lesions, since T1 gadolinium enhancing lesions are transient (average duration of 3
weeks72) and a single scan will miss cumulative new inflammation over a period of
time. Instead, given the (generally) non-transient nature of the T2 lesions, ‘new T2
lesions’ with respect to the last scan would capture cumulative new inflammation
between the last and the current scans. Nonetheless, In particular, the ‘number of
gadolinium-enhancing lesions’ during or at the end of follow-up is the most widely
used trial outcome in all phase III trials (Table 3). Gadolinium enhancement signifies
breakdown of the blood-brain barrier as a consequence of acute inflammation in the
CNS. T1-hypointense lesions are visible in both the acute phase of a lesion
development (corresponding to the lesional oedema) and the chronic phase73,74; in
the latter case they are called permanent black holes (PBH), which have been mostly
used as a post-hoc measure of tissue destruction and recovery13.
Lesion-derived measures can be divided into three categories: (i) outcomes that
measure the occurrence of new lesional activity during the trial, such as the number
of new and/or enlarging T2 lesions or new T1 gadolinium enhancing lesions, (ii)
outcomes that quantify the total lesion volume, either T2-hyperintense, T1-
hypointense or gadolinium-enhancing lesion volume, and (iii) those that estimate the
inflammatory activity as a binary phenomenon, such as the proportion of patients
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without gadolinium enhancing lesions. Finally, there would be a set of metrics that
could be included within the first group, since they reflect new, acute lesional activity,
and that are derived from the combination of different MRI measures. An example of
these composite MRI measure is the number of combined unique active (CUA) lesions,
which describes the total number of active lesions in the widest sense and includes all
new, enlarging T2 lesions or new enhancing lesions, provided that the same focal
lesion is counted only once. This endpoint was originally proposed by Paty and Li and
was already used in the first clinical trials in RRMS. In CIS trials, it was used for the first
time in the early 2000 by the ETOMS study75, and in SPMS trials, it was first used in
the SPECTRIMS study76,77. So far, at least 13 phase III trials have used it (Table 3).
The greatest advantage of lesion-related markers is that they provide objective
measures of the underlying pathology and correlate with clinical outcomes in RRMS,
in particular with relapses, at least in the short/medium term78. It has been
demonstrated that more than 80% of the between-trial variability in terms of
treatment effects on relapses is explained by the between-trial variability in terms of
treatment effects on new T2 lesions on MRI79. In addition, treatment effects on
relapses of phase III trials can be predicted by the treatment effects on lesion-related
outcome measures in the corresponding phase II trials that used the same drug80.
Another advantage of lesion-related measures is that, given their high sensitivity, they
allow the comparison of two active drugs, which can be difficult when the outcome is
clinical relapses. For instance, in the GATE study, which compared generic glatiramer
acetate with the originally branded drug, lesion-related outcomes were used to show
equivalence of the two drugs81.
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The counting of new T2 lesions can be limited by factors such as high pre-existing
lesion load, suboptimal repositioning of serial scans and poor inter-observer
reproducibility. Image subtraction has been proposed to overcome these issues, thus
providing good visualization and quantification of both active and shrunken or
resolved T2 lesions82. The combination of automated identification of new/enlarging
lesions with automated lesion subtraction may be useful to improve cost-
effectiveness and reduce the risk of adverse events associated with gadolinium
administration83.
Brain atrophy measures
The rationale behind the use of brain atrophy in clinical trials is that it reflects
neurodegeneration, which is the pathological process most consistently linked to
accrual of disability84-86. Total brain volume/fraction is the non-lesional outcome
measure most commonly used in phase III trials (Table 3). It is generally used as a
secondary outcome measure in phase II and III trials, such as the FREEDOMS study14,
where fingolimod was compared to placebo, or the CARE-MS I29 or II30 studies, where
alemtuzumab was compared to interferon beta-1a. Nonetheless, it has recently been
used for the first time as primary endpoint in phase II50 and phase III trials in secondary
progressive MS (http://www.ms-smart.org, accessed on 29/061/2017; and
https://clinicaltrials.gov/ct2/show/NCT01910259?term=MS+smart&rank=1,
accessed on 29/061/2017), and also in the ongoing phase II ARPEGGIO trial in PPMS87.
In RRMS, the treatment effect on brain atrophy correlates with the effect on disability
progression over 2 years, independently of the effect on active MRI lesions66.
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There are two types of brain volume-derived metrics (Table 3 and Supplementary
Tables 5 and 6): (i) metrics that calculate global brain atrophy, as either brain
parenchymal volume88 or fraction40 (which is the ratio of brain parenchymal volume
to the total volume within the brain surface contour), and their change over time, and
(ii) metrics that estimate regional volumes, such as white matter and grey matter, and
change thereof during the trial89.
The most widely used measures in the first group are the brain parenchymal fraction
(BPF), a segmentation-based technique that reduces the variability caused by
individual variation in brain size and has high test–retest reproducibility when
compared with raw brain volume90, and the percentage brain volume change (PBVC),
a registration-based difference map of brain contours over time91,92. BPF has been
used in studies such as the phase II trial with natalizumab in RRMS93 or the phase II
trial with interferon beta-1b in PPMS94. PBVC has been used in the phase III fingolimod
trials, i.e. the TRANSFORMS95 and FREEDOMS I14 and II47 studies, and the phase III
laquinimod trials, i.e. the BRAVO96 and the ALLEGRO13 studies.
In addition to the well-known technical sources of measurement error, such as
changes in magnet, gradients, coils, distortion corrections and image-contrast
changes that affect tissue segmentation, global atrophy metrics are susceptible to: (i)
the phenomenon of pseudo-atrophy, likely due to resolution of inflammation and
oedema and especially seen in patients on active treatment with greater gadolinium-
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enhancing lesion volume at baseline97,98, (ii) physiological (circadian) variations in
hydration status99, and (iii) smoking and other cardiovascular risk factors100.
The measures in the second group most commonly used are the grey and the white
matter volumes. The change in the volume of CSF (normalised by the total intracranial
volume) has also been used in phase III trials101,102, as an attempt to quantify indirectly
loss of neural tissue. A single phase II trial used the partial (central) cerebral volume,
a surrogate estimate of global atrophy89. The same trial showed that a reduction in
grey matter volume over time is greater than that in the white matter, and is less
affected by pseudoatrophy98, as other observational studies have also reported103.
Grey matter and thalamic volumes have also been used as additional outcome
measures in the phase III ALLEGRO study13. Therefore, if these partial volumes are
confirmed to show a greater change over time than global measures89,104,105, they will
result in higher sensitivity and a smaller sample size.
Spinal cord atrophy
Spinal cord atrophy is usually measured at the cervical level, and has been associated
with long-term development of motor disability, not only in progressive MS but also
in relapse-onset MS106,107. The rate of brain atrophy in MS is about 0.5% a year108,
whilst that of spinal cord atrophy has been shown to be higher, up to 2.2% a year in
SPMS109, suggesting that spinal cord atrophy may be a sensitive and meaningful
marker of neurodegeneration. Trials in PPMS or SPMS have used the change in cord
area54 as a secondary endpoint (Supplementary Ttable 7). However, there are
methodological factors that affect the noise of this measurement in multi-centre
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trials, mostly related to the limited spatial resolution of current MRI scanners relative
to the small cord size and cord movement. This translates into larger sample sizes than
those estimated from a single centre/scanner study110. Additionally, spinal cord
atrophy-related measures are calculated using semi-automated segmentation-based
methods, which are subject to inter-rater variability.
Novel imaging outcomes for neurodegeneration and remyelination
New outcomes have been proposed and used over the last 5 years to detect the effect
of drugs at a microscopic level. The advantage of such measures is that they are
expected to be more tissue-specific for the underlying pathophysiological processes
than conventional MRI measures, and, therefore, may detect changes reflecting the
underlying mechanisms of damage caused by the action of the experimental
medication. These novel measures may provide complementary information to that
given by conventional imaging endpoints and insights into the mechanistic efficacy of
the medication.
The most widely used measure is the change in magnetic transfer ratio (MTR) in the
whole brain13,16,111 (Table 3 and Supplementary Table 4). MTR changes are thought to
reflect the process of demyelination112 and remyelination113. Apart from whole brain
MTR, regional MTR, such as grey matter, white matter and lesional MTR, have also
been used (e.g., in the phase III, ALLEGRO trial in RRMS13).
Other measures –used mostly in the past– to show an effect of DMTs are metabolite
concentrations, estimated by MR spectroscopy imaging, such as N-Acetyl
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Aspartate13,114. Novel secondary outcome measures currently used in phase II trials in
secondary progressive MS are diffusion metrics parameters derived from NODDI
(Neurite orientation dispersion and density imaging), which estimate the
microstructural complexity of dendrites and axons in vivo115 and sodium imaging116
(https://clinicaltrials.gov/ct2/show/NCT02104661?term=oxcarbazepine+multiple+scl
erosis&rank=1, accessed 29/06/ January 2017).
Optical Coherence Tomography (OCT) measures axonal and neuronal loss within the
anterior visual pathway, which not only correlate with the visual function117,118, but
also reflect whole-brain process of neurodegeneration, especially in progressive
MS119. For that reason, it has been proposed as outcome measure in both optic
neuritis120 and non-optic neuritis MS trials, such as the PROXIMUS (add-on oral
oxcarbazepine vs. placebo in progressive MS)51, the FLUOX-PMS (oral fluoxetine vs.
placebo in monotherapy in progressive MS)121 and the ACTiMuS (bone marrow-
derived cellular therapy in progressive MS)122 trials. Please see Box 1 and
Supplementary Table 8 for more details on OCT-related outcome measures.
Combined clinical and MRI outcomes
Although the use of these types of measures emerged in MS trials in 2012 with the
CombiRx trial, the concept dates back to 2006, when Rio et al. showed that the
absence of relapses, disability, and inflammatory activity visible in the MRI (at certain
thresholds) after a given time on treatment would possibly indicate so minimal disease
activity that the risk of progression over a longer follow-up was negligible5. In 2014,
the outcome measure called “no evidence of disease activity” (NEDA)4 was defined as
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no relapses, no progression of disability, and no MRI activity (new/enlarging T2 lesions
and T1 gadolinium enhancing lesions). It had been initially defined as “Disease Activity
Freedom” (DAF) in the natalizumab AFFIRM trial123 and later re-termed as NEDA. It
has been recently used in phase III (Table 3 and Supplementary Table 1)29,30,101 and
phase II trials124,125. NEDA has also been used to compare the efficacy of medications
among trials; for example, AHSCT (autologous haemopoietic stem cell
transplantation) trials have shown a greater proportion of patients reaching the NEDA
status than other treatments126. Since brain volume loss reflects neurodegeneration
(the main determinant of progressive disability), it has been proposed to include it in
the definition of no evidence of disease activity (so-called “NEDA-4”), together with
relapses, MRI disease activity and clinical progression127.
Another combined endpoint is the event-free survival128, used in AHSCT trials, which
includes death as an outcome in addition to worsening of disability, relapse and new
MRI lesions, suggesting that combined measures can be designed to reflect the
expected efficacy and main adverse events of the drug.
The main objections to the use of these combined measures in clinical trials are that
the net effect of the experimental drug on the composite metric may be difficult to
interpret, if the effect on the different components is not the same, and there is
uncertainty in respect to the clinical relevance for individual cases53,129.
Outcomes in the clinical setting
In this section, we describe the clinical and neuroimaging measures that are currently
used in clinical practice.
29
Clinical measures
In clinical practice, the most widely used clinical measures are related to the
occurrence of relapses and clinical progression, generally measured with the EDSS.
Relapses
The number of relapses occurred within a given time frame, usually 6-12 months, is
the clinical outcome most commonly used in clinical practice. It traditionally requireds
taking a medical history (which may could be associated with a recall bias) and
inspecting the clinical notes. The use of high-quality prospectively designed databases
can allow a more precise retrieval of relapse-related data in the clinic, successfully
enabling clinicians to assess treatment effects in clinical practice130,131. The presence
of relapses while on treatment, in combination with other factors such as EDSS
increase5 or MRI activity132, has been considered as a surrogate for future disability.
Along these lines, a recently published study from the MAGNIMS group, which
included 1,280 patients with RRMS on disease-modifying treatment, showed that the
presence of at least 2 relapses (or 1 relapse and ≥3 new T2 lesions) during the first 
year of treatment with interferon beta was associated with 48% risk of treatment
failure, defined as a confirmed EDSS worsening (≥1 point increase in EDSS if starting 
EDSS <5.5, or ≥0.5 increase if EDSS ≥5.5) or a switch to other therapies for lack of 
efficacy, and 29% risk of EDSS worsening over 3 years133.
Measures of disability
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The most common measure collected in clinical practice is the EDSS, which is used in
the outpatient clinics to assess the severity of clinical relapses and monitor treatment
effects. This scale is based on the standard neurological examination, which is part of
any clinical assessment, and clinicians are very familiar with the meaning of scores
above 4.0, which are based on walking ability. Therefore, the EDSS may be easy to
interpret clinically. However, as mentioned above, it has low intra- and inter-rater
reproducibility, especially for patients with mild to moderate disability. Besides, the
EDSS is not sensitive to important aspects of clinical progression, such as cognitive
dysfunction.
The MSFC is not used in the clinic as frequently as the EDSS or as often as in clinical
trials. One of the MSFC subtests, the PASAT test134,135, assesses the speed of (auditory)
information processing and calculation ability, and may compensate for the fact that
cognitive impairment is not captured by the EDSS. The TWT may be routinely
performed in the clinical setting when assessing patients’ ability to walk before and
after fampridine, to know whether the patient has benefited from the drug136.
However, the MSFC and its subtests have been designed to be used in clinical trials,
for group analyses, rather than to be used in the clinic, at the individual level39. To use
the MSFC or its components, it is required an a priori definition of a clinically
meaningful change. Besides, the reference population affects the values of the MSFC
z-scores, which means they cannot be easily interpreted in the clinic. Other limitations
include the practice effects137,138, which may influence the PASAT, and the fact that
the PASAT can be too distressful139.
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Considering the prevalence of cognitive dysfunction in MS and its impact on patients’
day-to-day lives, a committee of experts on cognitive dysfunction in MS agreed on the
need of regular cognitive assessments in patients with MS and proposed a brief
battery to be administered in the clinic, the Brief International Cognitive Assessment
for Multiple Sclerosis (BICAMS)140. This includes the Symbol Digit Modalities Test
(SDMT)141, which is also included in the Rao’s battery142, and is the most widely used
cognitive test. It measures attention and speed of information processing and lower
scores have been associated with the severity of white matter damage143. It has been
shown to be more valid and reliable than the PASAT, in part because it is a less
distressful test144. It requires a few minutes in total to be performed and the person
who administers the test does not require a specific training142. For all these reasons,
it is considered the best test to be administered if the time allocated to cognitive
assessment is very limited140. In addition to the SDMT, the BICAMS includes The
California Verbal Learning Test (Second Edition) and The Brief Visuospatial Memory
Test (Revised Version), and tests of verbal and visuospatial memory140. Apart from
the SDMT and the PASAT, the remainder of the tests included in the Rao’s battery can
also be used in the clinic, although training of the health professional is required142.
Finally, the Cogstate battery, a computerized tool made of simple rapid tests
measuring processing speed, attention, working memory, executive function and
verbal learning has been used in several neurological conditions, including MS145. In
general, cognitive tests in the clinic are difficult to administer due to time constraints.
Thus, more novel batteries such as the Cogstate, which can be self-administered
online, are potentially more promising in clinical practice. Additionally, it is neutral to
language and culture, being therefore preferable to other tests that may be influenced
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by education. Additional factors to consider are the effects of depression, anxiety and
fatigue on performanceBesides, age, education, depression and anxiety, and fatigue
may affect performance on all cognitive tests.
The PROMs discussed above can also be used in the clinic. In particular, the fatigue
scales, such as the FSSatigue Severity Scale60, the Modified Fatigue Impact Scale
(MFIS)146 or the Visual Analogue Scale for fatigue147, may be used. Other useful PROMs
are those that relate to depression, anxiety, pain or quality of life. Interestingly, in the
near future, the usefulness of PROMs in the clinic may substantially increase with the
help of the new technologies, since PROM-related information can be collected and
displayed to clinicians electronically.
Neuroimaging measures
In this section we review the T2 lesions, which is the most commonly used response
measure in the clinical setting, followed by brain atrophy and combined outcome
measures, which have recently started to emerge and are therefore also discussed.
Lesion-related measures
MRI has become a very usefulvital tool in clinical practice. According to international
recommendations, patients should be scanned regularly, usually at least once a
year148,149, especially if they are on treatment, or even more frequently, if they are on
certain treatments such as natalizumab, fingolimod or dimethyl fumarate, and
considered to be at risk of John Cunningham virus (JCV)-positive progressive multifocal
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leukoencephalopathy150. However, other time frames may still be possible and it is
not fully clear which is the best to adopt for routine, non-urgent MRI scans148,151.
International consensus recommends to perform a brain and/or a spinal cord MRI
scan when unexpected or atypical symptoms appear148,151. Ideally, when brain MRI is
used for monitoring of disease activity and treatment efficacy, it should be performed
on the same MRI system, using the same imaging protocol (i.e., the same pulse
sequences and spatial resolution) as the reference (baseline) scan148.
The most common response measure is the number of new (or enlarging) T2 lesions,
as compared with the previous scan, which is also referred as the number of active T2
lesions148. The number of active lesions is useful to monitor treatment response, since
the presence of new T2 lesions while on treatment has been associated to a worse
clinical outcome6,148 and may indicate the need for a treatment change6. The
occurrence of at least 3 new T2 lesions in the first year of interferon beta therapy was
associated with 27% risk of treatment failure (defined as confirmed EDSS increase or
switch to other therapies for lack of efficacy) and 22% risk of EDSS worsening over 3
years133. A disadvantage of the number of active T2 lesions as a response measure in
the clinic is that it requires previous MRI scans of the patient to be available for
comparison, and an experienced radiologist. Recently, the feasibility and reliability of
automated lesion segmentation algorithms using clinically acquired scans has started
to be assessed, showing promising results152. Therefore, in the near future, these
algorithms may allow the automatic computation of total T2 lesion load in the clinic,
potentially improving the monitoring of patients with MS.
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Another MRI measure used in the clinic is the number of Gd-enhancing lesions, which
provides information on acute inflammation and does not require the availability of
previous MRI scans. The predictive value of Gd-enhancing lesions seems to be
equivalent to that of the presence of new/enlarged (active) T2 lesions148. Additionally,
the enhancement, as happens with the presence of new lesions, has a role in
demonstrating the dissemination in time, as defined in the revised McDonald
criteria21. For the dissemination in space criteria, the recent MAGNIMS consensus
guidelines146 for the MRI criteria for the diagnosis of MS have suggested to include (i)
cortical lesions (together with the juxta-cortical lesions); and (ii) optic nerve lesions.
Yet at present, these lesions are looked for in selected, ad-hoc cases.
Over longer periods of observation, though, the number of new T2 lesions may be
preferable to Gd-enhancing lesions to detect subclinical disease activity, as the latter
only depicts disease activity in recent weeks. Other reasons for this include the higher
costs associated to gadolinium usage and the fact that gadolinium infusions entail
some rare medical risks, the most serious of which is the nephrogenic systemic
fibrosis, although the risk may depend on the type of the gadolinium-containing
contrast media153. Gadolinium can also deposit in the brain154, yet the clinical
consequences of this deposition remain unknown. Gadolinium administration is not
recommended in routine MRI safety monitoring of patients receiving natalizumab155.
Brain atrophy and other MRI measures
The use of atrophy in the clinic is currently controversial156-158. Although the
contribution of brain atrophy to clinical and cognitive deficits is well-established at a
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group level148, there are several factors that may limit the application of atrophy in
the clinical setting. These are: the lack of normative values for brain volume changes
in healthy individuals and in patients with MS, the intra-individual variability, due to
physiological variations (for example, dehydration, alcohol consumption), the
presence of co-morbidities and disease-related factors, such as the initiation of a DMT,
which may induce “pseudoatrophy”97,103,148. There a number of current techniques in
development to try to overcome these issues: Jacobian integration159 or lateral
ventricle volume estimation160, using T1-weighted or T2-weighted images,
respectively, are being developed to improve the reliability of atrophy metrics in the
clinic. It is important to bear in mind that Ddifferences in the MRI hardware and
software packages used for analysis or processing can generate variability in brain
atrophy measures148. Additionally, ; MRI scanner upgrades or replacements can make
the images acquired at different time points non-less comparable161. Ideally, of
course, the same MS patient should be scanned on the same scanner and with the
same protocol, whenever possible.
Combined clinical and MRI measures
A MAGNIMS study mentioned above showed that combining MRI activity with clinical
relapses during the first year of treatment with interferon may identify patients who
have a high risk of treatment failure and EDSS worsening in the short term133. In actual
fact, escalation from first line DMT to a second line DMT is routinely advised in the
clinical setting as a consequence of clinical and radiological evidence of disease
activity.
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There is no strong evidence to support the use of NEDA in clinical practice. In 2015
Rotstein et al. found, in a longitudinal study carried out in 219 patients, that those
who maintained NEDA for 2 years had a very high probability (78.3%) of not showing
any disability progression (defined as an increase in EDSS of >0.5 points), at 7 years of
follow-up. However, a recent study that included 517 consecutive MS patients has
found that achieving NEDA after the first two years of follow-up was not associated to
a better prognosis at 10-year follow-up162. Although this was an observational study
carried out in a heterogeneous cohort, where not all patients were on treatment
(which may have been adjusted based on MRI and clinical findings), NEDA might not
be a useful measure to predict a long-term outcome. In fact, it is likely that despite its
high positive predictive value, NEDA has a low negative predictive value, so losing
NEDA during the follow-up does not necessarily mean that prognosis is significantly
worse, whereas maintaining NEDA is definitely a good prognostic marker. The
implementation of NEDA-4, which includes brain atrophy, in the clinical setting is
associated with the limitations described above and has not been validated for use in
individual patients.
Translation from Trials to Clinical usage
We have demonstrated in the two sections above that most outcome measures used
in clinical trials are not used in routine practice, and when they are, their use is limited
and simplified. This is because in the clinical trials they are used for investigating drug
effects at a population level, whilst in the clinical setting they are employed at the
37
individual level to assess the response to the medication (response measure), monitor
patients (monitoring measure), or guide treatment decisions. In this section, we will
compare the outcomes in clinical trials versus those used in the clinic. Although a
translation of outcome measures used to demonstrate the effects of the drug to the
clinical setting should be sought, there are elements in the clinical practice that go
beyond treatment efficacy and influence patient management, such as patient’s
perception of risks and patient’s priorities. An attractive field of outcome measure
which may overcome some barriers to the translation of outcome measures from
trials to the clinical setting, such as the lack of time in the outpatient clinics, concerns
the development of novel outcome measures driven by the introduction of electronic
devices.
Outcomes in clinical trials versus monitoring in the clinic
Clinical or MRI outcome measures in clinical trials must be sensitive enough to be able
to detect subtle, though highly relevant, treatment changes. This is especially
important when the trial aims to compare a new drug not with placebo, but with
another active drug39. In clinical trials, if the outcome measures are specific but not
too sensitive, there may be a high risk of a falsely negative result, ultimately implying
that a potentially efficacious drug may never be launched. Response measures in the
clinic, instead, should probably be more specific than sensitive, since the
consequences of prematurely (or incorrectly) starting or stopping a drug may have
harmful consequences for the patient.
38
In clinical trials, clinical and MRI outcomes do not need to be meaningful at the
individual level, as far as they are meaningful at the group level. For example, the
outcome ‘changes in MSFC z-scores’ is only meaningful at the group level, and its
usefulness stems from the comparison between treatment groups. In particular, it has
been suggested that an increase in at least 20% in MSFC score or its subscores is a
clinically relevant increase48. Instead, in the clinic, any type of monitoring instrument
(or response measure) must be meaningful at the individual level. Importantly, in both
clinical trials and the clinical setting, outcomes must reflect relevant functional or
structural/pathological aspects of the condition and must be reproducible.
Regarding combined outcomes, whereas they have been extensively and successfully
used in clinical trials, their use in the clinic will again depend on their meaningfulness
at the individual level. Some of these combined outcomes, such as NEDA, have mainly
been used in the trials, although they could be valid at the individual level and used in
the clinic. In fact, when the factors associated with treatment response started to be
defined5, the underlying concept was the same as NEDA, although with a less
restrictive threshold.
In relation to PROMs, their implementation in the clinic may be hampered by their
inter and intra-patient variability. In clinical trials, this high variability may be
compensated by large numbers. Further limitations for the use of PROMs in the clinic
include that they can be time-consuming, that there is a very large number of
measuring tools available without a clear evidence of superiority of one over the
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others, and that the large amount of information that is produced needs to be
interpreted and turned into useful data.
Another difference between outcomes in clinical trials and in the clinic is that in clinical
trials there seems to be a trend towards a greater number of outcomes used over time
(Figure 2a), whereas this is not happening in the clinic, where the EDSS score has been
dominant for long time already. Interestingly, this increase in the number of trial
endpoints is accompanied by a clear increase in the number of participants per trial
(Figure 2b), which all together may be considered as an attempt to increase the power
of the trial to detect a treatment effect, without prolonging the trial duration (Figure
2c).
Finally, we need to acknowledge that patients and clinicians may have a different
perspective on what outcomes are relevant and desirable. For example, a comparison
of the opinions and judgements of clinicians with those of patients utilising the short-
form-36 showed that patients tend to prioritise general health and vitality, mental
health, and emotional role limitation, whilst clinicians consider that physical disability,
bodily pain and social functions are more important to the patient163. Undoubtedly,
these are also factors that need to be taken into account when translating outcomes
from trial to the clinic setting. Ultimately holistic approachesThus, rather holistic
approaches accommodating both patients’ and clinicians’ priorities, are probably
preferred in the clinical setting, whereas this may not be a priority in clinical trials.
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Conclusions
There are now over a dozen agents that can reduce the inflammatory component of
MS, but there is an unmet and urgent need to treat progressive MS and promote
tissue repair and neuroprotection. The availability of clinical and imaging measures in
trials is of the utmost importance to ensure the detection of drug efficacy – nowhere
more needed than in phase II trials of progression. The choice of the best set of
outcomes for a given trial may be difficult because of the large amount of possible
response measures described and used in the literature. Yet all trials should surely
include clinical measures of disease progression, ideally based on the EDSS, for which
there is a high experience, and other motor and/or cognitive measures, for which
there is less experience, but which potentially have a higher sensitivity to capture
subtle but relevant changes in disability. Besides, tThe time periods used to decide
confirmed disability progression should be as long as possible, even 12 months if
possible. Neuroimaging outcomes should include more traditional measures such as
those related to lesion load, and also measures of brain atrophy. The inclusion of more
novel measures is encouraged and their choice will possibly depend on the mechanism
of action of the drug or the mechanistic research question that needs to be answered.
In the clinic, the choice of response measures determines the decisions about
treatments and patient management. Although it would be ideal to use in the clinic
the same tools to measure treatment response as those used in the clinical trial that
led to licencingdrug being licenced, at present, most of the endpoints used in trials
cannot be used as response measures in the clinical setting. This is due to technical,
financial and logistic barriers, such as the time required to obtain these measures,
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training/standardisation, and the fact that their clinical meaning, when used at the
individual level, is very limited. Most importantly, validated cut-off values that predict
a favourable outcome in the long-run are lacking.
The use of PROMs and combined measures is important in both settings, since they
capture the impact (and effects) of the intervention on clinical disability, MRI
parameters, daily activities and quality of life. Further studies are needed to assess
the reliability, accuracy and robustness of the combination of PROMs and objective
(clinical and neuroimaging) measures, with the potential to comprehensively capture
the intrinsic multidimensional nature of MS.
Review criteria
For this review paper, we performed searches in PubMed and www.clinical.trials.gov
using the following search terms: ‘multiple sclerosis’, ‘phase trial’, ‘EDSS’,
‘progression’, ‘relapse rate’, ‘MRI’, ‘neuroimaging’, ‘OCT’, ‘PROMS’, ‘cognition’
(clinical trials sections); and ‘multiple sclerosis’, ‘EDSS’, ‘progression’, ‘relapse rate’,
‘MRI’, ‘neuroimaging’, ‘OCT’, ‘PROMS’, ‘cognition’, ‘electronic devices’. We did not
include any date limitations (the last date that we searched was June 2017). Papers
were included in this review only if they were written in English. For the clinical trial
section, only phase II or phase III controlled trials were included (uncontrolled and/or
phase 0/I trials were not included).
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Tables
Table 1. Main relapse-related and progression-related outcome measures used in
phase III trials
Outcome measure
Number of trials Trials/References
(in alphabetical order)
(*: it indicates the outcome measure was
the primary outcome)
Primary
outcome*
Primary or
secondary
outcome
Relapse-related outcome measures – CIS trials
Time to CDMS 6* 7 BENEFIT*21, CHAMPS*164, ETOMS*75,
ORACLE MS*165, PreCISe*88, REFLEX22,
TOPIC*23
%CDMS 0 5 BENEFIT21, CHAMPS164, ETOMS75, REFLEX22,
TOPIC23
Time to McDonald MS 2* 3 BENEFIT*21, REFLEX*22, TOPIC23
% McDonald MS 0 3 BENEFIT21, REFLEX22, TOPIC23
Relapse-related outcome measures – MS trials
Time to confirmed
relapse
1* 18 BEYOND11, CLARITY166, CombiRx101,
CONFIRM167, DEFINE111, EudraCT 2006-
004937-13168, EUSPMS169, EVIDENCE170,
FREEDOMS14, GALA171, NASPMS41, PRISMS17,
REGARD*172, SIMCOMBIN173,
SPECTRIMS76,77, TEMSO102, The copolymer 1
multiple sclerosis study31, The Nordic SPMS
study64
Time to confirmed
relapse or permanent
treatment
discontinuation
1* 1 TENERE15
ARR 23* 41 ADVANCE*16, AFFIRM*123, ALLEGRO*13,
ARIANNA40, BEYOND11, BRAVO*96, CARE-MS
I*29, CARE-MS II*30, CLARITY*166,
CombiRx*101, CONFIRM*167, DECIDE*174,
DEFINE111, ESIMS55, ETOMS75, EudraCT 2006-
004937-13*168, European/Canadian
glatiramer acetate study175, EUSPMS169,
EVIDENCE170, FORTE*176, FREEDOMS*14,
FREEDOMS II*47, GALA*171, GATE81,
LINOMIDE177, MAESTRO44, MSCRG178,
NASPMS41, PRISMS*17, REGARD172,
SENTINEL*179, SIMCOMBIN*173,
SPECTRIMS76,77, TEMSO*102, TENERE15, The
copolymer 1 multiple sclerosis study*31, The
IFNb multiple sclerosis study*180, The Nordic
SPMS study64, TOPIC23, TOWER*181,
TRANSFORMS*95
ARSR 0 6 ALLEGRO13, BEYOND11, GALA171, MAESTRO44,
PRISMS17, SPECTRIMS76,77, The IFNb multiple
sclerosis study180
% at least one relapse 1* 9 ADVANCE16, BEYOND11, CombiRx101,
CONFIRM167, DEFINE*111, ESIMS55, EudraCT
2006-004937-13168, PreCISe88, TENERE15
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% relapse free 2* 28 AFFIRM123, ALLEGRO13, ARIANNA40,
BEYOND11, BRAVO96, CARE-MS I29, CARE-MS
II30, CLARITY166, CombiRx101, DECIDE174,
EudraCT 2006-004937-13168, EVIDENCE*170,
FORTE176, FREEDOMS14, FREEDOMS II47,
GALA171, GATE81, NASPMS41, PRISMS17,
REGARD172, SENTINEL179, SIMCOMBIN173,
The copolymer 1 multiple sclerosis study31,
The IFNb Multiple Sclerosis Study*180, The
Nordic SMPS Study64, TEMSO102, TOWER181,
TRANSFORMS95
Other relapse-related
measures: mean
annualised rate of
relapses requiring
steroids, relapse risk*,
time between first and
second relapse
1* 2 BEYOND*11, SPECTRIMS76,77
Progression-related outcome measures
Change in EDSS 0 21 ARIANNA40, CARE-MS I29, CARE-MS II30,
ESIMS55, ETOMS75, EudraCT 2006-004937-
13168, EUSPMS169, FREEDOMS14, FREEDOMS
II47, GATE81, MAESTRO44, NASPMS41,
OLYMPUS25, PRISMS17, PROMISE182, The
Copolymer 1 Multiple Sclerosis study31, The
IFNb Multiple Sclerosis Study180, The Nordic
SMPS Study64, TOPIC23, TOWER181,
TRANSFORMS95
Change in MSFC or its
subscores (PASAT,
TWT, 9HPT)
1* 11 CARE-MS I29, CARE-MS II30, CombiRx101,
CUPID65, FREEDOMS14, FREEDOMS II47,
IMPACT*43, MAESTRO44, OLYMPUS25,
PROMISE182, TRANSFORMS95,
Change in other clinical
scales (physical
disability)
0 3 ETOMS75, PRISMS17, The Nordic SMPS
Study64
Change in other clinical
scales (cognitive
disability)
0 2 IMPACT43, MAESTRO44
% of 3m-CDP in EDSS 2* 23 ADVANCE16, AFFIRM*123, ALLEGRO13,
BEYOND11, BRAVO96, CONFIRM167,
DECIDE174, DEFINE111, ESIMS55, ETOMS75,
EudraCT 2006-004937-13168, EUSPMS169,
INFORMS54, LINOMIDE177, MSCRG178,
OLYMPUS25, PROMISE182, SENTINEL*179,
SIMCOMBIN173, SPECTRIMS76,77, TEMSO102,
The Copolymer 1 Multiple Sclerosis study31,
TOPIC23
% free from 3m-CDP in
EDSS
0 7 CLARITY166, FREEDOMS14, FREEDOMS II47,
PRISMS17, The Copolymer 1 Multiple
Sclerosis study31, TOWER181, TRANSFORMS95
% of 6m-CDP in EDSS 0 10 ARIANNA40, BRAVO96, CARE-MS I29, CARE-MS
II30, CombiRx101, INFORMS54, MAESTRO44,
OLYMPUS25, REGARD172, The Nordic SMPS
Study
% free from 6m-CDP in
EDSS
0 2 FREEDOMS14, FREEDOMS II47
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% sustained
improvement in EDSS
0 2 CARE-MS II30, The Copolymer 1 Multiple
Sclerosis study31
% 3m-CDP in MSFC
subscores
0 2 ESIMS55, INFORMS54
% 6m-CDP in MSFC
subscores
0 1 INFORMS54
% with 20% worsening
in MSFC
0 1 ARIANNA40
Time to EDSS 7.0 0 1 EUSPMS169
Time to 3m-CDP in
EDSS
8* 22 ALLEGRO13, BEYOND11, BRAVO96, CLARITY166,
CONFIRM167, DEFINE111, ESIMS*55,
EUSPMS*169,
FREEDOMS14, IMPACT43, INFORMS54,
LINOMIDE*177, MSCRG*178, OLYMPUS*25,
ORATORIO*26, PRISMS17, PROMISE*182,
SIMCOMBIN173, SPECTRIMS*76,77, TEMSO102,
TOPIC23, TOWER181
Time to 6m-CDP in
EDSS
6* 12 ALLEGRO13, BRAVO96, CARE-MS I*29, CARE-
MS II*30, CUPID*65, FREEDOMS14,
INFORMS54, MAESTRO*44, NASPMS*41,
ORATORIO26, SIMCOMBIN173, The Nordic
SMPS Study*
Time to 3m-CDP in
MSFC subscores
0 2 ESIMS55, INFORMS54
Time to 6m-CDP in
MSFC subscores
0 1 INFORMS54
Clinical scores at
follow-up
0 4 ALLEGRO13, EUSPMS169, PRISMS17, The
Copolymer 1 Multiple Sclerosis study31
Combined disability
outcomes (including
NECA)
1* 5 CARE-MS I29, CARE-MS II30, CombiRx101,
ESIMS55, INFORMS*54
Footnote table 1. The primary endpoint of the ARIANNA study40 was the changes in
brain volume fraction (i.e. this study did not have a clinical primary endpoint).
Abbreviations: ARR: annualised relapse rate; ARSR: annualised rate of severe relapses;
CDMS: clinically defined multiple sclerosis; CDP: confirmed disability progression;
EDSS: expanded disability status scale; 9HPT: nine-hole peg test; MSFC: multiple
sclerosis functional composite; NECA: No evidence of clinical activity; PASAT: paced
auditory serial addition test; TWT: 25-foot timed walk test.
47
Table 2. Main patient-reported outcome measures used as phase III trial endpoints
Outcome measure Number of trials Trials/References(in alphabetical order)
Arm index 2 PRISMS17, The Nordic SMPS Study
PRIMUS 1 INFORMS54
EQ-5D/MSQoL-54 4 BENEFIT21, FREEDOMS II47, INFORMS54, MAESTRO44
FIS 5 INFORMS54, TEMSO102, TENERE15, TOPIC23, TOWER181
MSWS-12 2 CUPID65, INFORMS54
MSIS-29 2 CUPID65, DECIDE174
SF-36 1 TOWER181
TSQM 1 TOWER181
Footnote table 2. Abbreviations: FIS (or UFIS): Unidimensional Fatigue Impact Scale;
MSIS-29: Multiple Sclerosis Impact Scale – 29 items; MSWS-12: Multiple Sclerosis
Walking Scale; SF-36: Short Form 36 Health Survey; PRIMUS: Patient-Reported Indices
for Multiple Sclerosis; TSQM: Treatment Satisfaction Questionnaire for Medication,
with domains for Effectiveness, Side-Effects, Convenience and Global Satisfaction.
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Table 3. Main MRI outcome measures used in phase III trials
Outcome measure Numberof trials
Trials/References
(in alphabetical order)
T2-lesion-related outcome measures
# new T2 lesions 8 AFFIRM123, BENEFIT21, BEYOND11, European/ Canadian
Glatiramer Acetate Study, FORTE176, IMPACT43, PreCISe88, The
IFNb Multiple Sclerosis Study180
# enlarging T2
lesions
1 AFFIRM123
# new or enlarging
T2 lesions
28 ADVANCE16, AFFIRM123, ALLEGRO13, BRAVO96, CARE-MS I29,
CARE-MS II30, CHAMPS164, CLARITY166, CONFIRM167, CUPID65,
DECIDE174, DEFINE111, ESIMS55, ETOMS75, EudraCT 2006-004937-
13168, EVIDENCE170, FREEDOMS14, FREEDOMS II47, GALA171,
INFORMS54, MAESTRO44, ORACLE MS165, PRISMS17, REGARD172,
SENTINEL179, SIMCOMBIN173, TRANSFORMS95, TEMSO102
Change in #T2
lesions
4 CombiRx101, PreCISe88, TEMSO102, TOPIC23
Change in T2 lesion
volume
33 ADVANCE16, AFFIRM123, BENEFIT21, BEYOND11, CARE-MS I29,
CARE-MS II30, CHAMPS164, CLARITY166, CombiRx101, CONFIRM167,
DECIDE174, DEFINE111, ESIMS55, ETOMS75, European/Canadian
Glatiramer Acetate Study175, EUSPMS169, FREEDOMS14,
FREEDOMS II47, IMPACT43, MAESTRO44, MSCRG178, NASPMS41,
OLYMPUS25, ORATORIO26, PRISMS17, PROMISE182, REGARD172,
SIMCOMBIN173, SPECTRIMS76,77, TEMSO102, The IFNb Multiple
Sclerosis Study180, TOPIC23, TRANSFORMS95
Gadolinium-enhancing lesion-related outcome measures
# Gd-enhancing T1
lesions at follow-up
36 ADVANCE16, AFFIRM123, ALLEGRO13, BENEFIT21, BEYOND11,
BRAVO96, CARE-MS I29, CARE-MS II30, CHAMPS164, CLARITY166,
CONFIRM167, DECIDE174, DEFINE111, ESIMS55, ETOMS75, EudraCT
2006-004937-13168, European/Canadian Glatiramer Acetate
Study175, FORTE176, FREEDOMS14, FREEDOMS II47, GALA171,
GATE81, IMPACT43, INFORMS54, MAESTRO44, MSCRG178,
NASPMS41, ORACLE MS165, PROMISE182, REGARD172,
SENTINEL179, SPECTRIMS76,77, TEMSO102, The IFNb Multiple
Sclerosis Study180, TOPIC23, TRANSFORMS95
% patients with Gd-
enhancing lesions
at follow-up
9 ARIANNA40, CLARITY166, FREEDOMS14, FREEDOMS II47,
INFORMS54, LINOMIDE177,183, REGARD172, TEMSO102,
TRANSFORMS95
Volume of Gd-
enhancing lesions
at follow-up
11 AFFIRM123, BENEFIT21, BEYOND11, CONFIRM167, DEFINE111,
European/Canadian Glatiramer Acetate Study175, IMPACT43,
MSCRG178, REGARD172, TOPIC23, TRANSFORMS95
Non-enhancing T1 lesion-related outcome measures
# new non-
enhancing T1
lesions
14 ADVANCE16, AFFIRM123, ALLEGRO13, BENEFIT21, CLARITY166,
CONFIRM167, CUPID65, DECIDE174, DEFINE111, GALA171,
INFORMS54, TEMSO102, TOPIC23, REGARD172
Change in T1 lesion
volume
14 ADVANCE16, AFFIRM123, BENEFIT21, BEYOND11, DECIDE174,
DEFINE111, ESIMS55, European/Canadian Glatiramer Acetate
Study175, FREEDOMS14, FREEDOMS II47, REGARD172,
SIMCOMBIN173, TEMSO102, TRANSFORMS95
Change in # T1
lesions
1 PreCISe88
Outcomes related
to permanent black
holes
1 ALLEGRO13
T1 and T2 lesion-related outcome measures
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Change in ratio
T1/T2 volume
2 AFFIRM123, ESIMS55
# combined unique
active lesions
13 ADVANCE16, BENEFIT21, CLARITY166, CombiRx101, ETOMS75,
EudraCT 2006-004937-13168, FREEDOMS14, FREEDOMS II47,
ORACLE MS165, REFLEX22, REGARD172, SPECTRIMS76,77, TEMSO102
Combined lesional
volume + CSF
volume
1 CombiRx101
Non-lesion-related MRI outcome measures
Change in whole-
brain
volume/fraction
25 ADVANCE16, AFFIRM123, ALLEGRO13, ARIANNA40, BEYOND11,
BRAVO96, CARE-MS I29, CARE-MS II30, CONFIRM167, CUPID65,
DEFINE111, FORTE176, FREEDOMS14, FREEDOMS II47, GALA171,
ESIMS55, INFORMS54, MAESTRO44, OLYMPUS25, ORATORIO26,
PreCISe88,REGARD172, SIMCOMBIN173, TOPIC23, TRANSFORMS95
Change in GM
volume/fraction
3 ALLEGRO13, CombiRx101, TEMSO102
Change in WM
volume/fraction
4 ALLEGRO13, CombiRx101, CUPID65, TEMSO102
Change in thalamic
volume
1 ALLEGRO13
Change in whole
brain MTR
4 ADVANCE16, ALLEGRO13, CONFIRM167, DEFINE111
Change in WM MTR 1 ALLEGRO13
Change in GM MTR 1 ALLEGRO13
Change in T2 lesion
MTR
1 ALLEGRO13
Changes in the ratio
NAA/creatinine
1 ALLEGRO13
Combined MRI and clinical outcomes
NEDA (no evidence
of disease activity)
3 CARE-MS I29, CARE-MS II30, CombiRx101
Footnote table 3. Abbreviations: CSF: cerebrospinal fluid; Gd: gadolinium; MTR:
magnetisation transfer ratio; NAA/Cr: N-acetyl aspartate-creatine ratio;
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Table 4 (New): Summary of the strengths and weaknesses of the main outcome
measures
Outcome measure
Used in clinical trials
(T), in the clinic (C) or
in both (B)
Strengths
In relation to their use in clinical
trials (T), in the clinic (C) or in both
(B)
Limitations
In relation to their use in clinical
trials (T), in the clinic (C) or in
both (B)
CLINICAL OUTCOME MEASURES
Relapse-centred outcome measures
# of relapses (C) or ARR
(T)
Easy to compute and understand (B) Only relevant for relapsing forms
of MS (B)
No specific for MS severity (B)
# of severe relapses (C)
or ARSR (T)
May reflect severity of MS relapses
(B)
High inter-site variability due to
absence of guidelines for relapse
management (T)
% of relapse-free
patients (T)
In line with the concept of no
disease activity, useful for trials with
powerful drugs (T)
Highly dependent on trial
duration, with statistical
implications (see main text for
more details) (T)
Time to confirmed
relapse (T)
Useful in CIS trials (T) Only relevant for relapsing forms
of MS (B)
No specific for MS severity (B)
Time to treatment
failure (T)
Accounts for efficacy, safety and
tolerability of the drug (i.e. reflects
real-life scenario) (T)
Unspecific (T)
Measures of disability progression
Change in EDSS and
EDSS scores at follow-
up (B)
Easy to understand by the MS
community (B)
EDSS score changes do not
reflect what functional system
changes (B)
Sensitive to relapse-related
transient deficits (B)
EDSS is not sensitive to upper
limb or cognitive disability (B)
Low inter- and intra-rater
reproducibility (especially if low
EDSS scores) (B)
Change in MSFC or its
subscores and MSFC
scores at follow-up (B)
No specific training required (B)
Sensitive to upper limb (NHPT) and
cognitive (PASAT) functions (B)
In the clinic, TWT is useful to
monitor drug effects, such as
fampridine (C)
Designed to be used in trials, at
group level (i.e. reduced
usefulness in the clinic) (C)
Definition of clinically meaningful
change is required (mainly CT)
Choice of a reference population
affects z-scores (T)
Practice effects (B)
PASAT may be stressful (B)
Change in other clinical
(mainly cognitive)
scales (B)
For SDMT, no specific training
required (B)
Sensitive to cognitive impairment (B)
Training may be required for
cognitive tests (exc. SDMT) (B)
Reference population often
needed to interpret results (C)
Age, anxiety, fatigue and
education may influence results
(B)
% of 3m/6m-CDP in
EDSS (T)
Easy to understand by the MS
community (T)
Overestimation of long-term
disability accumulation (T)
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Highly dependent on trial
duration, with statistical
implications (T)
% free from 3m/6m-
CDP in EDSS (T)
Easy to understand by the MS
community (T)
In line with the concept of no
disease activity, useful for trials with
powerful drugs (T)
Underestimation of % patients
free from long-term disability
accumulation (T)
Highly dependent on trial
duration (T)
% sustained
improvement in EDSS
(T)
Useful to detect improvements of
disability, largely overlooked in MS
trials (T)
May be unspecific in relation to
the pathophysiological process
underlying clinical improvement
(T)
% 3m/6m-CDP in MSFC
subscores (T)
Strengths of the MSFC-related
outcome measures and outcome
measures that consider progression
as a binary phenomenon (see above)
(T)
Limitations of the MSFC-related
outcome measures and outcome
measures that consider %
patients with disability
progression (see above) (T)
Time to 3m/6m-CDP in
EDSS/MSFC and time
to a given EDSS/MSFC
score (T)
Strengths of EDSS/MSFC-related
measures (T)
Informative about the effect of the
drug on immediate risk of CDP (as
opposed to ‘% patients with CDP’,
which considers the risk over a
relatively long period) (T)
Limitations of EDSS/MSFC-
related measures (T)
Combined disability
outcomes (including
NECA) (B)
Higher sensitivity than individual
components to detection of
disability progression, implying a
reduction in required sample
sizes/trial durations (T)
Reduction of the risk of type I error
(T)
NECA: comprehensive measure of
real-life treatment effect (B)
Individual components cannot be
analysed independently, unless
they were pre-defined as
outcome measures (T)
Composite outcomes must
include measures causally
related to treatment (T)
PROMs
All PROMs (B) Information comes directly from the
patient (B)
Information is subjective and
may fluctuate within subjects (B)
NEUROIMAGING & NEUROPHYSIOLOGICAL OUTCOME MEASURES
Outcome measures related to focal lesions
T2-lesion-related
outcome measures (B)
Information on new and cumulative
inflammatory activity (B)
Temporal frameworks for new
inflammatory activity are
imprecise (B)
Gd-enhancing lesion-
related outcome
measures (B)
Information on recent inflammatory
activity (within 3-6 weeks prior scan
date) (B)
No information on cumulative
inflammatory activity (B)
Non-enhancing T1
lesion-related outcome
measures (B)
May inform about tissue destruction
secondary to inflammation and
repair (B)
The delineation of hypointense
T1 lesions may depend on
scanner parameters (B)
Combined unique
active lesions (B)
More sensitive than new T2 or
gadolinium-enhancing lesions
separately (B)
Their computation is slightly
more complex than new T2 or
gadolinium-enhancing lesions (B)
Non-lesion-related MRI outcome measures
Brain atrophy-related
metrics (B)
Reflect neurodegeneration, the
most important substrate of
disability accrual (B)
Susceptible to pseudo-atrophy
phenomenon (B)
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High intra-subject (physiological)
variation (B)
Spinal cord atrophy-
related metrics (T)
Reflect neurodegeneration in the
spinal cord, highly related to motor
disability (T)
Limited spatial resolution, which
hampers multi-centre studies (T)
Current segmentation methods
are semi-automated, implying
high inter-rater variability (T)
Novel imaging
outcomes (MTR, MR
spectroscopy,
diffusion-weighted,
PET-derived metrics)
(T)
Information on microstructural
features of brain damage,
complementary to that given by
lesion-related or atrophy-related
measures (T)
Standardisation of acquisition
protocols and analysis methods
still in progress (T)
OCT (B) Information on axonal and neuronal
loss within the anterior visual
pathway (related to
neurodegeneration) (B)
Useful to monitor drugs’ side effects
(fingolimod) (B)
Less reliable if previous history of
optic neuritis (B)
Combined MRI and
clinical outcomes
(including NEDA) (B)
NEDA: comprehensive measure of
real-life treatment effect (B)
Difficult interpretation of the net
effect of drugs on the outcome
measure (T)
Reduced usefulness in the clinic
(high positive predictive value
but low negative predictive
value) (C)
VEPs (T) May reflect remyelinating processes
secondary to experimental drugs (T)
Not sensitive enough to monitor
disease progression (B)
Footnote table 4. Abbreviations: ARR: annualised relapse rate; B: both clinical trial and
clinical setting; ARSR: annualised rate of severe relapses; C: clinical setting; CDMS:
clinically defined multiple sclerosis; CDP: confirmed disability progression; EDSS:
expanded disability status scale; Gd: gadolinium; 9HPT: nine-hole peg test; MSFC:
multiple sclerosis functional composite; MTR: magnetisation transfer ratio; NECA: No
evidence of clinical activity; NEDA: No evidence of disease activity; PASAT: paced
auditory serial addition test; OCT: optical coherence tomography; PET: positron
emission tomography; PROMs: patient-reported outcome measures; SDMT: symbol
digit modalities test; T: clinical trial; TWT: 25-foot timed walk test; VEPs: visual evoked
potentials.
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Boxes
Box 1 (New). Novel and future outcome measures
Possible future clinical outcomes include those obtained through the utilisation of ‘smart’
technology such as wearable sensors have started to be developed for their use mainly in
the clinic. Wearable sensors are electronic devices that can be attached to the body and
record information about the user’s quantity and quality of movement. This portable
technology can provide objective and quantitative data184 which may be useful to detect
response to therapeutic interventions in the real life. Besides, several strategies have been
developed to maximise the sensitivity to disease progression of current disability scores.
These include re-baselining the EDSS score according to both screening and first visits, and
using new metrics such as the area under the curve described by the disability score
trajectories over time131.
Possible future imaging outcomes include markers of remyelination, such as within-lesion
MTR185 or the level of [11C]PIB binding186, obtained with positron emission tomography
(PET). Markers of chronic inflammation, such as the presence of slowly enlarging lesions187,
and microglial activation, such as and level of TSPO binding188-190, also obtained through
PET, can be used as future outcome measures too. These potential outcomes can bring us
closer to achieving precision medicine189.
Advanced OCT techniques provide quantitative measurements of both retinal nerve fibre
layer (RNFL, axonal) and ganglion cell layer (GCL, neuronal) loss in vivo, representing an
ideal model for assessing the neuroprotective effects of novel agents118. Possible
advantages of OCT in trials are that the evaluation of the retinal structure might predict the
clinical response to treatment191 and the risk of developing specific ocular side effects192.
Finally, future neurophysiological outcomes would include visual evoked potentials and
multimodal evoked potentials, which have shown some ability to predict clinical evolution
in patients with MS193-195. Change in full-field VEPs latency at week-24 has been used as
the primary outcome measure in a phase 2 trial assessing the efficacy of a remyelinating
therapy after the first episode of optic neuritis196
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Box 2. Main clinical and neuroimaging outcomes and derived outcome measures
used in the clinical setting
Clinical outcomes
Relapses
 Number of relapses over a period of time
EDSS
 EDSS score at a given time point
 Change in EDSS score over a period of time
TWT
 TWT score (measured in seconds) at a given time point
9HPT
 9HPT score (measured in seconds) at a given time point
PASAT
 Number of successes (maximum: 60) during the test
SDMT
 Number of successes (no maximum) during the test (usually 1 minute)
FIS/FSS/MFIS
 Score at a given time point
Neuroimaging outcomes
Brain T2 lesions
 Number of lesions at a given time point
 Number of new or enlarging lesions
Brain Gd-enhancing lesions
 Number of lesions at a given time point
Brain non-enhancing T1 lesions
 Number of lesions at a given time point
Brain cortical lesions (in DIR sequences)
 Number of lesions at a given time point
Spinal cord T2 lesions
 Number of lesions at a given time point
Abbreviations:
DIR: double inversion recovery; EDSS: Expanded Disability Status Scale; FIS (or UFIS):
Unidimensional Fatigue Impact Scale; FSS: fatigue severity scale; 9HPT: Nine-Hole Peg
Test; MFIS: modified fatigue impact scale; PASAT: Paced Auditory Serial Addition Test;
SDMT: symbol digit modalities test; TWT: 25-Foot Timed Walk Test;
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Figure legends
Figure1: Number of phase III trials over time in relapsing and progressive MS
Figure 1 (legend).
This figure illustrates the increase in the number of phase III clinical trials carried out
over the last five years, especially in relapsing MS patients. Abbreviations: CIS:
clinically isolated syndrome; MS: multiple sclerosis; PPMS: primary progressive
multiple sclerosis; SPMS: secondary progressive multiple1 sclerosis.
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Figure 2: Trends over time in phase III trials
2a: Evolution of number of trial endpoints over time;
2b: Evolution of number of participants per trial over time;
2c: Evolution of trial duration over time.
Figure 2 (legend).
This figure illustrates the evolution over time of (a) the number of trial endpoints per
trial; (b) number of participants per trial; (c) trial duration. As can be observed, there
has been a clear increase in the number of trial endpoints per trial and the number of
participants per trial over the last 5-10 years, whereas the trial duration has remained
very similar. Most of the trials have a duration of 2 or 3 years. Abbreviations: MS:
multiple sclerosis;
57
References
1 Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502-1517,
doi:10.1016/S0140-6736(08)61620-7 (2008).
2 Trapp, B. D. & Nave, K. A. Multiple sclerosis: an immune or neurodegenerative
disorder? Annu Rev Neurosci 31, 247-269,
doi:10.1146/annurev.neuro.30.051606.094313 (2008).
3 Alliance, P. M. <http://www.progressivemsalliance.org/> (
4 Bevan, C. J. & Cree, B. A. Disease activity free status: a new end point for a new
era in multiple sclerosis clinical research? JAMA Neurol 71, 269-270,
doi:10.1001/jamaneurol.2013.5486 (2014).
5 Rio, J. et al. Defining the response to interferon-beta in relapsing-remitting
multiple sclerosis patients. Ann Neurol 59, 344-352, doi:10.1002/ana.20740
(2006).
6 Rio, J., Comabella, M. & Montalban, X. Predicting responders to therapies for
multiple sclerosis. Nat Rev Neurol 5, 553-560, doi:10.1038/nrneurol.2009.139
(2009).
7 Hobart, J. C., Cano, S. J., Zajicek, J. P. & Thompson, A. J. Rating scales as
outcome measures for clinical trials in neurology: problems, solutions, and
recommendations. Lancet Neurol 6, 1094-1105, doi:10.1016/S1474-
4422(07)70290-9 (2007).
8 Coster, W. J. Making the best match: selecting outcome measures for clinical
trials and outcome studies. Am J Occup Ther 67, 162-170,
doi:10.5014/ajot.2013.006015 (2013).
9 US Department of Health and Human Services Food and Drug Administration,
F. D. A. Guidance for industry: patient-reported outcome measures: use in
medical product development to support labeling
claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulato
ryInformation/Guidances/UCM193282.pdf. (2009).
10 Fox, R. J. et al. Setting a research agenda for progressive multiple sclerosis: the
International Collaborative on Progressive MS. Mult Scler 18, 1534-1540,
doi:10.1177/1352458512458169 (2012).
11 O'Connor, P. et al. 250 microg or 500 microg interferon beta-1b versus 20 mg
glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective,
randomised, multicentre study. Lancet Neurol 8, 889-897, doi:10.1016/S1474-
4422(09)70226-1 (2009).
12 Uitdehaag, B. M. et al. The changing face of multiple sclerosis clinical trial
populations. Curr Med Res Opin 27, 1529-1537,
doi:10.1185/03007995.2011.591370 (2011).
13 Comi, G. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
N Engl J Med 366, 1000-1009, doi:10.1056/NEJMoa1104318 (2012).
14 Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing
multiple sclerosis. N Engl J Med 362, 387-401, doi:10.1056/NEJMoa0909494
(2010).
15 Vermersch, P. et al. Teriflunomide versus subcutaneous interferon beta-1a in
patients with relapsing multiple sclerosis: a randomised, controlled phase 3
trial. Mult Scler 20, 705-716, doi:10.1177/1352458513507821 (2014).
58
16 Calabresi, P. A. et al. Pegylated interferon beta-1a for relapsing-remitting
multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Lancet Neurol 13, 657-665, doi:10.1016/S1474-4422(14)70068-7 (2014).
17 Randomised double-blind placebo-controlled study of interferon beta-1a in
relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and
Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study
Group. Lancet 352, 1498-1504 (1998).
18 Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to
the "McDonald Criteria". Ann Neurol 58, 840-846, doi:10.1002/ana.20703
(2005).
19 Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to
the McDonald criteria. Ann Neurol 69, 292-302, doi:10.1002/ana.22366
(2011).
20 McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis:
guidelines from the International Panel on the diagnosis of multiple sclerosis.
Ann Neurol 50, 121-127 (2001).
21 Kappos, L. et al. Treatment with interferon beta-1b delays conversion to
clinically definite and McDonald MS in patients with clinically isolated
syndromes. Neurology 67, 1242-1249,
doi:10.1212/01.wnl.0000237641.33768.8d (2006).
22 Comi, G. et al. Comparison of two dosing frequencies of subcutaneous
interferon beta-1a in patients with a first clinical demyelinating event
suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled
trial. Lancet Neurol 11, 33-41, doi:10.1016/S1474-4422(11)70262-9 (2012).
23 Miller, A. E. et al. Oral teriflunomide for patients with a first clinical episode
suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-
controlled, phase 3 trial. Lancet Neurol 13, 977-986, doi:10.1016/S1474-
4422(14)70191-7 (2014).
24 Business Wire, B. W.
(http://www.businesswire.com/news/home/20151021005273/en/Biogen-
Reports-Top-Line-Results-Phase-3-Study, 2015).
25 Hawker, K. et al. Rituximab in patients with primary progressive multiple
sclerosis: results of a randomized double-blind placebo-controlled multicenter
trial. Ann Neurol 66, 460-471, doi:10.1002/ana.21867 (2009).
26 Montalban, X. et al. Ocrelizumab versus Placebo in Primary Progressive
Multiple Sclerosis. N Engl J Med, doi:10.1056/NEJMoa1606468 (2016).
27 MS Society, M. <https://www.mssociety.org.uk/ms-research/treatments-in-
the-pipeline/siponimod> (
28 Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded
disability status scale (EDSS). Neurology 33, 1444-1452 (1983).
29 Cohen, J. A. et al. Alemtuzumab versus interferon beta 1a as first-line
treatment for patients with relapsing-remitting multiple sclerosis: a
randomised controlled phase 3 trial. Lancet 380, 1819-1828,
doi:10.1016/S0140-6736(12)61769-3 (2012).
30 Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis
after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet
380, 1829-1839, doi:10.1016/S0140-6736(12)61768-1 (2012).
59
31 Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability
in relapsing-remitting multiple sclerosis: results of a phase III multicenter,
double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis
Study Group. Neurology 45, 1268-1276 (1995).
32 Lublin, F. D., Baier, M. & Cutter, G. Effect of relapses on development of
residual deficit in multiple sclerosis. Neurology 61, 1528-1532 (2003).
33 Ebers, G. C., Heigenhauser, L., Daumer, M., Lederer, C. & Noseworthy, J. H.
Disability as an outcome in MS clinical trials. Neurology 71, 624-631,
doi:10.1212/01.wnl.0000313034.46883.16 (2008).
34 Noseworthy, J. H., Vandervoort, M. K., Wong, C. J. & Ebers, G. C. Interrater
variability with the Expanded Disability Status Scale (EDSS) and Functional
Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS
Study Group. Neurology 40, 971-975 (1990).
35 Mahoney, F. I. & Barthel, D. W. Functional Evaluation: The Barthel Index. Md
State Med J 14, 61-65 (1965).
36 Hobart, J. C. et al. Getting the measure of spasticity in multiple sclerosis: the
Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129, 224-234,
doi:10.1093/brain/awh675 (2006).
37 Hauser, S. L. et al. Intensive immunosuppression in progressive multiple
sclerosis. A randomized, three-arm study of high-dose intravenous
cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308, 173-180,
doi:10.1056/NEJM198301273080401 (1983).
38 Goodkin, D. E., Hertsgaard, D. & Seminary, J. Upper extremity function in
multiple sclerosis: improving assessment sensitivity with box-and-block and
nine-hole peg tests. Arch Phys Med Rehabil 69, 850-854 (1988).
39 Cutter, G. R. et al. Development of a multiple sclerosis functional composite as
a clinical trial outcome measure. Brain 122 ( Pt 5), 871-882 (1999).
40 Lanzillo, R. et al. No evidence for an effect on brain atrophy rate of atorvastatin
add-on to interferon beta1b therapy in relapsing-remitting multiple sclerosis
(the ARIANNA study). Mult Scler 22, 1163-1173,
doi:10.1177/1352458515611222 (2016).
41 Panitch, H., Miller, A., Paty, D., Weinshenker, B. & North American Study Group
on Interferon beta-1b in Secondary Progressive, M. S. Interferon beta-1b in
secondary progressive MS: results from a 3-year controlled study. Neurology
63, 1788-1795 (2004).
42 Rao, S. & Cognitive Function Group, N. A manual for the Brief Repeatable
Battery of neuropsychological tests in multiple sclerosis. (National Multiple
Sclerosis Society, New York, 1990).
43 Cohen, J. A. et al. Benefit of interferon beta-1a on MSFC progression in
secondary progressive MS. Neurology 59, 679-687 (2002).
44 Freedman, M. S. et al. A phase III study evaluating the efficacy and safety of
MBP8298 in secondary progressive MS. Neurology 77, 1551-1560,
doi:10.1212/WNL.0b013e318233b240 (2011).
45 Kalincik, T. et al. Defining reliable disability outcomes in multiple sclerosis.
Brain 138, 3287-3298, doi:10.1093/brain/awv258 (2015).
60
46 Kragt, J. J. et al. Responsiveness and predictive value of EDSS and MSFC in
primary progressive MS. Neurology 70, 1084-1091,
doi:10.1212/01.wnl.0000288179.86056.e1 (2008).
47 Calabresi, P. A. et al. Safety and efficacy of fingolimod in patients with
relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind,
randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13, 545-556,
doi:10.1016/S1474-4422(14)70049-3 (2014).
48 Bosma, L. V. et al. Progression on the Multiple Sclerosis Functional Composite
in multiple sclerosis: what is the optimal cut-off for the three components?
Mult Scler 16, 862-867, doi:10.1177/1352458510370464 (2010).
49 Tourbah, A. et al. MD1003 (high-dose biotin) for the treatment of progressive
multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult
Scler 22, 1719-1731, doi:10.1177/1352458516667568 (2016).
50 Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and
disability in secondary progressive multiple sclerosis (MS-STAT): a randomised,
placebo-controlled, phase 2 trial. Lancet 383, 2213-2221, doi:10.1016/S0140-
6736(13)62242-4 (2014).
51 ClinicalTrials.gov. US National Library of Medicine at the National Institutes of
Health, <http://www.clinicaltrials.gov/ (access date: July 2017)> (
52 Zhang, J., Waubant, E., Cutter, G., Wolinsky, J. & Leppert, D. Composite end
points to assess delay of disability progression by MS treatments. Mult Scler
20, 1494-1501, doi:10.1177/1352458514527180 (2014).
53 Prieto-Merino, D., Smeeth, L., Staa, T. P. & Roberts, I. Dangers of non-specific
composite outcome measures in clinical trials. BMJ 347, f6782,
doi:10.1136/bmj.f6782 (2013).
54 Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis
(INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet 387, 1075-1084, doi:10.1016/S0140-6736(15)01314-8 (2016).
55 Hommes, O. R. et al. Intravenous immunoglobulin in secondary progressive
multiple sclerosis: randomised placebo-controlled trial. Lancet 364, 1149-
1156, doi:10.1016/S0140-6736(04)17101-8 (2004).
56 Speight, J. & Barendse, S. M. FDA guidance on patient reported outcomes. BMJ
340, c2921, doi:10.1136/bmj.c2921 (2010).
57 Hobart, J. & Cano, S. Improving the evaluation of therapeutic interventions in
multiple sclerosis: the role of new psychometric methods. Health Technol
Assess 13, iii, ix-x, 1-177, doi:10.3310/hta13120 (2009).
58 Doward, L. C., McKenna, S. P., Meads, D. M., Twiss, J. & Eckert, B. J. The
development of patient-reported outcome indices for multiple sclerosis
(PRIMUS). Mult Scler 15, 1092-1102, doi:10.1177/1352458509106513 (2009).
59 Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W. & Ellison, G. W. A health-
related quality of life measure for multiple sclerosis. Qual Life Res 4, 187-206
(1995).
60 Krupp, L. B., LaRocca, N. G., Muir-Nash, J. & Steinberg, A. D. The fatigue severity
scale. Application to patients with multiple sclerosis and systemic lupus
erythematosus. Arch Neurol 46, 1121-1123 (1989).
61 Frith, J. & Newton, J. Fatigue Impact Scale. Occup Med (Lond) 60, 159,
doi:10.1093/occmed/kqp180 (2010).
61
62 Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R. & Thompson, A. J.
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale
(MSWS-12). Neurology 60, 31-36 (2003).
63 Hobart, J., Cano, S., Ingram, W. & Zajicek, J. A new path for the MS Walking
Scale: MSWS-12 version 2. . Mult Scler. 18, 334–335 (2012).
64 Andersen, O. et al. Multicentre, randomised, double blind, placebo controlled,
phase III study of weekly, low dose, subcutaneous interferon beta-1a in
secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 75,
706-710 (2004).
65 Zajicek, J. et al. Effect of dronabinol on progression in progressive multiple
sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 12,
857-865, doi:10.1016/S1474-4422(13)70159-5 (2013).
66 Hobart, J. Prolonged-release fampridine for multiple sclerosis: was the effect
on walking ability clinically significant? . Mult Scler 16(Suppl 10):S172. (2010).
67 Goodman, A. D. et al. Sustained-release oral fampridine in multiple sclerosis: a
randomised, double-blind, controlled trial. Lancet 373, 732-738,
doi:10.1016/S0140-6736(09)60442-6 (2009).
68 Novotna, A. et al. A randomized, double-blind, placebo-controlled, parallel-
group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy,
in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol
18, 1122-1131, doi:10.1111/j.1468-1331.2010.03328.x (2011).
69 Zajicek, J. et al. Cannabinoids for treatment of spasticity and other symptoms
related to multiple sclerosis (CAMS study): multicentre randomised placebo-
controlled trial. Lancet 362, 1517-1526, doi:10.1016/S0140-6736(03)14738-1
(2003).
70 Learmonth, Y. C., Motl, R. W., Sandroff, B. M., Pula, J. H. & Cadavid, D.
Validation of patient determined disease steps (PDDS) scale scores in persons
with multiple sclerosis. BMC Neurol 13, 37, doi:10.1186/1471-2377-13-37
(2013).
71 Barkhof, F. et al. MRI monitoring of immunomodulation in relapse-onset
multiple sclerosis trials. Nat Rev Neurol 8, 13-21,
doi:10.1038/nrneurol.2011.190 (2011).
72 Cotton, F., Weiner, H. L., Jolesz, F. A. & Guttmann, C. R. MRI contrast uptake in
new lesions in relapsing-remitting MS followed at weekly intervals. Neurology
60, 640-646 (2003).
73 Filippi, M., Preziosa, P. & Rocca, M. A. Magnetic resonance outcome measures
in multiple sclerosis trials: time to rethink? Curr Opin Neurol 27, 290-299,
doi:10.1097/WCO.0000000000000095 (2014).
74 Mitjana, R. et al. Diagnostic value of brain chronic black holes on T1-weighted
MR images in clinically isolated syndromes. Mult Scler 20, 1471-1477,
doi:10.1177/1352458514526083 (2014).
75 Comi, G. et al. Effect of early interferon treatment on conversion to definite
multiple sclerosis: a randomised study. Lancet 357, 1576-1582 (2001).
76 Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-
1a in, M. S. S. G. Randomized controlled trial of interferon- beta-1a in
secondary progressive MS: Clinical results. Neurology 56, 1496-1504 (2001).
62
77 Li, D. K., Zhao, G. J., Paty, D. W. & University of British Columbia, M. S. M. R. I.
A. R. G. T. S. S. G. Randomized controlled trial of interferon-beta-1a in
secondary progressive MS: MRI results. Neurology 56, 1505-1513 (2001).
78 Tintore, M. et al. Defining high, medium and low impact prognostic factors for
developing multiple sclerosis. Brain 138, 1863-1874,
doi:10.1093/brain/awv105 (2015).
79 Sormani, M. P. et al. Magnetic resonance imaging as a potential surrogate for
relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 65, 268-
275, doi:10.1002/ana.21606 (2009).
80 Sormani, M. P. & Bruzzi, P. MRI lesions as a surrogate for relapses in multiple
sclerosis: a meta-analysis of randomised trials. Lancet Neurol 12, 669-676,
doi:10.1016/S1474-4422(13)70103-0 (2013).
81 Cohen, J. et al. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis:
A Randomized Clinical Trial. JAMA Neurol 72, 1433-1441,
doi:10.1001/jamaneurol.2015.2154 (2015).
82 Moraal, B. et al. Long-interval T2-weighted subtraction magnetic resonance
imaging: a powerful new outcome measure in multiple sclerosis trials. Ann
Neurol 67, 667-675, doi:10.1002/ana.21958 (2010).
83 Tedeschi, E. et al. In vivo dentate nucleus MRI relaxometry correlates with
previous administration of Gadolinium-based contrast agents. Eur Radiol 26,
4577-4584, doi:10.1007/s00330-016-4245-2 (2016).
84 Fisniku, L. K. et al. Gray matter atrophy is related to long-term disability in
multiple sclerosis. Ann Neurol 64, 247-254, doi:10.1002/ana.21423 (2008).
85 Miller, D. H., Barkhof, F., Frank, J. A., Parker, G. J. & Thompson, A. J.
Measurement of atrophy in multiple sclerosis: pathological basis,
methodological aspects and clinical relevance. Brain 125, 1676-1695 (2002).
86 Sormani, M. P., Arnold, D. L. & De Stefano, N. Treatment effect on brain
atrophy correlates with treatment effect on disability in multiple sclerosis. Ann
Neurol 75, 43-49, doi:10.1002/ana.24018 (2014).
87 Barkhof, F., Giovannoni, G., Hartung, H.-P., Cree, B., Uccelli, A., Sormani, M.P.,
Krieger, S., Uitdehaag, B., Vollmer, T., Montalban, X., Steinerman, J., Sasson,
N., Gorfine, T. and Knappertz, V. ARPEGGIO: A randomized, placebo-controlled
study to evaluate oral laquinimod in patients with primary progressive multiple
sclerosis (PPMS). Neurology 84 (2015).
88 Comi, G. et al. Effect of glatiramer acetate on conversion to clinically definite
multiple sclerosis in patients with clinically isolated syndrome (PreCISe study):
a randomised, double-blind, placebo-controlled trial. Lancet 374, 1503-1511,
doi:10.1016/S0140-6736(09)61259-9 (2009).
89 Kapoor, R. et al. Lamotrigine for neuroprotection in secondary progressive
multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-
group trial. Lancet Neurol 9, 681-688, doi:10.1016/S1474-4422(10)70131-9
(2010).
90 Rudick, R. A., Fisher, E., Lee, J. C., Simon, J. & Jacobs, L. Use of the brain
parenchymal fraction to measure whole brain atrophy in relapsing-remitting
MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698-1704
(1999).
63
91 Smith, S. M., De Stefano, N., Jenkinson, M. & Matthews, P. M. Normalized
accurate measurement of longitudinal brain change. J Comput Assist Tomogr
25, 466-475 (2001).
92 Smith, S. M. et al. Accurate, robust, and automated longitudinal and cross-
sectional brain change analysis. Neuroimage 17, 479-489 (2002).
93 Miller, D. H. et al. MRI outcomes in a placebo-controlled trial of natalizumab
in relapsing MS. Neurology 68, 1390-1401,
doi:10.1212/01.wnl.0000260064.77700.fd (2007).
94 Montalban, X. et al. A single-center, randomized, double-blind, placebo-
controlled study of interferon beta-1b on primary progressive and transitional
multiple sclerosis. Mult Scler 15, 1195-1205, doi:10.1177/1352458509106937
(2009).
95 Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing
multiple sclerosis. N Engl J Med 362, 402-415, doi:10.1056/NEJMoa0907839
(2010).
96 Vollmer, T. L. et al. A randomized placebo-controlled phase III trial of oral
laquinimod for multiple sclerosis. J Neurol 261, 773-783, doi:10.1007/s00415-
014-7264-4 (2014).
97 Vidal-Jordana, A. et al. Brain Volume Loss During the First Year of Interferon-
Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional
Brain Volume Dynamics. J Neuroimaging 26, 532-538, doi:10.1111/jon.12337
(2016).
98 Molyneux, P. D. et al. The effect of interferon beta-1b treatment on MRI
measures of cerebral atrophy in secondary progressive multiple sclerosis.
European Study Group on Interferon beta-1b in secondary progressive
multiple sclerosis. Brain 123 ( Pt 11), 2256-2263 (2000).
99 Nakamura, K. et al. Diurnal fluctuations in brain volume: Statistical analyses of
MRI from large populations. Neuroimage 118, 126-132,
doi:10.1016/j.neuroimage.2015.05.077 (2015).
100 Nunes, P. V. et al. Factors associated with brain volume in major depression in
older adults without dementia: results from a large autopsy study. Int J Geriatr
Psychiatry, doi:10.1002/gps.4649 (2017).
101 Lublin, F. D. et al. Randomized study combining interferon and glatiramer
acetate in multiple sclerosis. Ann Neurol 73, 327-340, doi:10.1002/ana.23863
(2013).
102 O'Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple
sclerosis. N Engl J Med 365, 1293-1303, doi:10.1056/NEJMoa1014656 (2011).
103 Vidal-Jordana, A. et al. Early brain pseudoatrophy while on natalizumab
therapy is due to white matter volume changes. Mult Scler 19, 1175-1181,
doi:10.1177/1352458512473190 (2013).
104 Vidal-Jordana, A., Sastre-Garriga, J., Rovira, A. & Montalban, X. Treating
relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J
Neurol 262, 2617-2626, doi:10.1007/s00415-015-7798-0 (2015).
105 Fisher, E., Lee, J. C., Nakamura, K. & Rudick, R. A. Gray matter atrophy in
multiple sclerosis: a longitudinal study. Ann Neurol 64, 255-265,
doi:10.1002/ana.21436 (2008).
64
106 Brownlee, W. J. et al. Association of asymptomatic spinal cord lesions and
atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler,
doi:10.1177/1352458516663034 (2016).
107 Lin, X., Tench, C. R., Turner, B., Blumhardt, L. D. & Constantinescu, C. S. Spinal
cord atrophy and disability in multiple sclerosis over four years: application of
a reproducible automated technique in monitoring disease progression in a
cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg
Psychiatry 74, 1090-1094 (2003).
108 De Stefano, N. et al. Assessing brain atrophy rates in a large population of
untreated multiple sclerosis subtypes. Neurology 74, 1868-1876,
doi:10.1212/WNL.0b013e3181e24136 (2010).
109 Lukas, C. et al. Cervical spinal cord volume loss is related to clinical disability
progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 86, 410-418,
doi:10.1136/jnnp-2014-308021 (2015).
110 Cawley, N., Tur, C. ; Prados, F.; Plantone, D.; Kearney, H.; Abdel – Aziz, K.;
Ourselin, S.; Gandini Wheeler – Kingshott, C.A.M.; Miller, D.H.; Thompson,
A.J.; Ciccarelli, O. Spinal cord atrophy as a primary outcome measure in phase
II trials of progressive multiple sclerosis. Mult Scler Journal (under review)
(2016).
111 Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing
multiple sclerosis. N Engl J Med 367, 1098-1107, doi:10.1056/NEJMoa1114287
(2012).
112 Schmierer, K., Scaravilli, F., Altmann, D. R., Barker, G. J. & Miller, D. H.
Magnetization transfer ratio and myelin in postmortem multiple sclerosis
brain. Ann Neurol 56, 407-415, doi:10.1002/ana.20202 (2004).
113 Arnold, D. L. et al. Magnetization transfer ratio in the delayed-release dimethyl
fumarate DEFINE study. J Neurol 261, 2429-2437, doi:10.1007/s00415-014-
7504-7 (2014).
114 Narayanan, S. et al. Axonal metabolic recovery in multiple sclerosis patients
treated with interferon beta-1b. J Neurol 248, 979-986 (2001).
115 Zhang, H., Schneider, T., Wheeler-Kingshott, C. A. & Alexander, D. C. NODDI:
practical in vivo neurite orientation dispersion and density imaging of the
human brain. Neuroimage 61, 1000-1016,
doi:10.1016/j.neuroimage.2012.03.072 (2012).
116 Paling, D. et al. Sodium accumulation is associated with disability and a
progressive course in multiple sclerosis. Brain 136, 2305-2317,
doi:10.1093/brain/awt149 (2013).
117 Sergott, R. C. et al. ATON: results from a Phase II randomized trial of the B-cell-
targeting agent atacicept in patients with optic neuritis. J Neurol Sci 351, 174-
178, doi:10.1016/j.jns.2015.02.019 (2015).
118 Balcer, L. J. Clinical trials to clinical use: using vision as a model for multiple
sclerosis and beyond. J Neuroophthalmol 34 Suppl, S18-23,
doi:10.1097/WNO.0000000000000163 (2014).
119 Saidha, S. et al. Optical coherence tomography reflects brain atrophy in
multiple sclerosis: A four-year study. Ann Neurol 78, 801-813,
doi:10.1002/ana.24487 (2015).
65
120 Raftopoulos, R. et al. Phenytoin for neuroprotection in patients with acute
optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol
15, 259-269, doi:10.1016/S1474-4422(16)00004-1 (2016).
121 Cambron, M. et al. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS):
study protocol for a randomized controlled trial. Trials 15, 37,
doi:10.1186/1745-6215-15-37 (2014).
122 Rice, C. M. et al. Assessment of bone marrow-derived Cellular Therapy in
progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised
controlled trial. Trials 16, 463, doi:10.1186/s13063-015-0953-1 (2015).
123 Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for
relapsing multiple sclerosis. N Engl J Med 354, 899-910,
doi:10.1056/NEJMoa044397 (2006).
124 Burman, J. et al. Autologous haematopoietic stem cell transplantation for
aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg
Psychiatry 85, 1116-1121, doi:10.1136/jnnp-2013-307207 (2014).
125 Atkins, H. L. et al. Immunoablation and autologous haemopoietic stem-cell
transplantation for aggressive multiple sclerosis: a multicentre single-group
phase 2 trial. Lancet 388, 576-585, doi:10.1016/S0140-6736(16)30169-6
(2016).
126 Sormani, M. P., Muraro, P. A., Saccardi, R. & Mancardi, G. NEDA status in highly
active MS can be more easily obtained with autologous hematopoietic stem
cell transplantation than other drugs. Mult Scler,
doi:10.1177/1352458516645670 (2016).
127 Kappos, L. et al. Inclusion of brain volume loss in a revised measure of 'no
evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Mult Scler 22, 1297-1305, doi:10.1177/1352458515616701 (2016).
128 Nash, R. A. et al. High-dose immunosuppressive therapy and autologous
hematopoietic cell transplantation for relapsing-remitting multiple sclerosis
(HALT-MS): a 3-year interim report. JAMA Neurol 72, 159-169,
doi:10.1001/jamaneurol.2014.3780 (2015).
129 Assessment., E. N. f. H. T. Endpoints used for REA of pharmaceuticals:
composite endpoints, <http://www.eunethta.eu/outputs/methodological-
guideline-rea-pharmaceuticals-composite-endpoints> (2013).
130 Kalincik, T. et al. Treatment effectiveness of alemtuzumab compared with
natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple
sclerosis: a cohort study. Lancet Neurol 16, 271-281, doi:10.1016/S1474-
4422(17)30007-8 (2017).
131 Lorscheider, J. et al. Anti-inflammatory disease-modifying treatment and
short-term disability progression in SPMS. Neurology,
doi:10.1212/WNL.0000000000004330 (2017).
132 Sormani, M. P. et al. Combined MRI lesions and relapses as a surrogate for
disability in multiple sclerosis. Neurology 77, 1684-1690,
doi:10.1212/WNL.0b013e31823648b9 (2011).
133 Sormani, M. P. et al. Assessing response to interferon-beta in a multicenter
dataset of patients with MS. Neurology 87, 134-140,
doi:10.1212/WNL.0000000000002830 (2016).
66
134 Rudick, R. et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol
40, 469-479, doi:10.1002/ana.410400321 (1996).
135 Gronwall, D. M. Paced auditory serial-addition task: a measure of recovery
from concussion. Percept Mot Skills 44, 367-373,
doi:10.2466/pms.1977.44.2.367 (1977).
136 Fragoso, Y. D. et al. Real-life experience with fampridine (Fampyra(R)) for
patients with multiple sclerosis and gait disorders. NeuroRehabilitation 39,
301-304, doi:10.3233/NRE-161361 (2016).
137 Barker-Collo, S. L. Within session practice effects on the PASAT in clients with
multiple sclerosis. Arch Clin Neuropsychol 20, 145-152,
doi:10.1016/j.acn.2004.03.007 (2005).
138 Solari, A., Radice, D., Manneschi, L., Motti, L. & Montanari, E. The multiple
sclerosis functional composite: different practice effects in the three test
components. J Neurol Sci 228, 71-74, doi:10.1016/j.jns.2004.09.033 (2005).
139 Brooks, J. B. et al. Paced auditory serial addition test (PASAT): a very difficult
test even for individuals with high intellectual capability. Arq Neuropsiquiatr
69, 482-484 (2011).
140 Langdon, D. W. et al. Recommendations for a Brief International Cognitive
Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18, 891-898,
doi:10.1177/1352458511431076 (2012).
141 Smith, A. Symbol digit modalities test. . (Western Psychological Services,
1991).
142 Amato, M. P. et al. The Rao's Brief Repeatable Battery and Stroop Test:
normative values with age, education and gender corrections in an Italian
population. Mult Scler 12, 787-793 (2006).
143 Tur, C. et al. Grey matter damage and overall cognitive impairment in primary
progressive multiple sclerosis. Mult Scler 17, 1324-1332,
doi:10.1177/1352458511410341 (2011).
144 Sonder, J. M., Burggraaff, J., Knol, D. L., Polman, C. H. & Uitdehaag, B. M.
Comparing long-term results of PASAT and SDMT scores in relation to
neuropsychological testing in multiple sclerosis. Mult Scler 20, 481-488,
doi:10.1177/1352458513501570 (2014).
145 Jacques, F. H. et al. Cognitive evolution in natalizumab-treated multiple
sclerosis patients. Mult Scler J Exp Transl Clin 2, 2055217316657116,
doi:10.1177/2055217316657116 (2016).
146 Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J. & Murray, T. J. The impact
of fatigue on patients with multiple sclerosis. Can J Neurol Sci 21, 9-14 (1994).
147 Kos, D., Nagels, G., D'Hooghe, M. B., Duportail, M. & Kerckhofs, E. A rapid
screening tool for fatigue impact in multiple sclerosis. BMC Neurol 6, 27,
doi:10.1186/1471-2377-6-27 (2006).
148 Wattjes, M. P. et al. Evidence-based guidelines: MAGNIMS consensus
guidelines on the use of MRI in multiple sclerosis--establishing disease
prognosis and monitoring patients. Nat Rev Neurol 11, 597-606,
doi:10.1038/nrneurol.2015.157 (2015).
149 Traboulsee, A. et al. Revised Recommendations of the Consortium of MS
Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for
67
the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol 37,
394-401, doi:10.3174/ajnr.A4539 (2016).
150 Scolding, N. et al. Association of British Neurologists: revised (2015) guidelines
for prescribing disease-modifying treatments in multiple sclerosis. Pract
Neurol 15, 273-279, doi:10.1136/practneurol-2015-001139 (2015).
151 Rovira, A. et al. Evidence-based guidelines: MAGNIMS consensus guidelines on
the use of MRI in multiple sclerosis-clinical implementation in the diagnostic
process. Nat Rev Neurol 11, 471-482, doi:10.1038/nrneurol.2015.106 (2015).
152 Pareto, D. et al. Lesion filling effect in regional brain volume estimations: a
study in multiple sclerosis patients with low lesion load. Neuroradiology 58,
467-474, doi:10.1007/s00234-016-1654-5 (2016).
153 Kanda, T. et al. Gadolinium deposition in the brain. Magn Reson Imaging,
doi:10.1016/j.mri.2016.08.024 (2016).
154 Gulani, V. et al. Gadolinium deposition in the brain: summary of evidence and
recommendations. Lancet Neurol 16, 564-570, doi:10.1016/S1474-
4422(17)30158-8 (2017).
155 McGuigan, C. et al. Stratification and monitoring of natalizumab-associated
progressive multifocal leukoencephalopathy risk: recommendations from an
expert group. J Neurol Neurosurg Psychiatry 87, 117-125, doi:10.1136/jnnp-
2015-311100 (2016).
156 Chard, D. Brain atrophy measurements should be used to guide therapy
monitoring in MS - Commentary. Mult Scler 22, 1526-1527,
doi:10.1177/1352458516656061 (2016).
157 Barkhof, F. Brain atrophy measurements should be used to guide therapy
monitoring in MS - NO. Mult Scler 22, 1524-1526,
doi:10.1177/1352458516649452 (2016).
158 Zivadinov, R., Dwyer, M. G. & Bergsland, N. Brain atrophy measurements
should be used to guide therapy monitoring in MS - YES. Mult Scler 22, 1522-
1524, doi:10.1177/1352458516649253 (2016).
159 Smeets, D. et al. Reliable measurements of brain atrophy in individual patients
with multiple sclerosis. Brain Behav 6, e00518, doi:10.1002/brb3.518 (2016).
160 Dwyer, M. G. et al. Neurological software tool for reliable atrophy
measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-
FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 15, 769-779,
doi:10.1016/j.nicl.2017.06.022 (2017).
161 Vrenken, H. et al. Recommendations to improve imaging and analysis of brain
lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol
260, 2458-2471, doi:10.1007/s00415-012-6762-5 (2013).
162 University of California, S. F. M. S. E. T. et al. Long-term evolution of multiple
sclerosis disability in the treatment era. Ann Neurol 80, 499-510,
doi:10.1002/ana.24747 (2016).
163 Rothwell, P. M., McDowell, Z., Wong, C. K. & Dorman, P. J. Doctors and patients
don't agree: cross sectional study of patients' and doctors' perceptions and
assessments of disability in multiple sclerosis. BMJ 314, 1580-1583 (1997).
164 Jacobs, L. D. et al. Intramuscular interferon beta-1a therapy initiated during a
first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J
Med 343, 898-904, doi:10.1056/NEJM200009283431301 (2000).
68
165 Leist, T. P. et al. Effect of oral cladribine on time to conversion to clinically
definite multiple sclerosis in patients with a first demyelinating event (ORACLE
MS): a phase 3 randomised trial. Lancet Neurol 13, 257-267,
doi:10.1016/S1474-4422(14)70005-5 (2014).
166 Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing
multiple sclerosis. N Engl J Med 362, 416-426, doi:10.1056/NEJMoa0902533
(2010).
167 Miller, D. H. et al. Effects of delayed-release dimethyl fumarate on MRI
measures in the phase 3 CONFIRM study. Neurology 84, 1145-1152,
doi:10.1212/WNL.0000000000001360 (2015).
168 Massacesi, L. et al. Azathioprine versus beta interferons for relapsing-remitting
multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One 9,
e113371, doi:10.1371/journal.pone.0113371 (2014).
169 Placebo-controlled multicentre randomised trial of interferon beta-1b in
treatment of secondary progressive multiple sclerosis. European Study Group
on interferon beta-1b in secondary progressive MS. Lancet 352, 1491-1497
(1998).
170 Panitch, H. et al. Randomized, comparative study of interferon beta-1a
treatment regimens in MS: The EVIDENCE Trial. Neurology 59, 1496-1506
(2002).
171 Khan, O. et al. Three times weekly glatiramer acetate in relapsing-remitting
multiple sclerosis. Ann Neurol 73, 705-713, doi:10.1002/ana.23938 (2013).
172 Mikol, D. D. et al. Comparison of subcutaneous interferon beta-1a with
glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs
Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre,
randomised, parallel, open-label trial. Lancet Neurol 7, 903-914,
doi:10.1016/S1474-4422(08)70200-X (2008).
173 Sorensen, P. S. et al. Simvastatin as add-on therapy to interferon beta-1a for
relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-
controlled randomised phase 4 trial. Lancet Neurol 10, 691-701,
doi:10.1016/S1474-4422(11)70144-2 (2011).
174 Kappos, L. et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing
Multiple Sclerosis. N Engl J Med 373, 1418-1428, doi:10.1056/NEJMoa1501481
(2015).
175 Comi, G., Filippi, M. & Wolinsky, J. S. European/Canadian multicenter, double-
blind, randomized, placebo-controlled study of the effects of glatiramer
acetate on magnetic resonance imaging--measured disease activity and
burden in patients with relapsing multiple sclerosis. European/Canadian
Glatiramer Acetate Study Group. Ann Neurol 49, 290-297 (2001).
176 Comi, G. et al. Phase III dose-comparison study of glatiramer acetate for
multiple sclerosis. Ann Neurol 69, 75-82, doi:10.1002/ana.22316 (2011).
177 Noseworthy, J. H. et al. Linomide in relapsing and secondary progressive MS:
part I: trial design and clinical results. North American Linomide Investigators.
Neurology 54, 1726-1733 (2000).
178 Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in
relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research
Group (MSCRG). Ann Neurol 39, 285-294, doi:10.1002/ana.410390304 (1996).
69
179 Rudick, R. A. et al. Natalizumab plus interferon beta-1a for relapsing multiple
sclerosis. N Engl J Med 354, 911-923, doi:10.1056/NEJMoa044396 (2006).
180 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I.
Clinical results of a multicenter, randomized, double-blind, placebo-controlled
trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655-661 (1993).
181 Confavreux, C. et al. Oral teriflunomide for patients with relapsing multiple
sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3
trial. Lancet Neurol 13, 247-256, doi:10.1016/S1474-4422(13)70308-9 (2014).
182 Wolinsky, J. S. et al. Glatiramer acetate in primary progressive multiple
sclerosis: results of a multinational, multicenter, double-blind, placebo-
controlled trial. Ann Neurol 61, 14-24, doi:10.1002/ana.21079 (2007).
183 Wolinsky, J. S. et al. Linomide in relapsing and secondary progressive MS: part
II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health
Science Center, and the North American Linomide Investigators. Neurology 54,
1734-1741 (2000).
184 Balto, J. M., Kinnett-Hopkins, D. L. & Motl, R. W. Accuracy and precision of
smartphone applications and commercially available motion sensors in
multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and
Clinical, doi:DOI: 10.1177/ 2055217316634754 (2016).
185 Schwartzbach, C. J. et al. Lesion remyelinating activity of GSK239512 versus
placebo in patients with relapsing-remitting multiple sclerosis: a randomised,
single-blind, phase II study. J Neurol 264, 304-315, doi:10.1007/s00415-016-
8341-7 (2017).
186 Bodini, B. et al. Dynamic imaging of individual remyelination profiles in
multiple sclerosis. Ann Neurol, doi:10.1002/ana.24620 (2016).
187 Sethi, V. et al. Slowly eroding lesions in multiple sclerosis. Mult Scler 23, 464-
472, doi:10.1177/1352458516655403 (2017).
188 Ching, A. S. et al. Current paradigm of the 18-kDa translocator protein (TSPO)
as a molecular target for PET imaging in neuroinflammation and
neurodegenerative diseases. Insights Imaging 3, 111-119,
doi:10.1007/s13244-011-0128-x (2012).
189 Poutiainen, P., Jaronen, M., Quintana, F. J. & Brownell, A. L. Precision Medicine
in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive
Astrocytes. Front Mol Neurosci 9, 85, doi:10.3389/fnmol.2016.00085 (2016).
190 Herranz, E. et al. Neuroinflammatory component of gray matter pathology in
multiple sclerosis. Ann Neurol 80, 776-790, doi:10.1002/ana.24791 (2016).
191 Horton, L. et al. Effect of 4-aminopyridine on vision in multiple sclerosis
patients with optic neuropathy. Neurology 80, 1862-1866,
doi:10.1212/WNL.0b013e3182929fd5 (2013).
192 Zarbin, M. A. et al. Ophthalmic evaluations in clinical studies of fingolimod
(FTY720) in multiple sclerosis. Ophthalmology 120, 1432-1439,
doi:10.1016/j.ophtha.2012.12.040 (2013).
193 Fuhr, P., Borggrefe-Chappuis, A., Schindler, C. & Kappos, L. Visual and motor
evoked potentials in the course of multiple sclerosis. Brain 124, 2162-2168
(2001).
70
194 Jung, P., Beyerle, A. & Ziemann, U. Multimodal evoked potentials measure and
predict disability progression in early relapsing-remitting multiple sclerosis.
Mult Scler 14, 553-556, doi:10.1177/1352458507085758 (2008).
195 Pelayo, R. et al. Do multimodal evoked potentials add information to MRI in
clinically isolated syndromes? Mult Scler 16, 55-61,
doi:10.1177/1352458509352666 (2010).
196 Cadavid, D., Balcer, L., Galetta, S., Aktas, O., Ziemssen, T., Vanopdenbosch, L.,
Butzkueven, H., Ziemssen, F., Massacesi, L., Chai, Y., Xu, L., Freeman, S. Efficacy
Analysis of the Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic
Neuritis: the RENEW Trial Neurology 84 (2015).
1Supplementary Tables
Supplementary Table 1: Clinical outcome measures in phase III trials in relapsing-
remitting (RR) MS
Original clinical
outcome
Derived
outcome
measures
Trial Condition
(no. of
patients
randomised)
Drug, effect
(vs. placebo/
another active
arm)
Duration of
the trial
Relapses Mean
annualised
relapse rate (a)
The IFNB Multiple
Sclerosis Study
Group, Neurology
1993, phase III
RRMS
(n=372)
IFN beta-1b 1.6
MIU: 1.17, p
(vs. placebo) =
0.0101;
IFN beta-1b 8
MIU: 0.84, p
(vs. placebo) =
0.0001; p (vs.
1.6 MIU)
=0.0086;
Placebo: 1.27
24 months
Johnson et al.,
Neurology 1995,
phase III (The
Copolymer 1
Multiple Sclerosis
Study)
RRMS
(n=251)
Glatiramer
acetate 20mg
SC/day: 0.59;
Placebo: 0.84,
p=0.007
24 months
Jacobs et al., Ann
Neurol 1996, phase
III (MSCRG study)
Relapsing
MS (n=301)
IFN beta-1a
30mcg
IM/week: 0.61;
Placebo: 0.9,
p=0.03
104 weeks
PRISMS (Prevention
of Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
Placebo: 1.28;
IFN beta-1a
22mcg SC tiw:
0.91, p<0.005
(vs. placebo);
IFN beta-1a
44mcg SC tiw:
0.865, p<0.005
(vs. placebo);
(s)
24 months
Noseworthy et al.,
Neurology 2000,
phase III (linomide
study)
RMS (n=715) The study was
of insufficient
duration for
any of the
primary or
secondary
outcome
measures to
reach
significance
Early
termination
for safety
issues
(initially
planned: 36
months)
Comi et al., Ann
Neurol 2001, phase
RRMS
(n=249)
Glatiramer
Acetate vs.
9 months
2III
(European/Canadian
Glatiramer Acetate
Study)
Glatiramer
acetate 20mg
SC/day: 0.81;
Placebo: 1.21,
p=0.012
Polman et al., NEJM
2006, phase III
(AFFIRM study)
RRMS
(n=627)
Natalizumab
300mg/4
weeks: 0.23
(0.19 to 0.28);
Placebo: 0.73
(0.62 to 0.87),
p<0.001
24 months
Panitch et al.,
Neurology 2002;
Schwid et al.,
Clinical Therapeutics
2007, phase 4 –
post-
commercialisation
(EVIDENCE study)
RRMS
(n=677)
IFN beta-1a IM
30mcg/week:
0.65; IFN beta-
1a SC 44mcg
tiw: 0.54,
p=0.033
24 months
(0-12m:
comparative
phase; 12-
24m: cross-
over phase)
(n)
Rudick et al., NEJM
2006, phase III
(SENTINEL study)
RRMS
(n=1171)
Natalizumab
300mg/4 weeks
+ IFN beta-1a
IM
30mcg/week:
0.34 (0.29 to
0.39); IFN beta-
1a IM
30mcg/week:
0.75 (0.67 to
0.84), p=0.001
24 months
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study)
RRMS
(n=2244)
IFN beta-1b
500mcg SC eod:
0.33; IFN beta-
1b 250mcg SC
eod: 0.36; GA
20mg SC/day:
0.34, p-values
(all
comparisons) >
0.05
24 months
Cohen et al., NEJM
2010, phase III
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod
0.5mg/day:
0.16 (0.12 to
0.21), p (vs.
IFN) <0.001;
Fingolimod
1.25mg/day:
0.20 (0.16 to
0.26), p (vs.
IFN) <0.001; IFN
beta-1a IM
30mcg/week:
0.33 (95% CI
0.26 to 0.42);
12 months
Kappos et al., NEJM RRMS Fingolimod 24 months
32010, phase III
(FREEDOMS study)
(n=1272) 0.5mg/day:
0.18 (0.15 to
0.22), p (vs.
placebo)
<0.001;
Fingolimod
1.25mg/day:
0.16 (0.13 to
0.19) , p (vs.
placebo)
<0.001;
Placebo: 0.40
(95% CI 0.34 to
0.47);
Giovannoni et al.,
NEJM 2010, phase
III (CLARITY study)
RRMS
(n=1326)
Cladribine
3.5mg/Kg: 0.14
(0.12 to 0.17), p
(vs. placebo)
<0.001;
Cladribine
5.25mg/Kg:
0.15 (0.12 to
0.17), p (vs.
placebo)
<0.001;
Placebo: 0.33
(95% CI 0.29 to
0.38);
96 weeks
Comi at el., Ann
Neurol 2011, phase
III (FORTE study)
RRMS
(n=1155)
GA 20mg
SC/day: 0.33
(SD 0.81); GA
40mg SC/day:
0.35 (SD 0.99),
p=0.486
12 months
O’Connor et al.,
NEJM 2011, phase
III (TEMSO study)
Relapsing
MS (n=1088)
Teriflunomide
7mg PO/day:
0.37 (0.32–
0.43), p (vs.
placebo)
<0.001;
Teriflunomide
14mg PO/day:
0.37 (0.31–
0.44), p (vs.
placebo)
<0.001;
Placebo: 0.54
(0.47–0.62)
108 weeks
Sorensen et al.,
Lancet Neurology
2011, phase 4
(SIMCOMBIN study)
RRMS
(n=307)
IFN beta-1a
30mcg
IM/week +
simvastatin
80mg/day:
0.188 (95% CI
0.126 to 0.281);
IFN beta-1a
12 months
after last
patient was
included
430mcg
IM/week +
Placebo: 0.144
(95% CI 0.092
to 0.227), p =
0.35
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
Alemtuzumab
12mg IV/day x
5 days: 0.18
(0.13 to 0.23);
IFN beta-1a
44mcg SC tiw:
0.39 (95% CI:
0.29 to 0.53),
p<0.0001
24 months
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
Alemtuzumab
12mg IV/day x
5 days: 0.26
(95% CI 0.21 to
0.33); IFN beta
1a 44mcg SC
tiw: 0.52 (95%
CI 0.41 to 0.66),
p<0.0001
24 months
Comi et al., NEJM
2012, phase III
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod
0.6mg OD: 0.30
(SE 0.02), p (vs.
placebo)
=0.002;
Placebo: 0.39
(SE 0.03);
24 months
Fox et al., NEJM
2012, phase III
(CONFIRM study)
RRMS
(n=1417)
BG-12 240mg
BD: 0.22 (95%
CI 0.18 to 0.28),
p (vs. placebo)
<0.001; BG-12
240mg TDS:
0.20 (95% CI
0.16 to 0.25), p
(vs. placebo)
<0.001; GA
40mg SC/day:
0.29 (95% CI
0.23 to 0.35), p
(vs. placebo)
<0.05; Placebo:
0.40 (95% CI
0.33 to 0.49);
24 months
Gold et al., NEJM
2012, phase III
(DEFINE study)
RRMS
(n=1234)
BG-12 240mg
BD: 0.17 (95%
CI 0.14 to 0.21),
p (vs. placebo)
<0.001; BG-12
240mg TDS:
0.19 (95% CI
0.15 to 0.23), p
24 months
5(vs. placebo)
<0.001;
Placebo: 0.36
(95% CI 0.30 to
0.44);
Khan et al., Ann
Neurol 2013, phase
III (GALA study)
RRMS
(n=1404)
GA 40mg SC
tiw: 0.331 (95%
CI 0.280 to
0.392) vs.
placebo: 0.505
(0.418 to
0.609),
p<0.0001
12 months
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
IFN beta-1a
30mcg SC/week
+ GA 20mg
SC/day: 0.23 vs.
IFN: 0.32,
p=0.001;
IFN+GA: 0.23
vs. GA: 0.23,
p=0.44; IFN vs.
GA: p=0.008
36 months
after last
patient was
included
Calabresi et al.
Lancet Neurol 2014,
phase III (ADVANCE
study)
RRMS
(n=1516)
Peginterferon
beta-1a
125mcg SC/2
weeks vs.
placebo: 0.256
(0.206–0.318)
vs. 0.397
(0.328–0.481),
p=0.0007;
Peginterferon
beta-1a
125mcg SC/4
weeks vs.
placebo: 0.288
(0·234–0.355)
vs. 0.397
(0.328–0.481),
p=0.0114
24 months
(but
primary
endpoint:
48 weeks,
which is the
placebo-
controlled
phase)
Calabresi et al.,
Lancet Neurol 2014,
phase III
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod
0.5mg: 0·21
(0·17–0·25);
placebo: 0.40
(95% CI 0.34–
0.48), p<0·0001
24 months
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg: 0·39
(0·33–0·46); p
(vs. placebo)
=0·0183
Teriflunomide
14mg: 0·32
(0·27–0·38); p
(vs. placebo)
48 weeks
after the
last patient
was
included
(MRI results
not
published)
6=0·0001
Placebo: 0·50
(95% CI 0·43–
0·58)
Massacesi et al.,
PLoS ONE 2014,
phase III
RRMS
(n=150)
Azathioprine
(target dose: 3
mg/kg/d) vs.
BIFN beta (1a
or 1b): 0.26
(95% CI: 0.19–
0.37) vs. 0.39
(95% CI: 0.30–
0.51), p=0.07
24 months
Mikol et al., Lancet
Neurol 2014, phase
III (REGARD study)
RRMS
(n=764)
IFN beta-1a
44mcg SC tiw:
0.30, vs.
Glatiramer
acetate 20mg
SC/day: 0.29; p
= 0.828
96 weeks
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
Teriflunomide
7mg: 0.41 (0.27
to 0.64), p (vs.
IFN) =0.03;
Teriflunomide
14mg: 0.26
(0.15 to 0.44), p
(vs. IFN) =0.59;
IFN beta-1a:
0.22 (0.11 to
0.42);
48 weeks
after the
last patient
was
included
Vollmer et al., J
Neurol 2014, phase
III (BRAVO study)
RRMS
(n=1331)
Laquinimod
0.6mg: 0.28
(0.03);
IFN-beta 30
mcg IM: 0.26
(0.02);
Placebo: 0.34
(0.03);
p (Laq vs.
placebo)=0.075;
p (IFN vs.
placebo)=0.007
24 months
Cohen et al., JAMA
Neurol 2015, phase
III (GATE study)
RRMS
(n=796)
Generic GA
20mg/d vs.
brand GA
20mg/d vs.
placebo: 0.31
(0.20 to 0.48)
vs. 0.40 (0.26 to
0.62) vs. 0.38
(0.22 to 0.66)
(ns)
9 months
Kappos et al., New
Engl J Med 2015,
phase III (DECIDE
RRMS
(n=1841)
Daclizumab HYP
150mg SC/4
weeks vs. IFN
144 weeks
7study) beta-1a 30μg 
IM/week: 0.22
vs. 0.39
(p<0.001)
Lanzillo et al., Mult
Scler Journal 2015,
phase III (ARIANNA
study)
RRMS
(n=154)
Beta-IFN 1b eod
SC +
atorvastatin
40mg PO/day
vs. Beta-IFN 1b
eod SC +
placebo: 0.39
vs. 0.32,
(p>0.05)
24 months
Mean
annualised
severe relapse
rate (i)
The IFNB Multiple
Sclerosis Study
Group, Neurology
1993, phase III
RRMS
(n=372)
There was a
twofold
reduction in the
frequency of
moderate and
severe attacks
in the IFN beta-
1b 8 MIU
(probably vs.
placebo – not
specified in
abstract); p-
value not
specified.
24 months
PRISMS study group
(Prevention of
Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
IFN beta-1a
22mcg SC tiw:
0.355, p<0.005
(vs. placebo);
IFN beta-1a
44mcg SC tiw:
0.31, p<0.005
(vs. placebo);
Placebo: 0.495;
(s)
24 months
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study)
RRMS
(n=2244)
GA 20mg
SC/day at 2
years FU: 0.18;
IFN beta-1b
250mcg SC
EmTheOD at 2
years FU: 0.19;
IFN beta-1b
500mcg SC EOD
at 2 years FU:
0.18, p values
(all
comparisons) >
0.05
24 months
Comi et al., NEJM
2012, phase III
(ALLEGRO study)
RRMS
(n=1106)
Placebo: 0.33
(SE 0.02);
Laquinimod
0.6mg OD: 0.24
(SE 0.02), p (vs.
24 months
8placebo)
<0.001;
Khan et al., Ann
Neurol 2013, phase
III (GALA study)
RRMS
(n=1404)
GA 40mg sc tiw:
0.301 (95% CI
0.252 to 0.359)
vs. placebo:
0.466 (0.383 to
0.568),
p<0.0001
12 months
% patients with
at least 1
relapse (a) (l)
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study) (m)
RRMS
(n=2244)
GA 20mg
SC/day at 2
years FU: 27%;
IFN beta-1b
250mcg SC eod
at 2 years FU:
27%; IFN beta-
1b 500mcg SC
eod at 2 years
FU: 26%, p-
values (all
comparisons) >
0.05
24 months
Fox et al., NEJM
2012, phase III
(CONFIRM study)
RRMS
(n=1417)
Placebo: 41%;
BG-12 240mg
BD: 29%, p (vs.
placebo) ≤0.01; 
BG-12 240mg
TDS: 24%, p (vs.
placebo)
<0.001;
GA 40mg
SC/day: 32%, p
(vs. placebo)
≤0.01;
24 months
Gold et al., NEJM
2012, phase III
(DEFINE study)
RRMS
(n=1234)
Placebo: 46%;
BG-12 240mg
BD: 27%, p (vs.
placebo)
<0.001; BG-12
240mg TDS:
26%, p (vs.
placebo)
<0.001;
24 months
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
IFN+GA: 38.9%
vs. IFN: 44.4%,
p=0.19
IFN+GA: 38.9%
vs. GA: 35.9%,
p=0.21
IFN: 44.4% vs.
GA: 35.9%,
p=0.14
36 months
after last
patient was
included
Calabresi et al.
Lancet Neurol 2014,
phase III (ADVANCE
study)
RRMS
(n=1516)
Peginterferon
beta-1a
125μg/2 weeks 
SC vs. placebo:
24 months
(but
primary
endpoint:
90.187 (0.0178)
vs. 0.291
(0.0206),
p=0.0003;
Peginterferon
beta-1a
125μg/4 weeks 
SC vs. placebo:
0.222 (0.0191)
vs. 0.291
(0.0206),
p=0.02
48 weeks,
which is the
placebo-
controlled
phase)
Massacesi et al.,
PLoS ONE 2014,
phase III
RRMS
(n=150)
Azathioprine
(target dose: 3
mg/kg/d) vs.
beta-IFN (1a or
1b): 35.5% vs.
47.8%, p=0.22
(ns)
24 months
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
IFNβ-1a: 15.4%, 
p (vs
Teriflunomide
7mg) = 0.03, p
(vs
Teriflunomide
14mg) = 0.6;
Teriflunomide
7mg: 42.2%;
Teriflunomide
14mg: 23.4%;
48 weeks
after the
last patient
was
included
% relapse-free
patients at the
end of FU
The IFNB Multiple
Sclerosis Study
Group, Neurology
1993, phase III
RRMS
(n=372)
IFN beta-1b 8
MIU: 29%;
Placebo: 14.5%,
p=0.007
24 months
Johnson et al.,
Neurology 1995,
phase III (The
Copolymer 1
Multiple Sclerosis
Study)
RRMS
(n=251)
Glatiramer
acetate 20mg
SC/day: 33.6%;
Placebo: 27.0%,
p=0.098
24 months
PRISMS study group
(Prevention of
Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
IFN beta-1a
22mcg SC tiw:
27%, p≤0.05 
(vs. placebo);
IFN beta-1a
44mcg SC tiw:
32%, p<0.005
(vs. placebo);
Placebo: 16%
24 months
Panitch et al.,
Neurology 2002;
Schwid et al.,
Clinical Therapeutics
2007, phase 4 –
post-
RRMS
(n=677)
IFN beta-1a SC
44mcg tiw:
56%;
IFN beta-1a IM
30mcg/week:
48%, p=0.023
24 months
(0-12m:
comparative
phase; 12-
24m: cross-
over phase)
10
commercialisation
(EVIDENCE study)
(n)
Polman et al., NEJM
2006, phase III
(AFFIRM study)
RRMS
(n=627)
Natalizumab
300mg/4
weeks: 72%, p
(vs. placebo)
<0.05;
Placebo: 46%
(o)
24 months
Rudick et al., NEJM
2006, phase III
(SENTINEL study)
RRMS
(n=1171)
Natalizumab
300mg/4 weeks
+ IFN beta-1a
IM
30mcg/week:
61%, p (vs. IFN)
<0.05;
IFN beta-1a IM
30mcg/week:
37% (o)
24 months
Cohen et al., NEJM
2010, phase III
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod
0.5mg/day:
82.6% (79.0 to
86.3), p (vs.
IFN) <0.001;
Fingolimod
1.25mg/day:
79.8% (75.9 to
83.7), p (vs.
IFN) <0.001;
IFN beta-1a IM
30mcg/week:
69.3% (95% CI
64.8 to 73.8)
12 months
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study)
RRMS
(n=2244)
IFN beta-1b
500mcg SC eod
at 2 years FU:
60%;
IFN beta-1b
250mcg SC eod
at 2 years FU:
58%;
GA 20mg
SC/day at 2
years FU: 59%,
p values (all
comparisons) >
0.05
24 months
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day:
70.4% (66.0 to
74.8), p (vs.
placebo) <0.001
Fingolimod
1.25mg/day:
74.7% (70.4 to
24 months
11
78.9), p (vs.
placebo) <0.001
Placebo: 45.6%
(95% CI 40.7 to
50.6)
Giovannoni et al.,
NEJM 2010, phase
III (CLARITY study)
RRMS
(n=1326)
Cladribine
3.5mg/Kg:
79.7%, p (vs.
placebo)
<0.001;
Cladribine
5.25mg/Kg:
78.9%, p (vs.
placebo)
<0.001;
Placebo: 60.9%
96 weeks
Comi at el., Ann
Neurol 2011, phase
III (FORTE study)
RRMS
(n=1155)
GA 20mg
SC/day: 77.6%
(SD 17.4); GA
40mg SC/day:
77.0% (SD
17.7), p=0.999
12 months
O’Connor et al.,
NEJM 2011, phase
III (TEMSO study)
Relapsing
MS (n=1088)
Teriflunomide
7mg PO/day:
53.7% (48.3–
59.1), p (vs.
placebo) =0.01;
Teriflunomide
14mg PO/day:
56.5% (51.0–
62.0) , p (vs.
placebo)
=0.003;
Placebo: 45.6%
(95% CI: 40.2–
51.0)
108 weeks
Sorensen et al.,
Lancet Neurology
2011, phase 4
(SIMCOMBIN study)
RRMS
(n=307)
IFN beta-1a
30mcg
IM/week +
simvastatin
80mg/day:
75%;
IFN beta-1a
30mcg
IM/week +
Placebo: 81%, p
= 0.512
12 months
after last
patient was
included
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
Alemtuzumab
12mg IV/day x
5 days: 77.6%
(72.9 to 81.6);
IFN beta 1a
44mcg SC tiw:
58.7% (95% CI:
51.1 to 65.5),
p<0.0001
24 months
12
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
Alemtuzumab
12mg IV/day x
5 days: 65.4%
(95% CI 60.7 to
69.7);
IFN beta 1a
44mcg SC tiw:
46.7% (95% CI
39.5 to 53.5),
p<0.0001;
24 months
Comi et al., NEJM
2012, phase III
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod
0.6mg OD:
52.24%;
Placebo:
62.90%, p (vs.
placebo)
<0.001;
24 months
Khan et al., Ann
Neurol 2013, phase
III (GALA study)
RRMS
(n=1404)
GA 40mg sc tiw:
77.0% vs.
Placebo: 65.5%,
p<0.0001
12 months
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
IFN+GA: 61.1%
vs. IFN: 55.6%,
p=0.19
IFN+GA: 61.1%
vs. GA: 64.1%,
p=0.21
IFN: 55.6% vs.
GA: 64.1%,
p=0.14
36 months
after last
patient was
included
Calabresi et al.,
Lancet Neurol 2014,
phase III
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod
0.5mg: 71.5%
(66.6 to 76.4);
Placebo: 52.7%
(2.8; 47.2 to
58.2), p<0.0001
24 months
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg: 71.9%
(67.3 to 76.5), p
(vs. placebo)
=0.016
Teriflunomide
14mg: 76.3%
(71.7 to 81.0), p
(vs. placebo)
<0.0001
Placebo: 60.6%
(95% CI: 55.5 to
65.6);
48 weeks
after the
last patient
was
included
Massacesi et al.,
PLoS ONE 2014,
phase III
RRMS
(n=150)
Azathioprine
(target dose: 3
mg/kg/d) vs.
IFN beta (1a or
1b): 62.9% vs.
47.7%, p=0.22
(ns)
24 months
13
Mikol et al., Lancet
Neurol 2014, phase
III (REGARD study)
RRMS
(n=764)
IFN beta-1a
44mcg SC tiw:
62%;
Glatiramer
acetate 20mg
SC/day: 62%,
p=0.64;
96 weeks
Vollmer et al., J
Neurol 2014, phase
III (BRAVO study)
RRMS
(n=1331)
Laquinimod
0.6mg: 66%,
Placebo: 61%,
IFN-beta 30
mcg IM: 69%; p
(Laq vs.
placebo)=0.21;
p (IFN vs.
placebo)=0.023
24 months
Cohen et al., JAMA
Neurol 2015, phase
III (GATE study)
RRMS
(n=796)
Generic GA
20mg/d vs.
brand GA
20mg/d vs.
placebo: 79.3%
vs. 73.9% vs.
73.8% (ns)
9 months
Kappos et al., New
Engl J Med 2015,
phase III (DECIDE
study)
RRMS
(n=1841)
Daclizumab HYP
150mg/4 weeks
vs. IFN beta-1a
30μg/week: 
67% vs. 51%,
p<0.05
144 weeks
Lanzillo et al., Mult
Scler Journal 2015,
phase III (ARIANNA
study)
RRMS
(n=154)
IFN beta-1b 8
MIU eod SC +
atorvastatin
40mg PO vs.
IFN beta-1b
MIU eod SC +
placebo: 69%
vs. 75% (ns)
24 months
Time to first
confirmed
relapse
Johnson et al.,
Neurology 1995,
phase III (The
Copolymer 1
Multiple Sclerosis
Study)
RRMS
(n=251)
Median time:
Glatiramer
acetate 20mg
SC/day: 287
days, vs.
placebo: 198
days, p=0.097
24 months
PRISMS study group
(Prevention of
Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
Median time to
relapse:
delayed by 3 or
5 months, for
IFN beta-1a
22mcg SC tiw or
IFN beta-1a
44mcg SC tiw,
vs. placebo,
respectively
(p<0.05);
24 months
Panitch et al., RRMS IFN beta-1a SC 24 months
14
Neurology 2002;
Schwid et al.,
Clinical Therapeutics
2007, phase 4 –
post-
commercialisation
(EVIDENCE study)
(n=677) 44mcg tiw: 13.5
mo.; IFN beta-
1a IM
30mcg/week:
6.7 mo.; HR
(95% CI) 0.70
(0.56 to 0.88),
p=0.002
(0-12m:
comparative
phase; 12-
24m: cross-
over phase)
(n)
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study)
RRMS
(n=2244)
GA 20mg
SC/day at 2
years FU: 271
days (25th
percentile);
IFN beta-1b
250mcg SC EOD
at 2 years FU:
283 days (25th
percentile);
IFN beta-1b
500mcg SC EOD
at 2 years FU:
348 days (25th
percentile), p
values (all
comparisons) >
0.05
24 months
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day vs.
placebo: HR
(95% CI) 0.48
(0.39 to 0.61),
p<0.001
Fingolimod
1.25mg/day vs.
placebo: HR
(95% CI) 0.38
(0.30 to 0.48),
p<0.001
24 months
Giovannoni et al.,
NEJM 2010, phase
III (CLARITY study)
RRMS
(n=1326)
Cladribine
3.5mg/Kg vs.
placebo: HR
(95% CI) 0.44
(0.34 to 0.58),
p<0.001
Cladribine
5.25mg/Kg vs.
placebo: HR
(95% CI) 0.46
(0.36 to 0.60),
p<0.001
96 weeks
Sorensen et al.,
Lancet Neurology
2011, phase 4
(SIMCOMBIN study)
RRMS
(n=307)
IFN beta-1a
30mcg
IM/week +
simvastatin
80mg/day vs.
IFN beta-1a
12 months
after last
patient was
included
15
30mcg
IM/week +
Placebo: HR
(95% CI) 1.21
(0.74 to 1.99),
p=0.512
Fox et al., NEJM
2012, phase III
(CONFIRM study)
RRMS
(n=1417)
BG-12 240mg
BD vs. placebo:
HR (95% CI)
0.66 (0.51 to
0.86), p≤0.01;  
BG-12 240mg
TDS vs.
placebo: HR
(95% CI) 0.55
(0.42 to 0.73),
p<0.001;
GA 40mg
SC/day vs.
placebo: HR
(95% CI) 0.71
(0.55 to 0.92),
p≤0.01; 
24 months
Gold et al., NEJM
2012, phase III
(DEFINE study)
RRMS
(n=1234)
BG-12 240mg
BD vs. placebo:
HR (95% CI)
0.51 (0.40 to
0.66), p<0.001;
BG-12 240mg
TDS vs.
placebo: HR
(95% CI) 0.50
(0.39 to 0.65),
p<0.001;
24 months
O’Connor et al.,
NEJM 2011, phase
III (TEMSO study)
Relapsing
MS (n=1088)
Teriflunomide
7mg PO/day vs.
placebo: HR
(95% CI) 0.76
(0.61–0.94),
p=0.01;
Teriflunomide
14mg PO/day
vs. placebo: HR
(95% CI) 0.72
(0.58–0.90),
p=0.003;
108 weeks
Khan et al., Ann
Neurol 2013, phase
III (GALA study)
RRMS
(n=1404)
GA 40mg sc tiw
vs. placebo: HR
(95% CI) 0.606
(0.493 to
0.744),
p<0.0001
12 months
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
HRs not
specified,
p=0.19
36 months
after last
patient was
included
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Massacesi et al.,
PLoS ONE 2014,
phase III
RRMS
(n=150)
Azathioprine
(target dose: 3
mg/kg/d) vs.
IFN beta (1a or
1b) (hazard
ratio [95%CI]):
0.66 (0.40–
1.10) (ns)
24 months
Mikol et al., Lancet
Neurol 2014, phase
III (REGARD study)
RRMS
(n=764)
IFN beta-1a
44mcg SC tiw
vs. glatiramer
acetate 20mg
SC/day, HR
(95% CI) 0.94
(0.74–1.21),
p=0.64;
96 weeks
Time to failure,
defined as the
occurrence of
the first
confirmed
relapse or to
permanent
treatment
discontinuation
for any cause
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
Teriflunomide
7mg vs. IFNβ-
1a: HR (95% CI)
1.12 (0.75 to
1.67), p=0.52;
Teriflunomide
14mg vs. IFNβ-
1a: HR (95% CI)
0.86 (0.56 to
1.31), p=0.60
48 weeks
after the
last patient
was
included
Relapse risk
(assessed with
the Andersen–
Gill model for
time to
recurring
events)
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study)
RRMS
(n=2244)
IFN beta-1b
500mcg SC eod
vs. IFN beta-1b
250mcg SC eod:
HR (95% CI)
0·94 (0·82–
1·08), p=0·20;
IFN beta-1b
500mcg SC eod
vs. GA 20mg
SC/day: HR
(95% CI)1·00
(0·83–1·19),
p=0·48;
IFN beta-1b
250mcg SC eod
vs. GA 20mg
SC/day: HR
(95% CI) 1·06
(0·89–1·27),
p=0·74;
24 months
EDSS score Change in EDSS
score from
baseline to
follow-up (k)
The IFNB Multiple
Sclerosis Study
Group, Neurology
1993, phase III
RRMS
(n=372)
IFN beta-1b 1.6
MIU, IFN beta-
1b 8 MIU or
placebo: little
changes (not
significant – no
further details
given in the
abstract);
24 months
17
Johnson et al.,
Neurology 1995,
phase III (The
Copolymer 1
Multiple Sclerosis
Study)
RRMS
(n=251)
Glatiramer
acetate 20mg
SC/day: -0.05
(SE 1.13);
Placebo:
0.21(SE 0.99),
p=0.023
24 months
PRISMS study group
(Prevention of
Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
IFN beta-1a
22mcg SC tiw:
0.23 (SD 1.3),
p≤0.05 (vs. 
placebo);
IFN beta-1a
44mcg SC tiw:
0.24 (SD 1.1),
p≤0.05 (vs. 
placebo);
Placebo: 0.48
(SD 1.3);
24 months
Cohen et al., NEJM
2010, phase III
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod
0.5mg/day: -
0.08 (SD 0.79),
p (vs. IFN) =
0.06
Fingolimod
1.25mg/day: -
0.11 (SD 0.90),
p (vs. IFN) =
0.02
IFN beta-1a IM
30mcg/week:
0.01 (SD 0.78)
12 months
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day:
0.00 (SD 0.88),
p (vs. placebo)
= 0.002;
Fingolimod
1.25mg/day: -
0.03 (SD 0.88),
p (vs. placebo)
= 0.002;
Placebo: 0.13
(SD 0.94);
24 months
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
Alemtuzumab
12mg IV/day x
5 days: -0.14
(95% CI -0.25 to
-0.02)
IFN beta 1a
44mcg SC tiw: -
0.14 (95% CI -
0.29 to 0.01),
p=0.97
24 months
Coles et al., Lancet RRMS Alemtuzumab 24 months
18
2012, phase III
(CARE-MS II study)
previously
treated
(n=840)
12mg IV/day x
5 days: -0.17
(95% CI -0.29 to
-0.05);
IFN beta 1a
44mcg SC tiw:
0.24 (95% CI
0.07 to 0.41),
p<0.0001
Calabresi et al.,
Lancet Neurol 2014,
phase III
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod
0.5mg PO:
0·046 (SD:
1.02);
Placebo: 0.055
(SD: 1.20),
p=0.945
24 months
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg PO: 0.04
(0.05), p (vs.
placebo) =
0.4819;
Teriflunomide
14mg PO: -0.05
(0.05), p (vs.
placebo) =
0.0429;
Placebo: 0.09
(0.05);
48 weeks
after the
last patient
was
included
Massacesi et al.,
PLoS ONE 2014,
phase III
RRMS
(n=150)
Azathioprine
(target dose: 3
mg/kg/day PO)
vs. IFN beta (1a
or 1b SC) (mean
change
[95%CI]): 20.08
(20.3 to 0.16)
vs. 0.22 (20.03
to 0.47), p=0.08
24 months
Cohen et al., JAMA
Neurol 2015, phase
III (GATE study)
RRMS
(n=796)
Generic GA
20mg/d: (mean
change [range])
−0.11 (−0.22 to 
0.00);
Brand GA
20mg/d: (mean
change [range])
−0.08 (−0.19 to 
0.03);
Placebo: (mean
change
[range]): −0.02 
(−0.17 to 0.14); 
p-values (all
comparisons)
>0.05
9 months
Lanzillo et al., Mult RRMS IFN beta-1b 8 24 months
19
Scler Journal 2015,
phase III (ARIANNA
study)
(n=154) MIU SC eod +
atorvastatin
40mg/d: 0.3 vs.
IFN beta-1b 8
MIU SC eod +
placebo: 0.2,
p>0.05
Time to 3-
month CDP (g)
Jacobs et al., Ann
Neurol 1996, phase
III (MSCRG study)
Relapsing
MS (n=301)
IFN beta-1a
30mcg
IM/week vs.
placebo: HR <1,
p=0.02 (v)
104 weeks
PRISMS study group
(Prevention of
Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
IFN beta-1a
22mcg SC tiw:
18.5 months
(first quartile),
risk ratio (95%
CI) 0.68 (0.48 to
0.98): p (vs.
placebo) <0.05;
IFN beta-1a
44mcg SC tiw:
21.3 months
(first quartile),
risk ratio (95%
CI) 0.42 (0.18 to
0.99), p (vs.
placebo) <0.05;
Placebo: 11.9
months (first
quartile) (u)
24 months
Noseworthy et al.,
Neurology 2000,
phase III (linomide
study)
RMS (n=715) The study was
of insufficient
duration for
any of the
primary or
secondary
outcome
measures to
reach
significance
Early
termination
for safety
issues
(initially
planned: 36
months)
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study)
RRMS
(n=2244)
IFN beta-1b
500mcg SC EOD
at 2 years FU:
190 days (10th
percentile);
IFN beta-1b
250mcg SC EOD
at 2 years FU:
274 days (10th
percentile);
GA 20mg
SC/day at 2
years FU: 268
days (10th
percentile), p
24 months
20
values (all
comparisons) >
0.05
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day vs.
placebo: HR
(95% CI) 0.70
(0.52 to 0.96), p
= 0.02
Fingolimod
1.25mg/day vs.
placebo: HR
(95% CI) 0.68
(0.50 to 0.93), p
= 0.02
24 months
Giovannoni et al.,
NEJM 2010, phase
III (CLARITY study)
RRMS
(n=1326)
Cladribine
3.5mg/Kg vs.
placebo: HR
(95% CI) 0.67
(0.48 to 0.93),
p<0.001
Cladribine
5.25mg/Kg vs.
placebo: HR
(95% CI) 0.69
(0.49 to 0.96),
p<0.001
96 weeks
O’Connor et al.,
NEJM 2011, phase
III (TEMSO study)
Relapsing
MS (n=1088)
Teriflunomide
7mg PO/day vs.
placebo: HR
(95% CI) 0.76
(0.56–1.05),
p=0.08
Teriflunomide
14mg PO/day
vs. placebo: HR
(95% CI) 0.70
(0.51–0.97);
p=0.03
108 weeks
Sorensen et al.,
Lancet Neurology
2011, phase 4
(SIMCOMBIN study)
RRMS
(n=307)
IFN beta-1a
30mcg
IM/week +
simvastatin
80mg/day vs.
mThe
IFN beta-1a
30mcg
IM/week +
Placebo: HR
(95% CI) 1.01
(0.63 to 1.64),
p=0.953
12 months
after last
patient was
included
Comi et al., NEJM
2012, phase III
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod
0.6mg OD vs.
placebo: HR
(95% CI) 0.64
24 months
21
(0.45 to 0.91),
p=0.01
Fox et al., NEJM
2012, phase III
(CONFIRM study)
RRMS
(n=1417)
BG-12 240mg
BD vs. placebo:
HR (95% CI)
0.79 (0.52 to
1.19), p>0.05;
BG-12 240mg
TDS vs.
placebo: HR
(95% CI) 0.76
(0.50 to 1.16),
p>0.05
GA 40mg
SC/day vs.
placebo: HR
(95% CI) 0.93
(0.63 to 1.37),
p>0.05
24 months
Gold et al., NEJM
2012, phase III
(DEFINE study)
RRMS
(n=1234)
BG-12 240mg
BD vs. placebo:
HR (95% CI)
0.62 (0.44 to
0.87), p=0.005;
BG-12 240mg
TDS vs.
placebo: HR
(95% CI) 0.66
(0.48 to 0.92),
p=0.01;
24 months
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg vs.
placebo: HR
(95% CI) 0.95
(0.68 to 1.35),
p= 0.7620;
Teriflunomide
14mg vs.
placebo: HR
(95% CI) 0.68
(0.47 to 1.00),
p=0.0442
48 weeks
after the
last patient
was
included
Vollmer et al., J
Neurol 2014, phase
III (BRAVO study)
RRMS
(n=1331)
Laquinimod
0.6mg vs.
placebo: HR
(95% CI) 0.69
(0.46–1.02),
p=0.063;
IFN-beta 30
mcg IM vs.
placebo: HR
(95% CI0.74
(0.51–1.09),
p=0.13
24 months
% patients with
3-month CDP
Johnson et al.,
Neurology 1995,
RRMS
(n=251)
Glatiramer
acetate 20mg
24 months
22
phase III (The
Copolymer 1
Multiple Sclerosis
Study)
SC/day: 20.8%;
Placebo: 28.8%,
p=0.037
Jacobs et al., Ann
Neurol 1996, phase
III (MSCRG study)
Relapsing
MS (n=301)
IFN beta-1a
30mcg
IM/week:
21.9%;
Placebo: 34.9%,
p<0.05 (v)
104 weeks
Noseworthy et al.,
Neurology 2000,
phase III (linomide
study)
RMS (n=715) The study was
of insufficient
duration for
any of the
primary or
secondary
outcome
measures to
reach
significance
Early
termination
for safety
issues
(initially
planned: 36
months)
Polman et al., NEJM
2006, phase III
(AFFIRM study)
RRMS
(n=627)
Natalizumab
300mg/4
weeks: 17%, p
(vs. placebo)
<0.001;
Placebo: 29%
24 months
Rudick et al., NEJM
2006, phase III
(SENTINEL study)
RRMS
(n=1171)
Natalizumab
300mg/4 weeks
+ IFN beta-1a
IM
30mcg/week:
23%;
IFN beta-1a IM
30mcg/week:
29%, p=0.02
24 months
O’Connor et al.,
Lancet Neurol 2009,
phase III (BEYOND
study)
RRMS
(n=2244)
IFN beta-1b
500mcg SC EOD
at 2 years FU:
22%
IFN beta-1b
250mcg SC EOD
at 2 years FU:
21%;
GA 20mg
SC/day at 2
years FU: 20%,
p values (all
comparisons) >
0.05
24 months
O’Connor et al.,
NEJM 2011, phase
III (TEMSO study)
Relapsing
MS (n=1088)
Teriflunomide
7mg PO/day:
21.7 (17.1–
26.3), p (vs.
placebo) = 0.08;
Teriflunomide
14mg PO/day:
108 weeks
23
20.2 (15.6–
24.7), p (vs.
placebo) = 0.03;
Placebo: 27.3
(22.3–32.3)
Sorensen et al.,
Lancet Neurology
2011, phase 4
(SIMCOMBIN study)
RRMS
(n=307)
IFN beta-1a
30mcg
IM/week +
Placebo: 24%;
IFN beta-1a
30mcg
IM/week +
simvastatin
80mg/day:
28%, p=0.953
12 months
after last
patient was
included
Comi et al., NEJM
2012, phase III
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod
0.6mg OD:
11.1%, p (vs.
placebo) =0.01;
Placebo: 15.7%
24 months
Fox et al., NEJM
2012, phase III
(CONFIRM study)
RRMS
(n=1417)
BG-12 240mg
BD: 13%, p (vs.
placebo) >0.05;
BG-12 240mg
TDS: 13%, p (vs.
placebo) >0.05;
GA 40mg
SC/day: 16%, p
(vs. placebo)
>0.05;
Placebo: 17%
24 months
Gold et al., NEJM
2012, phase III
(DEFINE study)
RRMS
(n=1234)
BG-12 240mg
BD: 16%, p (vs.
placebo) =
0.005;
BG-12 240mg
TDS: 18%, p (vs.
placebo) = 0.01;
Placebo: 27%
24 months
Calabresi et al.
Lancet Neurol 2014,
phase III (ADVANCE
study)
RRMS
(n=1516)
Peginterferon
beta-1a
125μg/2 weeks 
SC vs. placebo:
0.068 (0.0119)
vs. 0.105
(0.0142),
p=0.0383;
Peginterferon
beta-1a
125μg/4 weeks 
SC vs. placebo:
0.068 (0.0119)
vs. 0.105
(0.0142),
p=0.0380 (e)
24 months
(but
primary
endpoint:
48 weeks,
which is the
placebo-
controlled
phase)
Massacesi et al., RRMS Azathioprine 24 months
24
PLoS ONE 2014,
phase III
(n=150) (target dose: 3
mg/kg/d) vs.
IFN beta (1a or
1b SC): 1.8% vs.
8%, p=0.19
Vollmer et al., J
Neurol 2014, phase
III (BRAVO study)
RRMS
(n=1331)
Laquinimod
0.6mg: 10%;
IFN-beta 30
mcg IM: 11%;
Placebo: 13%; p
(Laq vs.
placebo)=0.063;
p (IFN vs.
placebo)=0.13
24 months
Kappos et al., New
Engl J Med 2015,
phase III (DECIDE
study)
RRMS
(n=1841)
Daclizumab HYP
150mg/4 weeks
vs. IFN beta-1a
30mcg/week:
16% vs. 20%
(p=0.16)
144 weeks
Time to 6-
month CDP
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day vs.
placebo: HR
(95% CI) 0.63
(0.44 0.90), p =
0.01
Fingolimod
1.25mg/day vs.
placebo: HR
(95% CI) 0.60
(0.41 to 0.86), p
= 0.006
24 months
Sorensen et al.,
Lancet Neurology
2011, phase 4
(SIMCOMBIN study)
RRMS
(n=307)
IFN beta-1a
30mcg
IM/week +
simvastatin
80mg/day vs.
IFN beta-1a
30mcg
IM/week +
Placebo: HR
0.991, p=0.986
12 months
after last
patient was
included
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
IFN beta 1a
44mcg SC tiw
vs.
Alemtuzumab
12mg IV/day x
5 days: HR (95%
CI) 0.70 (0.40 to
1.23), p=0.22
24 months
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
IFN beta 1a
44mcg SC tiw
vs.
Alemtuzumab
12mg IV/day x
5 days: HR (95%
24 months
25
CI) 0.58 (0.38 to
0.87), p=0.0084
Comi et al., NEJM
2012, phase III
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod
0.6mg OD vs.
placebo: HR
(95% CI) 0.51
(0.34 to 0.79),
p=0.002
24 months
Vollmer et al., J
Neurol 2014, phase
III (BRAVO study)
RRMS
(n=1331)
Laquinimod
0.6mg vs.
placebo: HR
(95% CI) 0.610
(0.38 to 0.98),
p=0.042;
IFN-beta 30
mcg IM vs.
placebo: HR
(95% CI) 0.73
(0.47–1.14),
p=0.17
24 months
% patients with
6-month CDP
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
Alemtuzumab
12mg IV/day x
5 days: 8.00%
(95% CI 5.66 to
11.24);
IFN beta-1a
44mcg SC tiw:
11.12% (95% CI
7.32 to 16.71),
p=0.22
24 months
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
Alemtuzumab
12mg IV/day x
5 days: 12.71%
(95% CI 9.89 to
16.27);
IFN beta-1a
44mcg SC tiw:
21.13% (95% CI
15.95 to 27.68),
p=0.0084
24 months
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
IFN+GA: 23.9%
vs. IFN: 21.6%,
p>0.05
IFN+GA: 23.9%
vs. GA: 24.8%,
p>0.05
IFN: 21.6% vs.
GA: 24.8%,
p>0.05
36 months
after last
patient was
included
Vollmer et al., J
Neurol 2014, phase
III (BRAVO study)
RRMS
(n=1331)
Laquinimod
0.6mg: 7%;
IFN-beta 30
mcg IM: 8%;
Placebo: 10%; p
24 months
26
(Laq vs.
placebo)=0.042;
p (IFN vs.
placebo)=0.17
Lanzillo et al., Mult
Scler Journal 2015,
phase III (ARIANNA
study)
RRMS
(n=154)
IFN beta-1b SC
eod +
atorvastatin
40mg PO/day
vs.
IFN beta-1b SC
eod + placebo:
7.9 vs. 3.8,
p>0.05
24 months
% patients free
from EDSS
progression,
confirmed at 3
months
Johnson et al.,
Neurology 1995,
phase III (The
Copolymer 1
Multiple Sclerosis
Study)
RRMS
(n=251)
Glatiramer
acetate 20mg
SC/day: 78.4%,
Placebo: 75.4%,
p>0.05
24 months
(no MRI
results
published)
PRISMS (Prevention
of Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
IFN beta-1a
22mcg SC tiw: ~
60%, p (vs.
placebo) <0.05;
IFN beta-1a
44mcg SC tiw: ~
74%, p (vs.
placebo) <0.05;
Placebo: ~ 48%
24 months
Cohen et al., NEJM
2010, phase III
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod
0.5mg/day:
94.1% (91.8 to
96.3), p (vs.
IFN) = 0.25;
Fingolimod
1.25mg/day:
93.3% (90.9 to
95.8), p (vs.
IFN) = 0.50;
IFN beta-1a IM
30mcg/week:
92.1% (95% CI
89.4 to 94.7)
12 months
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day:
82.3% (78.6 to
86.1), p (vs.
placebo) = 0.03;
Fingolimod
1.25mg/day:
83.4% (79.7 to
87.1), p (vs.
placebo) = 0.01;
Placebo: 75.9%
(95% CI71.7 to
80.2)
24 months
Giovannoni et al., RRMS Cladribine 96 weeks
27
NEJM 2010, phase
III (CLARITY study)
(n=1326) 3.5mg/Kg:
85.7%, p (vs.
placebo) =0.02;
Cladribine
5.25mg/Kg:
84.9%, p (vs.
placebo) =0.03;
Placebo: 79.4%
Calabresi et al.,
Lancet Neurol 2014,
phase III
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod
0.5mg: 74.7%
(69.9 to 79.5);
Placebo: 71.0%
(65.9 to 76.1),
p=0.320
24 months
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg: 78.9%
(73.9 to 83.9),
p=0·7620;
Teriflunomide
14mg: 84.2%
(79.6 to 88.8),
p=0.0442;
Placebo: 80.3%
(75.9 to 84.8)
48 weeks
after the
last patient
was
included
% patients free
of EDSS
progression,
confirmed at 6
months
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day:
87.5% (84.7 to
90.7), p (vs.
placebo) = 0.01;
Fingolimod
1.25mg/day:
88.5% (85.3 to
91.6), p (vs.
placebo) =
0.004;
Placebo: 81.0%
(95% CI 77.1 to
84.9)
24 months
Calabresi et al.,
Lancet Neurol 2014,
phase III
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod
0.5mg: 86.2%
(82.3 to 90.0);
Placebo: 82.2%
(77.9 to 86.4),
p=0.101
24 months
Mikol et al., Lancet
Neurol 2014, phase
III (REGARD study)
RRMS
(n=764)
IFN beta-1a
44mcg SC tiw:
11.7%;
Glatiramer
acetate 20mg
SC/day: 8.7%,
p=0.117
96 weeks
% patients with
improvement
of EDSS after
24 months
Johnson et al.,
Neurology 1995,
phase III (The
Copolymer 1
Multiple Sclerosis
RRMS
(n=251)
Glatiramer
acetate 20mg
SC/day: 24.8%;
Placebo: 15.2%,
p=0.037
24 months
28
Study)
% patients with
sustained EDSS
reduction for 6
months
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
Alemtuzumab
12mg IV/day x
5 days: 28.82%
(95% CI 24.18
to 34.13);
IFN beta 1a
44mcg SC tiw:
12.93% (95% CI
8.34 to 19.77),
p=0.0002
24 months
MSFC Score at FU Comi et al., NEJM
2012, phase III
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod
0.6mg PO/day:
0.04 (-0.02 to
0.09);
Placebo: 0.06
(0.00 to 0.11),
p=0.59 (j)
24 months
Change in
MSFC z-score
from baseline
to follow-up (f)
(k)
Cohen et al., NEJM
2010, phase III
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod
0.5mg/day:
0.04 (SD 0.42),
p (vs. IFN) =
0.02;
Fingolimod
1.25mg/day:
0.08 (SD 0.46),
p (vs. IFN)
<0.001;
IFN beta-1a IM
30mcg/week: -
0.03 (SD 0.48)
12 months
Kappos et al., NEJM
2010, phase III
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod
0.5mg/day:
0.03 (SD 0.39),
p (vs. placebo)
= 0.01;
Fingolimod
1.25mg/day:
0.01 (SD 0.40),
p (vs. placebo)
= 0.02;
Placebo: -0.06
(SD 0.57)
24 months
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
Alemtuzumab
12mg IV/day x
5 days: 0·15 (SD
0·52);
IFN beta 1a
44mcg SC tiw:
0.07 (SD 0.45),
p=0.01
24 months
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
Alemtuzumab
12mg IV/day x
5 days: 0.08
(0.04 to 0.12);
IFN beta 1a
24 months
29
44mcg SC tiw: -
0.04 (95% CI -
0.10 to 0.02),
p=0.002;
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
IFN+GA: 0.1 (SD
0.5) vs. IFN: 0.1
(SD 0.5), p>0.05
IFN+GA: 0.1 (SD
0.5) vs. GA: 0.2
(SD 0.5), p>0.05
IFN: 0.1 (SD 0.5)
vs. GA: 0.2 (SD
0.5), p>0.05
36 months
after last
patient was
included
Calabresi et al.,
Lancet Neurol 2014,
phase III
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod
0.5mg PO/day:
0·00 (0·60);
Placebo: –0·07
(0·54), p=0·012
24 months
% patients with
decrease ≥20% 
in MSFC
Lanzillo et al., Mult
Scler Journal 2015,
phase III (ARIANNA
study)
RRMS
(n=154)
IFN beta-1b eod
SC +
atorvastatin
40mg PO/day:
0.08;
IFN beta-1b eod
SC + placebo:
0.09, p>0.05
24 months
Ambulation
index
Score at FU Johnson et al.,
Neurology 1995,
phase III (The
Copolymer 1
Multiple Sclerosis
Study)
RRMS
(n=251)
Glatiramer
acetate 20mg
SC/day: 0.27
(SE 0.94);
Placebo: 0.28
(SE 0.93),
p>0.05
24 months
PRISMS (Prevention
of Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
IFN beta-1a
44mcg SC tiw:
better than
placebo
(p<0.05); no
further details
given
24 months
% patients with
3-month CDP
(t)
PRISMS (Prevention
of Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
RRMS
(n=560)
IFN beta-1a
22mcg SC tiw:
12%, p>0.05
(vs. placebo);
IFN beta-1a
44mcg SC tiw:
7%, p≤0.05 (vs. 
placebo);
Placebo: 13%
24 months
Arm index Change from
baseline to FU
PRISMS (Prevention
of Relapses and
Disability by
Interferon beta-1a
Subcutaneously in
RRMS
(n=560)
IFN beta-1a
22mcg SC tiw,
IFN beta-1a
44mcg SC tiw,
placebo: no
24 months
30
Multiple Sclerosis)
Study Group, Lancet
1998, phase III
(PRISMS study)
changes in any
of the groups
(no differences
– no further
details given)
Rao’s Brief
Repeatable
Battery
% patients with
change in
cognitive
impairment (c)
Lanzillo et al., Mult
Scler Journal 2015,
phase III (ARIANNA
study)
RRMS
(n=154)
IFN beta-1b SC
eod +
atorvastatin
40mg/d: −37.1
IFN beta-1b SC
eod + placebo:
−35.2, p>0.05
24 months
No evidence of
clinical activity
(NECA)
% of patients
with no
evidence of
clinical activity
(no relapses
and no
progression of
disability)
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
Alemtuzumab
12mg IV/day x
5 days: 74%;
IFN beta 1a
44mcg SC tiw:
56%, p<0.0001
24 months
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
Alemtuzumab
12mg IV/day x
5 days: 60%;
IFN beta 1a
44mcg SC tiw:
41%, p<0.0001
24 months
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
IFN+GA: 45.4%
vs. IFN: 46.9%,
p=0.35;
IFN+GA: 45.4%
vs. GA: 47.4%,
p=0.35;
IFN: 46.9% vs.
GA: 47.4%,
p=0.92
36 months
after last
patient was
included
Unidimensional
Fatigue Impact
Scale (FIS or
UFIS)
Change from
baseline to FU
O’Connor et al.,
NEJM 2011, phase
III (TEMSO study)
Relapsing
MS (n=1088)
Teriflunomide
7mg PO/day:
2.3 (SD 1.6), p
(vs. placebo) =
0.39;
Teriflunomide
14mg PO/day:
3.8 (SD 1.7), p
(vs. placebo) =
0.83; Placebo:
4.3 (SD 1.7)
108 weeks
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg: 4.46
(1.66), p (vs.
placebo) =
0.3686;
Teriflunomide
14mg: 2.04
(1.68), p (vs.
placebo) =
0.0429;
48 weeks
after the
last patient
was
included
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Placebo:
6.31(1.67);
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
Teriflunomide
7mg: 0.97
(2.96), p (vs.
placebo) = 0.03;
Teriflunomide
14mg: 4.10
(3.03), p (vs.
placebo) = 0.18;
Placebo: 9.10
(SE 3.21)
48 weeks
after the
last patient
was
included
MSIS-29 % patients with
worsening in
MSIS-29 (global
score)
Kappos et al., New
Engl J Med 2015,
phase III (DECIDE
study)
RRMS
(n=1841)
Daclizumab HYP
150mg/4
weeks: 19%
IFN beta-1a
30mcg
IM/week: 23%
(d)
144 weeks
(this
outcome
was
evaluated at
96 weeks)
SF-36 Change in
physical
summary score
from baseline
to last FU
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg: -0.91
(0.44), p (vs.
placebo) =
0.1772;
Teriflunomide
14mg: -0.64
(0.44), p (vs.
placebo) =
0.0687;
Placebo: -1.63
(0.44)
48 weeks
after the
last patient
was
included
Change in
mental
summary score
from baseline
to last FU
Confavreux et al.,
Lancet Neurol 2014,
phase III (TOWER
study)
RRMS
(n=1169)
Teriflunomide
7mg: -1.70
(0.60), p (vs.
placebo) =
0.1363;
Teriflunomide
14mg: -1.09
(0.59), p (vs.
placebo) =
0.0224;
Placebo: -2.79
(0.59)
48 weeks
after the
last patient
was
included
TSQM Effectiveness
domain, score
at FU
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
Teriflunomide
7mg: 67.25 (SE
2.70), p (vs.
placebo) = 0.02;
Teriflunomide
14mg: 63.13 (SE
2.75), p (vs.
placebo) = 0.28;
Placebo: 59.30
(SE 2.97)
48 weeks
after the
last patient
was
included
Side-effects
domain, score
at FU
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
Teriflunomide
7mg: 95.29
(2.31), p (vs.
48 weeks
after the
last patient
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placebo)
<0.0001;
Teriflunomide
14mg: 93.15
(2.34), p (vs.
placebo) =
<0.0001;
Placebo: 71.38
(SE 2.50)
was
included
Convenience
domain, score
at FU
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
Teriflunomide
7mg: 88.30
(1.97), p (vs.
placebo)
<0.0001;
Teriflunomide
14mg: 89.85
(1.98), p (vs.
placebo)
<0.0001;
Placebo: 61.90
(SE 2.11)
48 weeks
after the
last patient
was
included
Global
satisfaction
domain, score
at FU
Vermersch et al.,
MSJ 2014, phase III
(TENERE study)
Relapsing
MS (n=324)
Teriflunomide
7mg: 68.29
(2.77), p (vs.
placebo) = 0.02;
Teriflunomide
14mg: 68.82
(2.78), p (vs.
placebo) = 0.02;
Placebo: 60.98
(SE 2.94)
48 weeks
after the
last patient
was
included
No evidence of
disease activity
(NEDA)
% of patients
with no
evidence of
disease activity
(no relapses +
no progression
of disability +
no MRI activity
(h))
Cohen et al., Lancet
2012, phase III
(CARE-MS I study)
RRMS
previously
untreated
(n=581)
IFN beta 1a
44mcg SC tiw:
27% vs.
Alemtuzumab
12mg IV/day x
5 days: 39%,
p=0.006
24 months
Coles et al., Lancet
2012, phase III
(CARE-MS II study)
RRMS
previously
treated
(n=840)
IFN beta 1a
44mcg SC tiw:
14% vs.
Alemtuzumab
12mg IV/day x
5 days: 32%,
p<0.0001
24 months
Lublin et al., Ann
Neurol 2013, phase
III (CombiRx study)
RRMS
(n=1008)
IFN+GA: 26.9%
vs. IFN: 17.1%,
p=0.002;
IFN+GA: 26.9%
vs. GA: 16.1%,
p=0.001;
IFN: 17.1% vs.
GA: 16.1%,
p=0.762
36 months
after last
patient was
included
33
Table footnote:
(a) ARR refers to mean ARR per each group; it includes confirmed relapse rate, which
includes rate of relapses with confirmed increase in EDSS (Voskuhl et al., Lancet
Neurol 2016) and also adjusted mean relapse rate (Vollmer et al., J Neurol 2014)
(b) No detailed figures provided
(c) Cognitive impairment was defined on the number of failed tests, as mild (one to
two tests failed) or moderate–severe (three or more tests failed)
(d) Defined as ≥7.5 points increase in MSIS-29 
(e) CDP: Confirmed disability progression was defined as an increase of Expanded
Disability Status Scale score of at least 1·0 point for patients with a baseline score of
1·0 or more, or an increase of at least 1·5 points for patients with a baseline score of
0, confirmed after 12 weeks. For the rest, EDSS increase of ≥1 point if EDSS ≤5.5; 
EDSS increase of ≥0.5 point if EDSS > 5.5;  
(f) Includes adjusted MSFC z-score; also it may include values obtained at an early
termination time point if this occurred after 12 months.
(g) Includes time to sustained accumulation of disability, which is considered as
increase in 1 point in EDSS sustained for a minimum of 12 weeks (Confavreux et al.,
Lancet Neurol 2014, TOWER trial)
(h) No MRI activity includes: no new/enlarging lesions and no gadolinium-enhancing
lesions
(i) Includes relapses requiring hospitalization/IV steroids (Comi et al., NEJM 2012,
ALLEGRO study)
(j) Adjusting for baseline values of MSFC z-score, ANCOVA model
(k) Mean change reported, unless otherwise specified
(l) It includes ‘at least 1 major relapse’
(m) The authors also estimated the proportion of patients with: i) at least one MS-
related admission to hospital; ii) at least 1 MS-rekated steroid course
(n) The results shown refer to the comparative phase (0-12m) of the trial, where half
of the patients were receiving IFN beta-1a IM 30mcg/week and the other half IFN
beta-1a SC 44mcg tiw.
(o) p-value not specified
(p) this analysis refers to disability progression in both hands
(q) worsening in 9HPT is defined as deterioration greater or equal to 20%
(r) confirmed at 2 months
(s) mean number of relapses per patient during the trial/2 years (duration of trial)
(t) defined as 2-step increase (sustained for 3 months)
(u) in this context, this outcome measure (risk ratio or odds ratio) is equivalent to
hazard ratio in the survival model
(v) timing for CDP not specified. Assumed 3 months
(w) this study looked at disability progression at the end of FU, so it is possible that
just progression confirmed at just 3 months is also included here
(x) This refers to McDonald 2005 criteria
Abbreviations. BD: twice per day; CDP: confirmed disability progression; CI:
confidence interval; eod: every other day; FU: follow-up; GA: glatiramer acetate; HR:
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hazard ratio; IA & AHSCT: immunoablation and autologous haemopoietic stem-cell
transplantation; IFN: interferon; IQR: interquartile range; MIU: million international
units; MSCT: mesenchymal stem cell transplantation; MSFC: Multiple Sclerosis
Functional Composite; MSIS-29: Multiple Sclerosis Impact Scale – 29 items; PO: per
oral; RFSS: Regional Functional System Score; SC: subcutaneous; SF-36: Short Form
36 Health Survey (SF-36); SNRS: Scripps Neurological Rating Scale; TDS: three times
per day; tiw: three times in a week; TSQM: Treatment Satisfaction Questionnaire for
Medication, with domains for Effectiveness, Side-Effects, Convenience and Global
Satisfaction
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Table 2: Clinical outcome measures in phase III trials in clinically isolated
syndromes (CIS)
Original clinical
outcome
Derived
outcome
measures
Trial Condition
(no. of
patients
randomised)
Drug, effect
(vs. placebo/
another active
arm)
Duration of
the trial
Relapses Time to
CDMS
Jacobs et al.,
NEJM 2000,
phase III
(CHAMPS
study)
CIS (n=383) IFN beta-1a
30mcg IM/week
vs. placebo: rate
ratio (95% CI) 0.56
(0.38 to 0.81),
p=0002
Early
termination:
obvious
superiority
of IFN over
placebo
(initially
planned: 36
months)
Comi et al.,
Lancet 2001,
phase III
(ETOMS
study)
CIS (n=308) IFN beta-1a
22mcg SC/week:
mean time (95%
CI) 569 days (317
to infinity) (30th
percentile);
Placebo: mean
time (95% CI) 252
days (173 to 413)
(30th percentile),
p= 0.034
24 months
Kappos et
al.,
Neurology
2006, phase
III (BENEFIT
study)
CIS (n=487) IFN beta-1b
250mcg SC/eod:
mean time: 618
days (25th
percentile), vs.
placebo: mean
time: 255 days
(25th percentile);
HR (95% CI) 0.50
(0.36 to 0.70),
p<0.0001
24 months
Comi et al.,
Lancet 2009,
phase III
(PreCISe
study)
CIS (n=481) GA 20mg SC/day
vs. placebo: HR
(95% CI) 0.55
(0.40 to 0.77),
p=0.0005
36 months
Comi et al.,
Lancet
Neurol 2012,
phase III
(REFLEX
study)
CIS (n=517) IFN beta-1a
44mcg SC/week
vs. placebo:
HR (95% CI) 0·53
(0·35 to 0·79), p =
0.0023;
IFN beta-1a
44mcg SC tiw vs.
placebo: HR (95%
CI) 0·48 (0·31 to
0·73), p = 0.0004;
IFN beta-1a
44mcg SC tiw vs.
108 weeks
36
IFN beta-1a
44mcg SC/week:
HR (95% CI) 0.90
(0.56 to 1.43), p =
0.7737
Leist et al.,
Lancet
Neurol 2014,
phase III
(ORACLE MS
study)
CIS (n=616) Cladribine
5.25mg/Kg vs.
placebo: HR
(95%CI): 0·38,
95% CI 0·25–0·58,
p<0·0001;
Cladribine
3.5mg/Kg vs.
placebo: HR
(95%CI): 0·33,
0·21–0·51,
p<0·0001
96 weeks
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
study)
CIS (n=618) Teriflunomide
7mg vs. placebo:
0·628 (0·416–
0·949), p=0.0271;
Teriflunomide
14mg vs. placebo:
0·574 (0·379–
0·869), p=0.0087
108 weeks
% patients
with CDMS
Jacobs et al.,
NEJM 2000,
phase III
(CHAMPS
study)
CIS (=383) IFN beta-1a
30mcg IM/week:
35%; Placebo:
50%, p=0002
Early
termination:
obvious
superiority
of IFN over
placebo
(initially
planned: 36
months)
Comi et al.,
Lancet 2001,
phase III
(ETOMS
study)
CIS (n=308) IFN beta-1a
22mcg SC/week:
34%; Placebo:
45% , p=0.047
24 months
Kappos et
al.,
Neurology
2006, phase
III (BENEFIT
study)
CIS (n=487) IFN beta-1b
250mcg SC/eod:
28%; Placebo:
45%, p<0.00001
24 months
Comi et al.,
Lancet
Neurol 2012,
phase III
(REFLEX
study)
CIS (n=517) IFN beta-1a
44mcg SC/week:
21.6%, p (vs.
placebo) = 0.0023;
IFN beta-1a
44mcg SC tiw:
20.6%, p (vs.
placebo) = 0.0004;
Placebo: 37.5%
108 weeks
Miller et al.,
Lancet
CIS (n=618) Teriflunomide
7mg: 19%, p (vs.
108 weeks
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Neurol 2014,
phase III
(TOPIC
study)
placebo) = 0.0271;
Teriflunomide
14mg: 18%, p (vs.
placebo) = 0.0087;
Placebo: 28%
Time to
McDonald
MS (x)
Kappos et
al.,
Neurology
2006, phase
III (BENEFIT
study)
CIS (n=487) IFN beta-1b
250mcg SC/eod
vs. placebo: HR
(95% CI) 0.54
(0.43 to 0.67),
p<0.00001
24 months
Comi et al.,
Lancet
Neurol 2012,
phase III
(REFLEX
study)
CIS (n=517) IFN beta-1a
44mcg SC/week
vs. placebo: HR
(95% CI) 0·69
(0·54–0·87), p =
0.0080; IFN beta-
1a 44mcg SC tiw
vs. placebo: HR
(95% CI) 0·49
(0·38–0·64),
p<0.0001; IFN
beta-1a 44mcg SC
tiw vs. IFN beta-1a
44mcg SC/week:
HR (95% CI) 0·71
(0·54–0·91), p =
0.0087
108 weeks
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
study)
CIS (n=618) Teriflunomide
7mg vs. placebo:
0·686 (0·540–
0·871), p=0.0020;
Teriflunomide
14mg vs. placebo:
0·651 (0·515–
0·822), p=0.0003
108 weeks
% patients
with
McDonald
MS (x)
Kappos et
al.,
Neurology
2006, phase
III (BENEFIT
study)
CIS (n=487) IFN beta-1b
250mcg SC/eod:
69%; Placebo:
85%, p<0.00001
24 months
Comi et al.,
Lancet
Neurol 2012,
phase III
(REFLEX
study)
CIS (n=517) IFN beta-1a
44mcg SC/week:
75.5%, p (vs.
placebo) = 0.0080;
IFN beta-1a
44mcg SC tiw:
62.5%, p (vs.
placebo) <0.0001;
Placebo: 85.8%
108 weeks
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
CIS (n=618) Teriflunomide
7mg: 62%, p (vs.
placebo) = 0.0020;
Teriflunomide
14mg: 64%, p (vs.
108 weeks
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study) placebo) = 0.0003;
Placebo: 76%
Mean
annualised
relapse rate
(a)
Comi et al.,
Lancet 2001,
phase III
(ETOMS
study)
CIS (n=308) IFN beta-1a
22mcg SC/week:
0.33; Placebo:
0.43, p=0.045
24 months
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
study)
CIS (n=618) Teriflunomide
7mg: 0·190
(0·139–0·260), p
(vs. placebo) =
0.0541;
Teriflunomide
14mg: 0·194
(0·143–0·263), p
(vs. placebo) =
0.0579; Placebo:
0·284 (0·214–
0·378)
108 weeks
% patients
with at
least 1
relapse (a)
(l)
Comi et al.,
Lancet 2009,
phase III
(PreCISe
study)
CIS (n=481) Placebo: 42.9%;
GA 20mg SC/day:
24.7%, p<0.0001
36 months
EDSS score Change in
EDSS score
from
baseline to
follow-up
(k)
Comi et al.,
Lancet 2001,
phase III
(ETOMS
study)
CIS (n=308) IFN beta-1a
22mcg SC/week:
median (IQR) 0 (-1
to 0); Placebo:
median (IQR) 0 (-1
to 0), p=0.521
24 months
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
study)
CIS (n=618) Teriflunomide
7mg: –0·250 (SD
0·937), p (vs.
placebo) = 0.0334;
Teriflunomide
14mg: –0·265 (SD
0·849), p (vs.
placebo) = 0.0443;
Placebo: –0·056
(SD 0·955)
108 weeks
Time to 3-
month CDP
(g)
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
study)
CIS (n=618) Teriflunomide
7mg PO vs.
Placebo: HR 0.978
(0.521–1.835),
p=0.9953;
Teriflunomide
14mg PO vs.
placebo: HR 0.701
(0.360–1.366),
p=0.4244
108 weeks
% patients
with 3-
month CDP
Comi et al.,
Lancet 2001,
phase III
(ETOMS
study)
CIS (n=308) IFN beta-1a
22mcg SC/week:
15%; Placebo:
20%, p-value not
specified
(probably not
24 months
39
significant) (w)
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
study)
CIS (n=618) Teriflunomide
7mg: 10%, p (vs.
placebo) = 0.9953;
Teriflunomide
14mg: 7%, p (vs.
placebo) = 0.4244;
Placebo: 10%
108 weeks
SNRS Change
from
baseline to
FU
Comi et al.,
Lancet 2001,
phase III
(ETOMS
study)
CIS (n=308) IFN beta-1a
22mcg SC/week:
median (IQR) 0 (-1
to 2); Placebo:
median (IQR) 0 (-1
to 2), p=0.747
24 months
Unidimensional
Fatigue Impact
Scale (FIS or
UFIS)
Change
from
baseline to
FU
Miller et al.,
Lancet
Neurol 2014,
phase III
(TOPIC
study)
CIS (n=618) Teriflunomide
7mg: –2·730 (SD
30·410), p (vs.
placebo) = 0.9974;
Teriflunomide
14mg: –4·487 (SD
32·519), p (vs.
placebo) = 0.8492;
Placebo: –3·535
(29·298);
108 weeks
Table footnote:
(a) ARR refers to mean ARR per each group; it includes confirmed relapse rate, which
includes rate of relapses with confirmed increase in EDSS (Voskuhl et al., Lancet
Neurol 2016) and also adjusted mean relapse rate (Vollmer et al., J Neurol 2014)
(b) No detailed figures provided
(c) Cognitive impairment was defined on the number of failed tests, as mild (one to
two tests failed) or moderate–severe (three or more tests failed)
(d) Defined as ≥7.5 points increase in MSIS-29 
(e) CDP: Confirmed disability progression was defined as an increase of Expanded
Disability Status Scale score of at least 1·0 point for patients with a baseline score of
1·0 or more, or an increase of at least 1·5 points for patients with a baseline score of
0, confirmed after 12 weeks. For the rest, EDSS increase of ≥1 point if EDSS ≤5.5; 
EDSS increase of ≥0.5 point if EDSS > 5.5;  
(f) Includes adjusted MSFC z-score; also it may include values obtained at an early
termination time point if this occurred after 12 months.
(g) Includes time to sustained accumulation of disability, which is considered as
increase in 1 point in EDSS sustained for a minimum of 12 weeks (Confavreux et al.,
Lancet Neurol 2014, TOWER trial)
(h) No MRI activity includes: no new/enlarging lesions and no gadolinium-enhancing
lesions
(i) Includes relapses requiring hospitalization/IV steroids (Comi et al., NEJM 2012,
ALLEGRO study)
(j) Adjusting for baseline values of MSFC z-score, ANCOVA model
(k) Mean change reported, unless otherwise specified
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(l) It includes ‘at least 1 major relapse’
(m) The authors also estimated the proportion of patients with: i) at least one MS-
related admission to hospital; ii) at least 1 MS-rekated steroid course
(n) The results shown refer to the comparative phase (0-12m) of the trial, where half
of the patients were receiving IFN beta-1a IM 30mcg/week and the other half IFN
beta-1a SC 44mcg tiw.
(o) p-value not specified
(p) this analysis refers to disability progression in both hands
(q) worsening in 9HPT is defined as deterioration greater or equal to 20%
(r) confirmed at 2 months
(s) mean number of relapses per patient during the trial/2 years (duration of trial)
(t) defined as 2-step increase (sustained for 3 months)
(u) in this context, this outcome measure (risk ratio or odds ratio) is equivalent to
hazard ratio in the survival model
(v) timing for CDP not specified. Assumed 3 months
(w) this study looked at disability progression at the end of FU, so it is possible that
just progression confirmed at just 3 months is also included here
(x) This refers to McDonald 2005 criteria
Abbreviations. BD: twice per day; CDP: confirmed disability progression; CI:
confidence interval; eod: every other day; FU: follow-up; GA: glatiramer acetate; HR:
hazard ratio; IA & AHSCT: immunoablation and autologous haemopoietic stem-cell
transplantation; IFN: interferon; IQR: interquartile range; MIU: million international
units; MSCT: mesenchymal stem cell transplantation; MSFC: Multiple Sclerosis
Functional Composite; MSIS-29: Multiple Sclerosis Impact Scale – 29 items; PO: per
oral; RFSS: Regional Functional System Score; SC: subcutaneous; SF-36: Short Form
36 Health Survey (SF-36); SNRS: Scripps Neurological Rating Scale; TDS: three times
per day; tiw: three times in a week; TSQM: Treatment Satisfaction Questionnaire for
Medication, with domains for Effectiveness, Side-Effects, Convenience and Global
Satisfaction
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Table 3: Clinical outcome measures in phase III trials in progressive MS
Original clinical
outcome
Derived outcome
measures
Trial Condition (no. of
patients
randomised)
Drug, effect
(vs. placebo/
another active
arm)
Duration of the
trial
Relapses Mean annualised
relapse rate (a)
European Study
Group on IFN
beta-1b in SPMS,
Lancet 1998,
phase III (EUSPMS
study)
SPMS (n=718) IFN beta-1b 8
million IU eod:
0.44; Placebo:
0.64, p=0.0002
Early termination:
obvious
superiority of IFN
vs. placebo
(initially planned:
39 months)
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw:
0.50 (0.44 to
0.56), p (vs.
placebo) <0.001;
IFN beta-1a
44mcg SC tiw:
0.50 (0.45 to
0.56), p (vs.
Placebo) <0.001;
Placebo: 0.71
(0.65 to 0.78)
36 months
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week:
0.25;
Placebo: 0.27,
p=0.55
36 months
Hommes et al.,
Lancet 2004,
phase III (ESIMS
study)
SPMS (n=318) IVIG
1g/Kg/month:
0.46
Placebo: 0.46,
p>0.05
24 months
North American
Study Group on
IFN beta-1b in
SPMS, Neurology
2004, phase III
(NASPMS study)
SPMS (n=939) Pooled IFN beta-
1b (250mcg SC
eod or
160mcg/m2 SC
eod) vs. placebo:
reduction of ARR
in 36%, p<0.05
Early termination
for futility
(initially planned:
36 months)
Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months:
0.13;
Placebo: 0.14,
p=0.633
24 months
Mean annualised
severe relapse
rate (i)
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw:
0.26 (0.22 to
0.31), p (vs.
placebo) = 0.002;
IFN beta-1a
36 months
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44mcg SC tiw:
0.27 (0.23 to
0.31), p (vs.
placebo) = 0.003;
Placebo: 0.39
(0.34 to 0.44);
% patients with
at least 1 relapse
(a) (l)
Hommes et al.,
Lancet 2004,
phase III, (ESIMS
study)
SPMS (n=318) IVIG
1g/Kg/month:
48.4%, p=0.58
Placebo: 52.2%
24 months
% relapse-free
patients at the
end of FU
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week:
61%;
Placebo: 62%,
p=0.89
36 months
North American
Study Group on
IFN beta-1b in
SPMS, Neurology
2004, phase III
(NASPMS study)
SPMS (n=939) IFN beta-1b
250mcg SC eod:
71%, p (vs.
Placebo) =0.018;
Placebo: 62%
Early termination
for futility
(initially planned:
36 months)
Time to first
confirmed
relapse
European Study
Group on IFN
beta-1b in SPMS,
Lancet 1998,
phase III (EUSPMS
study)
SPMS (n=718) Median time:
Placebo: 403
days; IFN beta-1b
8 million IU eod:
644 days,
p=0.0083
39 months
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw vs.
placebo: HR =
0.87 (0.69 to
1.10), p=0.237;
IFN beta-1a
44mcg SC tiw vs.
placebo: HR 0.77
(0.61 to 0.98),
p=0.034;
36 months
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo: no
differences (not
specified)
36 months
North American
Study Group on
IFN beta-1b in
SPMS, Neurology
2004, phase III
(NASPMS study)
SPMS (n=939) Placebo: 487 days
(30th percentile)
IFN beta-1b
250mcg SC eod:
1051 days (30th
percentile),
p=0.010
Early termination
for futility
(initially planned:
36 months)
Time between
first and second
relapse
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
SPMS (n=618) IFN beta-1a
22mcg SC tiw vs.
placebo: HR =
36 months
43
study) 0.50 (0.37 to
0.69), p < 0.001;
IFN beta-1a
44mcg SC tiw vs.
placebo: HR =
0.60 (0.44 to
0.81), p = 0.001;
Mean annualised
hospitalisation
rate due to MS
exacerbations
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw:
0.14 (0.11 to
0.17), p (vs.
placebo) = 0.006;
IFN beta-1a
44mcg SC tiw:
0.15 (0.12 to
0.18), p (vs.
placebo) = 0.005;
Placebo: 0.22
(0.18 to 0.26);
36 months
Mean annualised
rate of steroid
courses
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw:
0.31 (0.27 to
0.36), p (vs.
placebo) = 0.001;
IFN beta-1a
44mcg SC tiw:
0.34 (0.30 to
0.39), p (vs.
placebo) = 0.006;
Placebo: 0.52
(0.46 to 0.58);
36 months
EDSS score Score at FU European Study
Group on IFN
beta-1b in SPMS,
Lancet 1998,
phase III (EUSPMS
study)
SPMS (n=718) IFN beta-1b 8
million IU eod:
5.57; placebo:
5.84, p=0.0750
39 months
Change in EDSS
score from
baseline to
follow-up (k)
European Study
Group on IFN
beta-1b in SPMS,
Lancet 1998,
phase III (EUSPMS
study)
SPMS (n=718) IFN beta-1b 8
million IU eod:
0.47;
Placebo: 0.60,
p=0.0299
39 months
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo: mean
change 0.258 vs.
0.272,
respectively,
p=0.362
24 months
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo: no
36 months
44
SPMS study) differences (no
further details
given)
Hommes et al.,
Lancet 2004,
phase III, (ESIMS
study)
SPMS (n=318) IVIG
1g/Kg/month:
median change
(range): 0.5 (-3.0
to 5.0); Placebo:
0.5 (-3.0 to 5.0),
p>0.05
24 months
North American
Study Group on
IFN beta-1b in
SPMS, Neurology
2004, phase III
(NASPMS study)
SPMS (n=939) Pooled IFN beta-
1b (250mcg SC
eod or
160mcg/m2 SC
eod) vs. placebo:
no difference (no
further details
given)
Early termination
for futility
(initially planned:
36 months)
Wolinsky et al.,
Ann Neurol 2007,
phase III
(PROMiSe study)
PPMS (n=943) GA 20mg SC/day:
0.58 (SD 1.00);
Placebo: HR (95%
CI): 0.61 (SD
1.13), p>0.05
Early termination
for futility
(initially planned:
36 months)
Hawker et al., Ann
Neurol 2009,
phase II/3
(OLYMPUS study)
PPMS (n=439) Rituximab
1000mg IV/24
weeks: 0.33 (1.0);
Placebo: 0.45 (SD
1.0), p=0.34
96 weeks
Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months: 0.22
(SE 0.06);
Placebo: 0.17 (SE
0.06), p=0.465
24 months
Time to EDSS 7.0 European Study
Group on IFN
beta-1b in SPMS,
Lancet 1998,
phase III (EUSPMS
study)
SPMS (n=718) IFN beta-1b 8
million IU eod vs.
placebo: OR (95%
CI) 0.66 (0.47 to
0.93), p=0.0133
39 months
Time to 3-month
CDP (g)
European Study
Group on IFN
beta-1b in SPMS,
Lancet 1998,
phase III (EUSPMS
study)
SPMS (n=718) IFN beta-1b 8
million IU eod vs.
placebo: odds
ratio of 0.65 (95%
CI 0.52–0.83), p
=0.0008 (u)
39 months
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw vs.
placebo: HR 0.88,
p = 0.305; IFN
beta-1a 44mcg SC
tiw vs. placebo:
HR (95% CI) 0.83
36 months
45
(0.65 to 1.07),
p=0.146
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo: HR
(95% CI): 0.977
(0.679 to 1.407),
p=0.90
24 months
Hommes et al.,
Lancet 2004,
phase III, (ESIMS
study)
SPMS (n=318) IVIG 1g/Kg/month
vs. placebo: HR
(95% CI) 1.11(0.80
to 1.53), p=0.53;
24 months
Wolinsky et al.,
Ann Neurol 2007,
phase III
(PROMiSe study)
PPMS (n=943) GA 20mg SC/day
vs. placebo: HR
(95% CI) 0.87
(0.71 to 1.07),
p=0.1753
36 months
Hawker et al., Ann
Neurol 2009,
phase II/3
(OLYMPUS study)
PPMS (n=439) Rituximab
1000mg IV/24
weeks vs.
placebo: HR (95%
CI) 0.77 (0.55 to
1.09), p=0.1442
96 weeks
Lublin et al.,
Lancet 2016,
INFORMS study,
phase III
PPMS (n=970) Fingolimod
0.5mg/d vs.
placebo: HR (95%
CI) 0.88 (0.71 to
1.08), p=0.217
36 months
Montalban et al.,
N Engl J Med.
2016 (ORATORIO
study)
PPMS (n=732) Ocrelizumab
600mg (300mg
x2) /24 weeks IV
vs. placebo:
HR=0.76;
p=0.0321
120 weeks
% patients with
3-month CDP
European Study
Group on IFN
beta-1b in SPMS,
Lancet 1998,
phase III (EUSPMS
study)
SPMS (n=718) IFN beta-1b 8
million IU eod:
38.9%;
Placebo: 49.7%, p
=0.0048
39 months
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw: no
differences vs.
placebo (no more
details reported);
IFN beta-1a
44mcg SC tiw: no
differences vs.
placebo (no more
details reported)
36 months
Hommes et al.,
Lancet 2004,
SPMS (n=318) IVIG
1g/Kg/month:
24 months
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phase III (ESIMS
study)
48.4%;
Placebo: 44%,
p=0.53
Wolinsky et al.,
Ann Neurol 2007,
phase III
(PROMiSe study)
PPMS (n=943) GA 20mg SC/day:
39.6%;
Placebo: 45.2%,
p>0.05
36 months
Hawker et al., Ann
Neurol 2009,
phase II/3
(OLYMPUS study)
PPMS (n=439) Placebo: 38.5%;
Rituximab
1000mg IV/24
weeks: 30.2%,
p=0.1442
96 weeks
Lublin et al.,
Lancet 2016,
INFORMS study,
phase III
PPMS (n=970) Fingolimod
0.5mg/d vs.
placebo: 54.3%
(47.16–61.45) vs.
58.7% (53.30–
64.18), p>0.05
36 months
Time to 6-month
CDP
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo: HR (95%
CI) 1.13 (0.82 to
1.57), p=0.45
36 months
North American
Study Group on
IFN beta-1b in
SPMS, Neurology
2004, phase III
(NASPMS study)
SPMS (n=939) Pooled IFN beta-
1b (250mcg SC
eod or
160mcg/m2 SC
eod) vs. placebo:
no difference,
p=0.712
Early termination
for futility
(initially planned:
36 months)
Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months vs.
placebo: HRs not
reported, but not
significant
24 months
Zajicek et al.,
Lancet Neurol
2013, phase
unspecified
(CUPID study)
PPMS (n=191),
SPMS (n=302)
(randomised:
n=498)
Dronabinol (max.
dose: 28mg/day,
titrated against
bodyweight) vs.
placebo: HR (95%
CI) 0.92 (0.68 to
1.23), p=0.57
36 months
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod
0.5mg/d vs.
placebo: HR (95%
CI) no different
from 1.0 (p>0.05,
data not shown,
no further details
given)
36 months
Montalban et al.,
N Engl J Med.
PPMS (n=732) Ocrelizumab
600mg (300mg
120 weeks
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2016 (ORATORIO
study)
x2) /24 weeks IV
vs. placebo: HR=
0.75; p=0.0365
% patients with
6-month CDP
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week:
41%;
Placebo: 38%,
p=0.45
36 months
Hawker et al., Ann
Neurol 2009,
phase II/3
(OLYMPUS study)
PPMS (n=439) Rituximab
1000mg IV/24
weeks: 27.3%;
Placebo: 30.4%,
p=0.59
96 weeks
Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months:
30.7%;
Placebo: 27.8%,
p=0.527 (in
patients DR2+ or
DR4+)
24 months
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod
0.5mg/d vs.
placebo: similar
percentages
(p>0.05, data not
shown, no further
details given)
36 months
IDSS: Integrated
Disability Status
Score (IDSS,
defined by area
under an EDSS
time-curve
adjusted for
baseline
SPECTRIMS study
group, Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a
22mcg SC tiw: no
differences vs.
placebo (no more
details reported);
IFN beta-1a
44mcg SC tiw: no
differences vs.
placebo (no more
details reported)
36 months
TWT z-score Change in TWT z-
score from
baseline to FU
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo (SD):
0.979 (2.62) vs.
1.191 (3.13),
p=0.378
24 months
Hawker et al., Ann
Neurol 2009,
phase II/3
(OLYMPUS study)
PPMS (n=439) Rituximab
1000mg IV/24
weeks: (median) -
0.08;
Placebo: (median)
-0.14 (greater
worsening than
rituximab arm),
p=0.015
96 weeks
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Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months:
0.99;
Placebo: 1.57,
p=0.096
24 months
Time to 3-month
CDP
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day vs.
placebo: HR (95%
CI) 0.94 (0.78 to
1.14), p=0.546;
36 months
% patients with
3-month CDP
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod
0.5mg/d: 62.9%
(57.10 to 68.62)
Placebo: 70.0%
(61.78 to 78.21),
p=0.546
36 months
Montalban et al.,
N Engl J Med.
2016 (ORATORIO
study)
PPMS (n=732) Ocrelizumab
600mg (300mg
x2) /24 weeks IV
vs. placebo: 39%
vs. 55%, p=0.0404
120 weeks
Time to 6-month
CDP
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day vs.
placebo: similar
to 3-month CDP
analysis (no
further details
given)
36 months
% patients with
6-month CDP
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day vs.
placebo: similar
to 3-month CDP
analysis (no
further details
given)
36 months
9HPT z-score Change in 9HPT z-
score from
baseline to FU
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo: 0.202
(SD 0.476) vs.
0.290 (SD 0.494),
p=0.024
24 months
Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months: -
0.08;
Placebo: -0.04,
p=0.537
24 months
Time to 3-month
CDP
Hommes et al.,
Lancet 2004,
phase III, (ESIMS
study) (q)
SPMS (n=318) IVIG 1g/Kg/month
vs. placebo: HR
(95% CI) 1.09
(0.75 to 1.59),
p=0.67
24 months
Lublin et al., PPMS (n=970) Fingolimod 0.5mg 36 months
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Lancet 2016
(INFORMS study)
PO/day vs.
placebo: HR (95%
CI) 0·93 (0·71–
1·22), p=0·607;
% patients with
3-month CDP
Hommes et al.,
Lancet 2004,
phase III, (ESIMS
study) (q)
SPMS (n=318) IVIG 1g/Kg/month
vs. placebo:
34.6%;
Placebo: 33.3%,
p=0.67 (p)
24 months
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day: 33.6%
(26.11–41.08);
Placebo: 41.3%
(32.10–50.55), p=
0.607
36 months
Time to 6-month
CDP
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day vs.
placebo: similar
to 3-month CDP
analysis (no
further details
given)
36 months
% patients with
6-month CDP
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day vs.
placebo: similar
to 3-month CDP
analysis (no
further details
given)
36 months
PASAT z-score Change from
baseline to FU
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo: 0.094
(SD 0.498) vs.
0.004 (SD 0.473),
p=0.061
24 months
Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months:
0.24;
Placebo: 0.17,
p=0.393
24 months
MSFC Change in MSFC
z-score from
baseline to
follow-up (f) (k)
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo: 0.362
(SD 1.41) vs.
0.495 (SD 1.58),
p=0.033
24 months
Wolinsky et al.,
Ann Neurol 2007,
phase III
(PROMiSe study)
PPMS (n=943) GA 20mg SC/day
vs. placebo: no
differences
between groups
(no further details
given)
36 months
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Hawker et al., Ann
Neurol 2009,
phase II/3
(OLYMPUS study)
PPMS (n=439) Rituximab
1000mg IV/24
weeks: median
change -0.06;
Placebo: median
change -0.10,
p=0.089
96 weeks
Freedman et al.,
Neurology 2011,
phase III
(MAESTRO study)
SPMS (n=612) MBP8298 500mg
IV/6 months: -
0.28;
Placebo: -0.46,
p=0.137
24 months
Zajicek et al.,
Lancet Neurol
2013, phase
unspecified
(CUPID study)
PPMS (n=191),
SPMS (n=302)
(randomised:
n=498)
Dronabinol [max.
dose: 28mg/day,
titrated against
bodyweight]:
yearly change –
0·17 (SD 0·28);
Placebo: yearly
change –0·16 (SD
0·30), p=0.72
36 months
RFSS Change from
baseline to FU
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo: no
differences (not
specified)
36 months
Time to an
increase ≥ 2% in 
RFSS score
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo:
HR (95% CI) 0.93
(0.68 to 1.28),
p=0.67
36 months
% patients with
an increase ≥ 2%
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week:
44%;
Placebo: 44%,
p=0.45
36 months
Ambulation index Change from
baseline to FU
Andersen et al.,
JNNP 2004, phase
III (Nordic SPMS
study)
SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo: no
differences (not
specified)
36 months
Arm index Change from
baseline to FU
Andersen et al.,
JNNP 2004, phase
III (The Nordic
SPMS study)
SPMS (n=371) IFN beta-1a SC
22mcg/week vs.
placebo: no
differences (not
specified)
36 months
Rao’s Brief
Repeatable
Battery
% patients with
change in
cognitive
impairment (c)
North American
Study Group on
IFN beta-1b in
SPMS, Neurology
2004, phase III
SPMS (n=939) Pooled IFN beta-
1b (250mcg SC
eod or
160mcg/m2 SC
eod) vs. placebo:
Early termination
for futility
(initially planned:
36 months)
51
(NASPMS study) no difference (not
specified)
Composite
progressive
disability score
Time to CDP,
defined as
presence of at
least 1 out of the
3:
-Increase in EDSS
(0.5 if EDSS≤5.5; 
1.0 if EDSS >6.0)
-Increase in ≥20% 
in 9HPT
-Increase ≥20% in 
TWT
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day: 62.9%
(57.10–68.62);
Placebo: 70.0%
(61.78–78.21),
p>0.05
36 months
% patients with
at least one of
the three
situations
(confirmed at
3m):
-Increase in EDSS
(0.5 if EDSS≤5.5; 
1.0 if EDSS >6.0)
-Increase in ≥20% 
in 9HPT
-Increase ≥20% in 
TWT
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
PO/day: 62.9%
(57.10–68.62);
Placebo: 70.0%
(61.78–78.21),
p>0.05
36 months
Time to 3-month
CDP, using EDSS
or 9HPT (q)
Hommes et al.,
Lancet 2004,
phase III, (ESIMS
study)
SPMS (n=318) IVIG 1g/Kg/month
vs. placebo: HR
(95% CI) 1.12
(0.84 to 1.49),
p=0.44
24 months
% of patients
with 3-month
CDP, using EDSS
or 9HPT (q)
Hommes et al.,
Lancet 2004,
phase III, (ESIMS
study)
SPMS (n=318) Placebo: 57.9%
IVIG 1g/Kg/month
vs. placebo:
61.6%, p=0.44
24 months
Multiple Sclerosis
Walking Scale
(MSWS-12)
Change from
baseline to FU
Zajicek et al.,
Lancet Neurol
2013, phase
unspecified
(CUPID study)
PPMS (n=191),
SPMS (n=302)
(received
treatment: n=493;
randomised:
n=498)
Dronabinol [max.
dose: 28mg/day,
titrated against
bodyweight]:
yearly change
0.37 (SD 2.33);
Placebo: yearly
change 0.52
(2.68); p=0.74
36 months
MSIS-29 Change from
baseline to FU
(physical score)
Zajicek et al.,
Lancet Neurol
2013, phase
unspecified
(CUPID study)
PPMS (n=191),
SPMS (n=302)
(received
treatment: n=493;
randomised:
n=498)
Dronabinol [max.
dose: 28mg/day,
titrated against
bodyweight]:
yearly change
0.62 (SD 3.29);
Placebo: yearly
change 1.03 (SD
36 months
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3.74); p=0.11
Table footnote:
(a) ARR refers to mean ARR per each group; it includes confirmed relapse rate, which
includes rate of relapses with confirmed increase in EDSS (Voskuhl et al., Lancet
Neurol 2016) and also adjusted mean relapse rate (Vollmer et al., J Neurol 2014)
(b) No detailed figures provided
(c) Cognitive impairment was defined on the number of failed tests, as mild (one to
two tests failed) or moderate–severe (three or more tests failed)
(d) Defined as ≥7.5 points increase in MSIS-29 
(e) CDP: Confirmed disability progression was defined as an increase of Expanded
Disability Status Scale score of at least 1·0 point for patients with a baseline score of
1·0 or more, or an increase of at least 1·5 points for patients with a baseline score of
0, confirmed after 12 weeks. For the rest, EDSS increase of ≥1 point if EDSS ≤5.5; 
EDSS increase of ≥0.5 point if EDSS > 5.5;  
(f) Includes adjusted MSFC z-score; also it may include values obtained at an early
termination time point if this occurred after 12 months.
(g) Includes time to sustained accumulation of disability, which is considered as
increase in 1 point in EDSS sustained for a minimum of 12 weeks (Confavreux et al.,
Lancet Neurol 2014, TOWER trial)
(h) No MRI activity includes: no new/enlarging lesions and no gadolinium-enhancing
lesions
(i) Includes relapses requiring hospitalization/IV steroids (Comi et al., NEJM 2012,
ALLEGRO study)
(j) Adjusting for baseline values of MSFC z-score, ANCOVA model
(k) Mean change reported, unless otherwise specified
(l) It includes ‘at least 1 major relapse’
(m) The authors also estimated the proportion of patients with: i) at least one MS-
related admission to hospital; ii) at least 1 MS-rekated steroid course
(n) The results shown refer to the comparative phase (0-12m) of the trial, where half
of the patients were receiving IFN beta-1a IM 30mcg/week and the other half IFN
beta-1a SC 44mcg tiw.
(o) p-value not specified
(p) this analysis refers to disability progression in both hands
(q) worsening in 9HPT is defined as deterioration greater or equal to 20%
(r) confirmed at 2 months
(s) mean number of relapses per patient during the trial/2 years (duration of trial)
(t) defined as 2-step increase (sustained for 3 months)
(u) in this context, this outcome measure (risk ratio or odds ratio) is equivalent to
hazard ratio in the survival model
(v) timing for CDP not specified. Assumed 3 months
(w) this study looked at disability progression at the end of FU, so it is possible that
just progression confirmed at just 3 months is also included here
(x) This refers to McDonald 2005 criteria
53
Abbreviations. BD: twice per day; CDP: confirmed disability progression; CI:
confidence interval; eod: every other day; FU: follow-up; GA: glatiramer acetate; HR:
hazard ratio; IA & AHSCT: immunoablation and autologous haemopoietic stem-cell
transplantation; IFN: interferon; IQR: interquartile range; MIU: million international
units; MSCT: mesenchymal stem cell transplantation; MSFC: Multiple Sclerosis
Functional Composite; MSIS-29: Multiple Sclerosis Impact Scale – 29 items; PO: per
oral; RFSS: Regional Functional System Score; SC: subcutaneous; SF-36: Short Form
36 Health Survey (SF-36); SNRS: Scripps Neurological Rating Scale; TDS: three times
per day; tiw: three times in a week; TSQM: Treatment Satisfaction Questionnaire for
Medication, with domains for Effectiveness, Side-Effects, Convenience and Global
Satisfaction
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Table 4: Brain MRI outcome measures in phase III trials in relapsing-remitting MS
Brain MRI
Inclusion criteria: controlled phase III clinical trials
Exclusion criteria: incomplete data presentation (e.g. missing values); descriptive findings in absence
of any statistical analysis; secondary analyses of clinical trials and extension studies evaluating the
same clinical endpoints of the main trial in population subgroups or during longer observation time.
Original
neuroimaging
outcome
Derived
outcome
measures
Trial Condition
(no. of
patients
randomised)
Drug, effect
(vs. placebo/ another
active arm)
Duration of
the trial
T2 lesions Number of
new lesions
The Interferon beta
Multiple Sclerosis
Study group; Paty et
al., Neurology 1993
(Interferon beta
Multiple Sclerosis
Study Group)
RRMS
(n=372)
Interferon beta-1b vs.
Placebo, median new
lesion rate 0.5 vs. 2.0
(p=0.0026)
24 months
Comi et al., Ann
Neurol 2001
(European/Canadian
Glatiramer Acetate
Study)
RRMS
(n=249)
Glatiramer Acetate vs.
Placebo, number of
lesions 9.4 vs. 13.7
(p<0.003) after 9 months
9 months
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
number of lesions 1.1 vs.
5.8 after 1 year
(p<0.001), 0.7 vs. 4.4
after 2 years (p<0.001),
and 1.8 vs. 10.2 overall
(p<0.001)
24 months
O'Connor et al.,
Lancet Neurol 2009
(BEYOND study)
RRMS
(n=2244)
Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, number of
lesions 3.3 vs. 3.3 vs. 4.6
after 2 years (p=0.25;
p=0.0009; p=0.011)
24 months
Comi et al., Ann
Neurol 2011
(FORTE study)
RRMS
(n=980)
Glatiramer Acetate 20mg
vs. 40mg, number of
lesions 2.87 vs. 2.72 (ns)
after 12 months
12 months
Number of
enlarging
lesions
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
number of lesions 0.1 vs.
0.4 after 1 year
(p<0.001), 0.0 vs. 0.4
after 2 years (p<0.001),
and 0.1 vs. 0.8 overall
(p<0.001)
24 months
Number of
new or
enlarging
lesions
PRISMS Study
Group, Lancet 1998;
Li et al., Ann Neurol
1999
(PRISMS study)
RRMS
(n=560)
Interferon beta-1a 44μg 
vs. 22μg vs. Placebo, 
percent difference
compared to Placebo -
67% and -78% (p<0.0001)
after 2 years; median
number of lesions per
patient per scan 0.5 vs. -
24 months
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0.75 vs. 2.25 (p=0.0003;
p<0.0001; p<0.0001) after
6 months; percent of
scans with lesions 25% vs.
50% vs. 75% (p=0.0002;
p<0.0001; p<0.0001) after
6 months; and percent of
patients without lesions
31% vs. 19% vs. 8%
(p=0.0009; p<0.0001;
p<0.0001) after 6 months
Jacobs et al., New
Eng J Med 2000
(CHAMPS study)
CIS (n=383) Interferon beta-1a 30μg 
vs. Placebo, number of
lesions 1.5 vs. 2.8 after 6
months (p=0.01), 2.1 vs.
4.0 after 12 months
(p<0.001), 2.1 vs. 5.0 after
18 months (p<0.001)
Early
termination:
obvious
superiority
of IFNb over
placebo
(initially
planned: 36
months)
Comi et al., Lancet
2001
(ETOMS study)
CIS (n=309) Interferon beta-1a 22μg 
vs. Placebo, median
number of lesions per
patient per scan 2.0 vs.
3.0 after 2 years
(p<0.001)
24 months
Panitch et al.,
Neurology 2002;
Panitch et al., J
Neurol Sci. 2005
(EVIDENCE study)
RRMS
(n=677)
Interferon beta-1a 44μg 
vs. 30μg, number of 
lesions 0.9 vs. 1.4
(p<0.001), percent of
scans with lesions 27% vs.
44% (p<0.001), percent of
patients with no lesions
58% vs. 38% (p<0.001)
after 16 months
24 months
(0-12m:
comparative
phase; 12-
24m: cross-
over phase)
Polman et al., New
Eng J Neurol 2006
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
number of lesions 1.2 vs.
6.1 after 1 year
(p<0.001), 0.7 vs. 4.9
after 2 years (p<0.001),
and 1.9 vs. 11.0 overall
(p<0.001)
24 months
Rudick et al., New
Eng J Med 2006
(SENTINEL study)
RRMS
(n=1171)
Natalizumab+Interferon
beta-1a vs. Interferon
beta-1a, number of
lesions 0.9 vs. 5.4 after 2
years (p<0.001)
24 months
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.67 vs. 0.82
after 96 weeks (p=0.18);
proportion of scans per
patient with lesions
24.6% vs. 26.3% after 96
weeks (p=0.34); patients
96 weeks
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with no lesions 40% vs.
37% after 96 weeks
(p=0.51)
Cohen et al., New
Eng J Med 2010
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod 1.25mg and
0.5mg vs. Interferon beta-
1a (30μg/week), number 
of lesions 1.5 (p<0.001)
and 1.7 (p=0.004), vs. 2.6
after 12 months; percent
of patients free of lesions
48.0% (p=0.37) and 54.8%
(p=0.01), vs. 45.7% after
12 months
12 months
Kappos et al., New
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
number of lesions 1.1
(p<0.001) and 1.0
(p<0.011), vs. 3.6 after 6
months, 1.5 (p<0.001)
and 1.6 (p<0.011), vs. 5.5
after 12 months, 1.1
(p<0.001) and 0.9
(p<0.011), vs. 4.3
between 13 and 24
months, 2.5 (p<0.001)
and 2.5 (p<0.011), vs. 9.8
after 24 months; percent
of patients lesion-free
58.7% (p<0.001) and
57.4% (p<0.001) vs. 26.4%
after 12 months, 69.8%
(p<0.001) and 72.8%
(p<0.001) vs. 33.2%
between 12 and 24
months, and 51.9%
(p<0.001) and 50.5%
(p<0.001) vs. 21.2% after
24 months
24 months
Giovannoni et al.,
Lancet Neurol 2011;
Comi et al., J Neurol
2013
(CLARITY study)
RRMS
(n=1326)
Cladribine 3.5mg/kg and
Cladribine 5.25mg/kg vs.
Placebo, proportion of
patients lesion-free
61.8% (p<0.001) and
62.8% (p<0.001), vs.
27.6% after 96 weeks;
relative reduction 73.4%
(p<0.001) and 76.9%
(p<0.001) after 96 weeks
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, mean
difference from Placebo -
0.089 (p=0.0003) and -
0.053 (p=0.0317) after
108 weeks
108 weeks
Sorensen et al.,
Lancet Neurol 2011
RRMS
(n=307)
Interferon beta-1a 30 μg 
with vs. without
12 months
57
(SIMCOMBIN study) Simvastatin 80 mg, mean
number of lesions 2.96 vs.
2.52 after 12 months (ns)
Cohen et al., Lancet
2012
(CARE-MS I)
RRMS
(n=581)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
proportion of patients
with lesions 48% vs. 58%
after 2 years (p=0.04)
24 months
Coles et al., Lancet
2012
(CARE-MS II)
RRMS
(n=840)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
proportion of patients
with lesions 46% vs. 68%
after 2 years (p<0.0001)
24 months
Comi et al., New Eng
J Med. 2012
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
cumulative number of
lesions 5.03 vs. 7.14
(p<0.001) at 12 and 24
months
24 months
Fox et al., New Eng J
Med. 2012
(CONFIRM study)
RRMS
(n=682, MRI
cohort)
Dimethyl Fumarate
240mg BID or TID or
Glatiramer acetate vs.
Placebo, number of
lesions 5.1 (p<0.001), 4.7
(p<0.001), 8.0 (p<0.001),
vs. 17.4 after 2 years
24 months
Gold et al., New Eng
J Med 2012; Arnold
et al., J Neurol 2014
(DEFINE study)
RRMS
(n=1234)
Dimethyl Fumarate
240mg BID and TID vs.
Placebo, number of
lesions 2.6 (p=0.01) and
4.4 (p=0.01) vs. 17.6 after
96 weeks; in a sub-cohort
of 540 patients, 1.1
(p<0.0001) and 1.6
(p<0.0001) vs. 5.2 after 6
months, 1.6 (p<0.0001)
and 2.6 (p<0.0001) vs.
10.3 after 1 year, and 2.6
(p<0.0001) and 4.4
(p<0.0001) vs. 17.0 after 2
years
24 months
Khan et al., Ann
Neurol 2013;
Zivadinov et al., J
Neurol 2015
(GALA study)
RRMS
(n=1404)
Glatiramer acetate 40 mg
vs. Placebo, cumulative
number of lesions 3.650
vs. 5.592 after 6 and 12
months (p<0.0001)
12 months
Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 vs. 2 weeks vs.
Placebo, number of
lesions 4.6 vs. 2.2 vs. 5.8
(p<0.0001; p<0.0001;
p=0.023) after 24 weeks,
and 7.9 vs. 3.6 vs. 10.9
(p<0.0001; p<0.0001;
p=0.0008) after 48 weeks
24 months
Calabresi et al.,
Lancet Neurol 2014
RRMS
(n=1083)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
24 months
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(FREEDOMS II study) number of lesions 1.6
(p<0.001) and 2.3
(p<0.001), vs. 8.9 after 24
months; percent of
patients free of lesions
63% (p<0.001) and 50%
(p<0.001), vs. 26% after
24 months
Massacesi et al.,
PloS One 2014
(EudraCT 2006-
004937-13)
RRMS
(n=150)
Azathioprine
(3mg/kg/day) vs.
Interferon, annualised
number of lesions 0.76 vs.
0.69 after 2 years
(p=0.75); and number of
patients with new lesions
(0, 1-2, ≥3) 27/11/12 vs. 
21/18/8 after 2 years
(p=0.41)
24 months
Vollmer et al., J
Neurol 2014
(BRAVO)
RRMS
(n=1331)
Laquinimod or Interferon
beta-1a 30 μg vs. Placebo, 
cumulative number of
lesions 10.88 (p=0.078) or
6.37 (p<0.001) vs. 13.03
after 12 an 24 months
24 months
Kappos et al., New
Eng J Med 2015
(DECIDE study)
RRMS
(n=1841)
Daclizumab vs. Interferon,
number of lesions 2.14 vs.
3.81 (p<0.001) after 24
weeks; 4.3 vs. 9.4
(p<0.001) after 96 weeks
144 weeks
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681)
Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, number of
lesions 3.1 (p<0.0001), 2.8
(p<0.0001), and 4.6
(p<0.0001) vs. 9.5 after 1
year, 2.0 (p<0.0001), 1.9
(p<0.0001), and 3.4
(p<0.0001) vs. 8.0
between 1 and 2 years,
and 5.1 (p<0.0001), 4.7
(p<0.0001), and 8.0
(p<0.0001) vs. 17.4 after 2
years
24 months
Volume of T2
lesions
The Interferon beta
Multiple Sclerosis
Study group; Paty et
al., Neurology 1993
(Interferon beta
Multiple Sclerosis
Study Group)
RRMS
(n=327)
Interferon beta-1b vs.
Placebo, median percent
volume change -6.2% vs.
10.9% after 1 year
(p<0.001), -0.9% vs.
16.5% after 2 years
(p<0.001), -9.3% vs. 15.0
after 3 years (p=0.002)
24 months
Jacobs et al., Ann
Neurol 1996
(MSCRG study)
RRMS
(n=300)
Interferon beta-1a 30μg 
vs. Placebo, median
percent volume change -
13.1% vs. -3.3% after 1
104 weeks
59
year (P=0.02), and -13.2%
vs. -6.5% after 2 years
(p=0.36)
PRISMS Study
Group, Lancet 1998;
Li et al., Ann Neurol
1999
(PRISMS study)
RRMS
(n=533)
Interferon beta-1a 44μg 
vs. 22μg vs. Placebo, 
median percent volume
change -4.2% vs. -1.5% vs.
4.0% (p=0.0246;
p=0.0001; p=0.0001) after
6 months, -4.5% vs. -3.5%
vs. 6.4% (p=0.3809;
p=0.0001; p=0.0001) after
12 months, -3.1% vs. -
1.4% vs. 10.8% (p=0.0974;
p=0.0001; p=0.0001) after
18 months, and -3.8% vs.
-1.2% vs. 10.9%
(p=0.0537; p=0.0001;
p=0.0001) after 24
months
24 months
Comi et al., Ann
Neurol 2001
(European/Canadian
Glatiramer Acetate
Study)
RRMS
(n=249)
Glatiramer Acetate vs.
Placebo, volume change
3.0mL vs. 4.7mL (p=0.006)
after 9 months
9 months
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
lesion volume
14303.7mm3 vs.
15703.2mm3 after 1 year
(p=0.016), 14722.0mm3
vs. 17853.1mm3 lesions
after 2 years (p<0.001),
and 14722.0mm3 vs.
17853.0mm3 lesions
overall (p<0.001)
24 months
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, volume change -
2416.9mm3 vs. -
1583.5mm3 after 96
weeks (p=0.26)
96 weeks
O'Connor et al.,
Lancet Neurol 2009
(BEYOND study)
RRMS
(n=2244)
Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, percent volume
change 22.0% vs. 19.0%
vs. 25.0% after 2 years
(p=0.56; p=0.0008;
p=0.0001)
24 months
Cohen et al., New
Eng J Med 2010
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod 1.25mg and
0.5mg vs. Interferon beta-
1a (30μg/week), percent 
volume change 6.7%
(p=0.48) and 9.9%
(p=0.63), vs. 10.4% after
12 months
12 months
Kappos et al., New RRMS Fingolimod 1.25mg and 24 months
60
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
(n=1272) 0.5mg vs. Placebo,
percent volume change
2.7% (p<0.001) and 3.4%
(p<0.001), vs. 18.7% after
12 months, 1.6%
(p<0.001) and 10.6%
(p<0.001), vs. 33.8% after
24 months
Sorensen et al.,
Lancet Neurol 2011
(SIMCOMBIN study)
RRMS
(n=307)
Interferon beta-1a 30 μg 
with vs. without
Simvastatin 80 mg,
volume change 0.033mL
vs. 0.095mL after 12
months (p=0.612)
12 months
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, volume
change 0.39mL
(p<0.0001) and 0.81mL
(p=0.04) vs. 1.67mL after
108 weeks
108 weeks
Giovannoni et al.,
Lancet Neurol 2011;
Comi et al., J Neurol
2013
(CLARITY study)
RRMS
(n=1326)
Cladribine 3.5mg/kg and
Cladribine 5.25mg/kg vs.
Placebo, relative
reduction 24.0%
(p<0.001) and 41.2%
(p<0.001) after 96 weeks
96 weeks
Cohen et al., Lancet
2012
(CARE-MS I)
RRMS
(n=581)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
median percent volume
change -9.3% vs. -6.5%
after 2 years (p=0.31)
24 months
Coles et al., Lancet
2012
(CARE-MS II)
RRMS
(n=840)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
median percent volume
change -1.27% vs. -1.23%
after 2 years (p=0.14)
24 months
Gold et al., New Eng
J Med 2012; Arnold
et al., J Neurol 2014
(DEFINE study)
RRMS
(n=1234)
Dimethyl Fumarate
240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, median
percent volume change -
3.5% (p<0.001) and -1.7%
(p<0.01) vs. 1.6% after 6
months, -5.8% (p<0.0001)
and -3.7% (p<0.0001) vs.
6.5% after 1 year, and -
6.2% (p<0.0001) and -
1.9% (p<0.0001) vs. 20.1%
after 2 years
24 months
Lublin et al., Ann
Neurol 2013
(CombiRx study)
RRMS
(n=1008)
IFN beta-1a 30mcg
SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: volume
change -1.38mL vs. -
0.25mL vs. 0.01mL
36 months
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(p=0.008; p=0.48) after 36
months
Calabresi et al.,
Lancet Neurol 2014
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
median percent volume
change -7.69% (p<0.001)
and 13.74% (p<0.001), vs.
25.06% after 24 months
24 months
Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 and 2 weeks vs.
Placebo, volume change
0.14cm3 (p=0.0006) and -
0.22cm3 (p<0.0001) vs.
0.34cm3 after 24 weeks,
and 0.06cm3 (p<0.0001)
and -0.26cm3 (p<0.0001)
vs. 0.77cm3 after 48
weeks
24 months
Kappos et al., New
Eng J Med 2015
(DECIDE study)
RRMS
(n=1841)
Daclizumab vs. Interferon,
median percent volume
change -1.4% vs. 3.4%
(p=0.02) after 24 weeks;
0.2% vs. 8.6% (p<0.001)
after 96 weeks; volume of
new or newly enlarged T2
lesions 217.0mm3 vs.
463.1mm3 (p<0.001) after
24 weeks, and 225.7mm3
vs. 556.8mm3 (p<0.001)
after 96 weeks
144 weeks
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681)
Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, median percent
volume change -4.2%
(p<0.0001), -0.3%
(p<0.0001), and -3.4%
(p<0.0001) vs. 4.8% after
1 year, and -7.4%
(p<0.0001), -1.5%
(p<0.0001), and -6.3%
(p<0.0001) vs. 14.6% after
2 years
24 months
Gd-enhancing
lesions
Number of
Gd-
enhancing
lesions
The Interferon beta
Multiple Sclerosis
Study group; Paty et
al., Neurology 1993
(Interferon beta
Multiple Sclerosis
Study)
RRMS
(n=327)
Interferon beta-1b vs.
Placebo, median
percentage of scans with
lesions 5.9% vs. 29.4%
after 3 years (p=0.0062);
median number of lesions
per year 0.5 vs. 3.0
(p=0.0089)
24 months
Jacobs et al., Ann
Neurol 1996
(MSCRG study)
RRMS
(n=300)
Interferon beta-1a 30μg 
vs. Placebo, number of
lesions 1.04 vs. 1.59 after
1 year (p=0.02), and 0.80
vs. 1.65 after 2 years
104 weeks
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(p=0.05); scans with
lesions 29.9% vs. 42.3%
after 1 year (p=0.05)
Comi et al., Ann
Neurol 2001
(European/Canadian
Glatiramer Acetate
Study)
RRMS
(n=249)
Glatiramer Acetate vs.
Placebo, mean
cumulative number of
lesions 36.8 vs. 26.0
(p=0.003) after 9 months;
mean number of lesions
per patient 2.9 vs. 4.1
(p<0.005) after 9 months;
total number of new
lesions 17.4 vs. 26
(p<0.003) after 9 months;
mean percent of scans
without lesions 28.7% vs.
35.8% (p=0.04) after 9
months
9 months
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
number of lesions 0.1 vs.
1.3 after 1 year (p<0.001),
0.1 vs. 1.2 after 2 years
(p<0.001), and 0.2 vs. 2.4
overall (p<0.001)
24 months
Rudick et al., New
Eng J Med 2006
(SENTINEL study)
RRMS
(n=1171)
Natalizumab + Interferon
beta-1a vs. Interferon
beta-1a, number of
lesions 0.1 vs. 0.9 after 2
years (p<0.001)
24 months
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.24 vs. 0.41
after 96 weeks
(p=0.0002); scans per
patient with lesions 9.8%
vs. 15.3% after 96 weeks
(p=0.005)
96 weeks
O'Connor et al.,
Lancet Neurol 2009
(BEYOND study)
RRMS
(n=2244)
Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, number of
lesions 1.0 vs. 0.9 vs. 1.2
after 2 years (p=0.80;
p=0.07; p=0.12)
24 months
Cohen et al., New
Eng J Med 2010
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod 1.25mg and
0.5mg vs. Interferon beta-
1a (30μg/week), number 
of lesions 0.14 (p<0.001)
and 0.23 (p<0.001), vs.
0.51 after 12 months
12 months
Kappos et al., New
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
number of lesions 0.3
(p<0.001) and 0.2
(p<0.011), vs. 1.3 after 6
months, 0.3 (p<0.001)
24 months
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and 0.2 (p<0.011), vs. 1.1
after 12 months, 0.2
(p<0.001) and 0.2
(p<0.011), vs. 1.1 after 24
months
Comi et al., Ann
Neurol 2011
(FORTE study)
RRMS
(n=980)
Glatiramer Acetate 20mg
vs. 40mg, number of
lesions 0.68 vs. 0.54 (ns)
after 12 months
12 months
Giovannoni et al.,
Lancet Neurol 2011;
Comi et al., J Neurol
2013
(CLARITY study)
RRMS
(n=1326)
Cladribine 3.5mg/kg and
Cladribine 5.25mg/kg vs.
Placebo, relative
reduction 85.7%
(p<0.001) and 87.9%
(p<0.001) after 96 weeks
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, lesions
per scan (relative risk
reduction) 0.26 (80.4%)
(p<0.0001) and 0.57
(57.2%) (p<0.0001), vs.
1.33 after 108 weeks
108 weeks
Cohen et al., Lancet
2012
(CARE-MS I)
RRMS
(n=581)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
patients with lesions 7%
vs. 19% (p<0.0001)
24 months
Coles et al., Lancet
2012
(CARE-MS II)
RRMS
(n=840)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
patients with lesions 9%
vs. 23% (p<0.0001)
24 months
Comi et al., NEJM
2012; Filippi et al., J
Neurol Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
cumulative number of
lesions 1.33 vs. 2.12
(p<0.001) at 12 and 24
months
24 months
Fox et al., New Eng J
Med. 2012
(CONFIRM)
RRMS
(n=682, MRI
cohort)
Dimethyl Fumarate
240mg BID or TID or
Glatiramer acetate vs.
Placebo, number of
lesions 0.5 (p<0.001), 0.4
(p<0.001), 0.7 (p<0.001),
vs. 2.0 after 2 years
24 months
Gold et al., New Eng
J Med 2012; Arnold
et al., J Neurol 2014
(DEFINE study)
RRMS
(n=1234)
Dimethyl Fumarate
240mg BID and TID vs.
Placebo, number of
lesions 0.1 (p<0.001), 0,5
(p<0.001), vs. 1.8 after 96
weeks; in a sub-cohort of
540 patients, 0.1
(p<0.0001) and 0.3
(p<0.0001) vs. 1.5 after 6
months, 0.1 (p<0.0001)
and 0.4 (p<0.0001) vs. 1.4
after 1 year, and 0.1
(p<0.0001) and 0.5
(p<0.0001) vs. 1.8 after 2
24 months
64
years
Khan et al., Ann
Neurol 2013;
Zivadinov et al., J
Neurol 2015
(GALA study)
RRMS
(n=1404)
Glatiramer acetate 40 mg
vs. Placebo, cumulative
number of lesions 0.905
vs. 1.639 after 6 and 12
months (p<0.0001)
12 months
Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 vs. 2 weeks vs.
Placebo, number of
lesions 1.2 vs. 0.3 vs. 1.6
(p<0.0001; p<0.0001;
p=0.099) after 24 weeks,
and 0.9 vs. 0.2 vs. 1.4
(p<0.0001; p<0.0001;
p=0.074) after 48 weeks
24 months
Calabresi et al.,
Lancet Neurol 2014
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
number of lesions 0.2
(p<0.001) and 0.4
(p<0.001), vs. 1.2 after 24
months
24 months
Massacesi et al.,
PloS One 2014
(EudraCT 2006-
004937-13)
RRMS
(n=150)
Azatioprine (3mg/kg/day)
vs. Interferon, number of
lesions 0.2 vs. 0.4 after 2
years (p=0.52); and
number of patients with
lesions (0, 1-2, ≥3) 41/8/0 
vs. 43/1/3 after 2 years
(p=0.39)
24 months
Vollmer et al., J
Neurol 2014
(BRAVO)
RRMS
(n=1331)
Laquinimod or Interferon
beta-1a 30 μg vs. Placebo, 
cumulative number of
lesions 1.84 (p=0.069) or
0.90 (p<0.001) vs. 2.34
after 12 an 24 months
24 months
Cohen et al., JAMA
Neurol 2015
(equivalence study)
(GATE study)
RRMS
(n=794)
Glatiramer acetate 20mg
generic or brand version
vs. Placebo, number of
lesions 0.42 (p<0.001), or
0.38 (p<0.001), vs. 0.82
during months 7 through
9; ratio of generic drug to
brand drug of 1.095
9 months
Kappos et al., New
Eng J Med 2015
(DECIDE study)
RRMS
(n=1841)
Daclizumab vs. Interferon,
number of lesions 0.5 vs.
0.8 (p<0.001) after 24
weeks
144 weeks
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681)
Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, number of
lesions 0.5 (p<0.0001), 0.5
(p<0.0001), and 1.6
(p<0.05) vs. 1.7 after 24
weeks, 0.4 (p<0.0001),
0.4 (p<0.0001), and 0.7
24 months
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(p<0.0001) vs. 2.2 after 1
year, and 0.5 (p<0.0001),
0.4 (p<0.001), and 0.8
(p<0.001) vs. 2.0 after 2
years
Proportion
on patients
with Gd-
enhancing
lesions
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, patients with no
lesions 81% vs. 67% after
96 weeks (p=0.0005)
96 weeks
Kappos et al., New
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
percent of patients free
of lesions -87.8%
(p<0.001) and 88.3
(p<0.001), vs. 64.3% after
12 months, 89.8%
(p<0.001) and 89.7%
(p<0.001), vs. 65.1% after
24 months
24 months
Cohen et al., New
Eng J Med 2010
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod 1.25mg and
0.5mg vs. Interferon beta-
1a (30μg/week), percent 
of patients free of lesions
91.2% (p<0.001) and
90.1% (p<0.001), vs.
80.8% after 12 months
12 months
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, percent
of patients free of lesions
64.1% (p<0.001) and
51.4% (p<0.001) vs. 39.0%
after 108 weeks
108 weeks
Giovannoni et al.,
Lancet Neurol 2011;
Comi et al., J Neurol
2013
(CLARITY study)
RRMS
(n=1326)
Cladribine 3.5mg/kg and
Cladribine 5.25mg/kg vs.
Placebo, percent of
patients free of lesions
87.2% (p<0.001) and
91.4% (p<0.001), vs.
78.9% after 96 weeks
96 weeks
Calabresi et al.,
Lancet Neurol 2014
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
percent of patients free
of lesions 96% (p<0.001)
and 87% (p<0.001), vs.
65% after 24 months
24 months
Lanzillo et al., Mult
Scler 2016
(ARIANNA study)
RRMS
(n=154)
Interferon beta-1b with
or without Atorvastatin
40 mg, percent of
patients with lesions 8%
vs. 18% after 2 years
(p=0.20)
24 months
Volume of
Gd-
enhancing
lesions
Jacobs et al., Ann
Neurol 1996
(MSCRG study)
RRMS
(n=300)
Interferon beta-1a 30μg 
vs. Placebo, lesion volume
70.0mm3 vs. 96.5mm3
after 1 year (p=0.02), and
104 weeks
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38.3mm3 vs. 48.5mm3
after 2 years (p=0.03)
Comi et al., Ann
Neurol 2001
(European/Canadian
Glatiramer Acetate
Study)
RRMS
(n=249)
Glatiramer Acetate vs.
Placebo, volume change -
245.3μL vs. -105.1μL 
(p=0.01) after 9 months
9 months
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
lesion volume of 21mm3
vs. 207mm3 after 1 year
(p<0.001), 32mm3 vs.
192mm3 after 2 years
(p<0.001); volume change
-343mm3 vs. -126mm3
after 1 year (p<0.001),
and -332mm3 vs. -
141mm3 after 2 years
(p<0.001)
24 months
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44μg 
vs. Glatiramer acetate 20
mg, volume change -
164.3mm3 vs. -162.6mm3
after 96 weeks (p=0.42)
96 weeks
O'Connor et al.,
Lancet Neurol 2009
(BEYOND study)
RRMS
(n=2244)
Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, cumulative
volume 0.11cm3 vs.
0.12cm3 vs. 0.14cm3 after
2 years (p=0.87; p=0.028;
p=0.017)
24 months
Cohen et al., New
Eng J Med 2010
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod 1.25mg and
0.5mg vs. Interferon beta-
1a (30μg/week), lesion 
volume 19.54mm3
(p<0.001) and 22.61mm3
(p<0.001), vs. 50.68mm3
after 12 months
12 months
Gold et al., New Eng
J Med 2012; Arnold
et al., J Neurol 2014
(DEFINE study)
RRMS
(n=1234)
Dimethyl Fumarate
240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, median
volume change -
203.2mm3 (p<0.01) and -
118.7mm3 (p<0.05) vs. -
1.8mm3 after 6 months, -
160.9mm3 (p<0.01) and -
110.2mm3 (p<0.01) vs. -
12.6mm3 after 1 year, and
-152.7mm3 (p<0.0001)
and -57.8mm3 (p<0.0001)
vs. 15.1mm3 after 2 years
24 months
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681)
Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, mean lesion
volume 46.0mm3
24 months
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(p<0.0001), 30.9mm3
(p<0.0001), and
162.5mm3 (p=0.0544) vs.
143.6mm3 after 24 weeks,
27.0mm3 (p<0.0001),
56.2mm3 (p<0.0001), and
77.0mm3 (p=0.0544) vs.
189.5mm3 after 1 year,
and 35.9mm3 (p<0.0001),
42.6mm3 (p<0.0001), and
45.6mm3 (p<0.0001) vs.
141.8mm3 after 2 years
T1 lesions Number of
new T1
lesions
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
number of lesions 0.6 vs.
2.3 after 1 year (p<0.001),
0.4 vs. 2.3 lesions after 2
years (p<0.001), and 1.1
vs. 4.6 overall (p<0.001)
24 months
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.23 vs. 0.24
after 96 weeks (p=0.15);
scans per patient with
lesions 10.5% vs. 12.4%
after 96 weeks (p=0.12);
patients with no lesions
75% vs. 70% after 96
weeks (p=0.29)
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, mean
difference from Placebo -
0.030 (p=0.0161) and -
0.016 (p=0.1916) after
108 weeks
108 weeks
Comi et al., New Eng
J Med 2012; Filippi
et al., J Neurol
Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
cumulative number of
lesions 1.61 vs. 2.23
(p=0.004) after 24 months
24 months
Fox et al., New Eng J
Med. 2012
(CONFIRM study)
RRMS
(n=682, MRI
cohort)
Dimethyl Fumarate
240mg BID or TID or
Glatiramer acetate vs.
Placebo, number of
lesions 3.0 (p<0.001), 2.4
(p<0.001), 4.1 (p=0.002),
vs. 7.0 after 2 years
24 months
Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 vs. every 2 weeks,
vs. Placebo, number of
lesions 2.0 vs. 1.2 vs. 2.1
(p<0.0001; p<0.0001;
p=0.23) after 24 weeks,
and 3.1 vs. 1.8 vs. 3.8
(p<0.0001; p<0.0001;
24 months
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p=0.082) after 48 weeks
Kappos et al., New
Eng J Med 2015
(DECIDE study)
RRMS
(n=1841)
Daclizumab vs. Interferon,
number of lesions 1.22 vs.
1.94 (p<0.001) after 24
weeks; 2.13 vs. 4.43
(p<0.001) after 96 weeks
144 weeks
Number of
new non-
enhancing T1
lesions
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
number of lesions 0.6 vs.
1.9 after 1 year
(p<0.001), 0.4 vs. 1.9
after 2 years (p<0.001),
and 1.0 vs. 3.8 overall
(p<0.001)
24 months
Giovannoni et al.,
Lancet Neurol 2011;
Comi et al., J Neurol
2013
(CLARITY study)
RRMS
(n=1326)
Cladribine 3.5mg/kg and
Cladribine 5.25mg/kg vs.
Placebo, relative
reduction 2.9% (p<0.001)
and 8.2% (p<0.001) after
96 weeks
96 weeks
Gold et al., New Eng
J Med 2012; Arnold
et al., J Neurol 2014
(DEFINE study)
RRMS
(n=1234)
Dimethyl Fumarate
240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, number
of lesions 0.8 (p<0.0001)
and 1.0 (p<0.001) vs. 1.9
after 6 months, 1.1
(p<0.0001) and 1.4
(p<0.0001) vs. 3.5 after 1
year, and 1.5 (p<0.0001)
and 2.1 (p<0.0001) vs. 5.6
after 2 years
24 months
Khan et al., Ann
Neurol 2013;
Zivadinov et al., J
Neurol 2015
(GALA study)
RRMS
(n=1404)
Glatiramer Acetate 40mg
vs. Placebo, number of
lesions 0.31 vs. 0.45
(p=0.0258) between 6
and 12 months;
proportion of new active
lesions converting to T1
lesions 15.8% vs. 19.8%
(p=0.0060) between 6
and 12 months
12 months
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681)
Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, number of
lesions 2.2 (p<0.001), 1.5
(p<0.0001), and 2.6
(p<0.05) vs. 3.7 after 1
year, 1.0 (p<0.0001), 0.9
(p<0.0001), and 1.5
(p<0.001) vs. 3.3 between
1 and 2 years, and 3.0
(p<0.0001), 2.4
(p<0.0001), and 4.1
(p<0.01) vs. 7.0 after 2
years
24 months
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Volume of T1
lesions
Comi et al., Ann
Neurol 2001
(European/Canadian
Glatiramer Acetate
Study)
RRMS
(n=249)
Glatiramer Acetate vs.
Placebo, volume change
0.8mL vs. 1.3mL (p=0.14)
after 9 months
9 months
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
volume after 1 (p=0.004)
and 2 years (p<0.001);
volume change of -
1508mm3 vs. 548mm3
overall (p<0.001); percent
change -23.5% vs. -1.5%
overall (p<0.001)
24 months
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, volume change -
667.0 mm3 vs. -377.3mm3
after 96 weeks (p=0.29)
96 weeks
O'Connor et al.,
Lancet Neurol 2009
(BEYOND study)
RRMS
(n=2244)
Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, percent volume
change 36.0% vs. 23.1%
vs. 40.6% after 2 years
(p=0.18; p=0.54; p=0.68)
24 months
Cohen et al., New
Eng J Med 2010
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod 1.25mg and
0.5mg vs. Interferon beta-
1a (30μg/week), percent 
volume change 34.7%
(p=0.09) and 24.1%
(p=0.17), vs. 15.0% after
12 months
12 months
Kappos et al., New
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
volume change 30mm3
(p<0.001) and 33mm3
(p=0.008), vs. 173mm3
after 24 months; percent
volume change 12.2%
(p=0.02) and 8.8%
(p=0.01), vs. 50.7% after
24 months
24 months
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS
(n=1088)
Teriflunomide 14mg and
7mg vs. Placebo, volume
change 0.33mL (p=0.02)
and 0.50mL (p=0.19) vs.
0.53mL after 108 weeks
108 weeks
Sorensen et al.,
Lancet Neurol 2011
(SIMCOMBIN study)
RRMS
(n=307)
Interferon beta-1a 30 μg 
with vs. without
Simvastatin 80 mg,
volume change -0.011mL
vs. 0.019mL after 12
months (p=0.547)
12 months
Gold et al., New Eng
J Med 2012; Arnold
et al., J Neurol 2014
(DEFINE study)
RRMS
(n=1234)
Dimethyl Fumarate
240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, median
24 months
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percent volume change
1.5% (ns) and 2.5% (ns)
vs. 4.3% after 6 months,
5.4% (p<0.05) and 4.7%
(ns) vs. 11.6% after 1
year, and 8.4% (p<0.0001)
and 12.7% (p<0.01) vs.
26.9% after 2 years
Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 and 2 weeks vs.
Placebo, volume change
0.31cm3 (p<0.0001) and -
0.18cm3 (p<0.0001) vs.
0.29cm3 after 24 weeks,
and 0.57cm3 (p=0.018)
and -0.32cm3 (p<0.0001)
vs. 0.54cm3 after 48
weeks
24 months
Calabresi et al.,
Lancet Neurol 2014
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
percent volume change -
4.69% (p=0.205) and
12.64% (p=0.372), vs.
26.42% after 24 months
24 months
Kappos et al., New
Eng J Med 2015
(DECIDE study)
RRMS
(n=1841)
Daclizumab vs. Interferon,
percent volume change
10.5% vs. 14.1% (p<0.001)
after 24 weeks; 22.8% vs.
33.4% (p<0.001) after 96
weeks
144 weeks
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681)
Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, median percent
volume change 1.5%
(p=0.2587), 2.8%
(p=0.6540), and 2.5%
(p=0.2741) vs. 7.9% after
1 year, and 10.7%
(p<0.001), 8.5% (p<0.01),
and 8.6% (p<0.01) vs.
19.5% after 2 years
24 months
Permanent
black holes
(PBH)
Comi et al., NEJM
2012; Filippi et al., J
Neurol Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo:
Number of PBH from Gd+
lesions: 1.0 vs. 2.1
(p=0.001); Number of
PBH from new T2 lesions:
0.87 vs. 1.67 (p=0.009);
Number of PBH from Gd+
lesions and new T2
lesions: 1.20 vs. 2.34
(p<0.001); Proportion of
Gd+ lesions converting to
PBH: 21% vs. 29%
(p=0.117); Proportion of
new T2 lesions converting
24 months
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to PBH: 23% vs. 26%
(p=0.572); Proportion of
Gd+ lesions and new T2
lesions converting to PBH:
23% vs. 28% (p=0.260);
T1/T2 lesion
volume ratio
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
ratio 0.270 vs. 0.311 after
2 years (p=0.002
adjusting for the baseline
ratio); changes in the
ratio -0.058 vs. vs. -0.03
(p=0.002 adjusting for the
baseline ratio)
24 months
Combined
measures
Combined
unique active
lesions
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, lesions per patient
per scan 0.91 vs. 1.22
after 96 weeks (p=0.010);
scans per patient with
lesions 26.4% vs. 32.3%
after 96 weeks (p=0.009);
patients with no lesions
38% vs. 31% after 96
weeks (p=0.125)
96 weeks
Kappos et al., New
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
percent of patients
lesion-free 58.7=2%
(p<0.001) and 57.4%
(p<0.001) vs. 27.1% after
12 months, 69.6%
(p<0.001) and 73.1%
(p<0.001) vs. 33.1%
between 12 and 24
months, and 52.0%
(p<0.001) and 50.7%
(p<0.001) vs. 21.0% after
24 months
24 months
Giovannoni et al.,
Lancet Neurol 2011;
Comi et al., J Neurol
2013
(CLARITY study)
RRMS
(n=1326)
Cladribine 3.5mg/kg and
Cladribine 5.25mg/kg vs.
Placebo, proportion of
patients with MRI lesion
activity-free 60.0%
(p<0.001) and 61.2%
(p<0.001), vs. 25.5% after
96 weeks; relative
reduction: 0.43 (p<0.001)
and 0.38 (p<0.001) vs.
1.72 after 96 weeks
96 weeks
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, lesions
per scan (percent
reduction vs Placebo)
0.75 (69.4%) (p<0.0001)
and 1.29 (47.7%)
(p<0.0001) vs. 2.46 after
108 weeks
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108 weeks
Comi et al., Lancet
Neurol 2012
(REFLEX study)
CIS (n=517) Interferon beta-1a three
times a week vs. once a
week vs. Placebo, number
of lesions per patient per
scan 0.60 vs. 1.23 vs. 2.70
(p<0.0001; p<0.0001;
p=0.0015) after 2 years
108 weeks
Lublin et al., Ann
Neurol 2013
(CombiRx study)
RRMS
(n=1008)
IFN beta-1a 30mcg
SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: percent of
patients free of lesions
49.2% vs. 32.2% vs. 32.5%
(p<0.0001; p=0.95) after
36 months
36 months
Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 vs. 2 weeks vs.
Placebo, percent of
patients without MRI
activity 24.9% vs. 40.9%
vs. 19.1% (p<0.0001;
p<0.0001; p=0.0318) after
48 weeks, 34.2% vs.
46.4% vs. 26.2%
(p=0.0002; p<0.0001;
p=0.0078) after 24 weeks,
and 39.8% vs. 65.4% vs.
31.5% (p<0.0001;
p<0.0001; p=0.0080)
between 24 and 48
weeks; mean number of
lesions 7.3 (p<0.001), and
3.7 (p<0.001) vs. 11.2
after 1 year
24 months
Calabresi et al.,
Lancet Neurol 2014
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
percent of patient free of
MRI activity 63%
(p<0.001) and 50%
(p<0.001), vs. 26% after
24 months
24 months
Massacesi et al.,
PloS One 2014
(EudraCT 2006-
004937-13)
RRMS
(n=150)
Azathioprine
(3mg/kg/day) vs.
Interferon, annualised
number of lesions 0.78 vs.
0.70 after 2 years
(p=0.53)
24 months
Z4 score
(Sum of Z-
scores for
volumes of
Gd+ lesion
volume, T2
lesions, T1
Noseworthy et al.,
Neurology 2000,
phase III; Wolinsky
et al., Neurology
2000
(Linomide study)
RMS (n=715) Linomide vs. Placebo, Z4
score -0.05 vs. 0.13
(p<0.0006) after 6 months
Early
termination
for safety
issues
(initially
planned: 36
months)
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lesions and
CSF)
O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, mean Z4
score difference from
Placebo -0.512 (p<0.0002)
and -0.333 (p=0.0008)
after 108 weeks
108 weeks
Brain atrophy Brain
parenchymal
fraction
Polman et al., New
Eng J Neurol 2006;
Miller et al.,
Neurology 2007
(AFFIRM study)
RRMS
(n=627)
Natalizumab vs. Placebo,
percent volume change -
0.56% vs. -0.40% after 1
year (p=0.002), -0.43% vs.
-0.24% after 2 years
(p=0.004), and -0.80 vs. -
0.82 overall (ns)
24 months
Mikol et al., Lancet
Neurol 2008
(REGARD study)
RRMS
(n=764)
Interferon beta-1a 44 μg 
vs. Glatiramer acetate 20
mg, percent volume
change -1.240% vs. -
1.073% after 96 weeks
(p=0.018)
96 weeks
O'Connor et al.,
Lancet Neurol 2009
(BEYOND study)
RRMS
(n=2244)
Interferon beta-1a 500μg 
vs. 250μg vs. Glatiramer 
acetate, percent volume
change -0.64% vs. -0.65%
vs. -0.61% after 2 years
(p=0.74; p=0.33; p=0.46)
24 months
Cohen et al., New
Eng J Med 2010
(TRANSFORMS
study)
RRMS
(n=1292)
Fingolimod 1.25mg and
0.5mg vs. Interferon beta-
1a (30μg/week), percent 
volume change -0.30%
(p<0.001) and -0.31%
(p<0.001), vs. -0.45%
after 12 months
12 months
Kappos et al., New
Eng J Med 2010;
Radue et al., Arch
Neurol 2012
(FREEDOMS study)
RRMS
(n=1272)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
percent volume change
(relative reduction
compared with Placebo)
(p=0.006) and -0.22%
(39.2%) (p=0.003) vs. -
0.34% after 6 months, -
0.44% (22.7%) (p=0.03)
and -0.50% (32.3%)
(p=0.001) vs. -0.65% after
12 months, -0.42%
(36.8%) (p=0.002) and -
0.37% (44.7%) (p<0.001)
vs. -0.67% between 12
and 24 months, -0.89%
(35.5%) (p<0.001) and -
0.84% (32.2%) (p<0.001)
vs. -1.31% after 24
months
24 months
Comi et al., Ann
Neurol 2011
RRMS
(n=980)
Glatiramer Acetate 20mg
vs. 40mg, percent volume
12 months
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(FORTE study) change -0.58% vs. -0.53%
(ns) after 12 months
Sorensen et al.,
Lancet Neurol 2011
(SIMCOMBIN study)
RRMS
(n=307)
Interferon beta-1a 30 μg 
with vs. without
Simvastatin 80 mg,
volume change -
0.0099mL vs. -0.00080mL
after 12 months (p=0.370)
12 months
Cohen et al., Lancet
2012
(CARE-MS I)
RRMS
(n=563)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
median percent volume
change -0.867% vs. -
1.488% after 2 years
(p<0.0001)
24 months
Coles et al., Lancet
2012
(CARE-MS II)
RRMS
(n=840)
Alemtuzumab 12mg vs.
Interferon beta-1a 44 μg, 
median percent volume
change -0.615% vs. -
0.810% after 2 years
(p=0.01)
24 months
Comi et al., New Eng
J Med. 2012
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
percent volume change -
0.87% vs. -1.30%
(p<0.001) after 24 months
24 months
Gold et al., New Eng
J Med 2012; Arnold
et al., J Neurol 2014
(DEFINE study)
RRMS
(n=1234)
Dimethyl Fumarate
240mg BID and TID vs.
Placebo, in a sub-cohort
of 540 patients, median
percent volume change -
0.64% (p<0.05) and -
0.77% (ns) vs. -0.81%
after 6 months, -0.46%
(p<0.05) and -0.55% (ns)
vs. -0.66% between 6
months and 2 years
24 months
Khan et al., Ann
Neurol 2013
Zivadinov et al., J
Neurol 2015
(GALA study)
RRMS
(n=1404)
Glatiramer acetate 40 mg
vs. Placebo, percent
volume change -0.706%
vs. -0.645% after 12
months (p=0.2058)
12 months
Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 vs. 2 weeks vs.
Placebo, mean percent
volume change -0.671%
(p=0.3747), and -0.721%
(p=0.0841), vs. -0.621%
after 1 year
24 months
Calabresi et al.,
Lancet Neurol 2014
(FREEDOMS II study)
RRMS
(n=1083)
Fingolimod 1.25mg and
0.5mg vs. Placebo,
percent volume change -
0.128% (p<0.001) and -
0.228% (p=0.012), vs. -
0.375% after 6 months; -
0.354% (p<0.001) and -
0.377% (p=0.0004), vs. -
0.629% after 12 months; -
24 months
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0.285% (p<0.001) and -
0.486% (p=0.013), vs. -
0.678% after 24 months
Vollmer et al., J
Neurol 2014
(BRAVO)
RRMS
(n=1331)
Laquinimod or Interferon
beta-1a 30 μg vs. Placebo, 
percent volume change -
0.75% (p<0.001) or -
1.14% (p=0.14) vs. -1.03%
after 24 months
24 months
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681) Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, median percent
volume change -0.320%
(p=0.6645), -0.450%
(p=0.9299), and -0.580%
(p=0.2593) vs. -0.440%
after 1 year, -0.400%
(p=0.0359), -0.400%
(p=0.0755), and -0.420%
(p=0.0805) vs. -0.590%
between 1 and 2 years,
and -0.660% (p=0.0645), -
0.750% (p=0.2636), and -
0.960% (p=0.8802) vs. -
0.945% after 2 years
24 months
Lanzillo et al., MSJ
2016
(ARIANNA study)
RRMS
(n=154)
Interferon beta-1b with
or without Atorvastatin
40 mg, percent volume
change -0.367% vs. -
0.302% after 1 year (ns), -
0.382% vs. -0.545% after
2 years (ns); percent
annualized volume
change -0.380% vs. -
0.316% (p=0.920)
24 months
Grey matter O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., MSJ
2013
(TEMSO study)
RMS (1088) Teriflunomide 14mg and
7mg vs. Placebo, volume
change –0.003mL
(p=0.35) and -0.003mL
(p=0.19) vs. -0.004mL
after 108 weeks
108 weeks
Filippi et al., J Neurol
Neurosurg
Psychiatry. 2013
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
median percent volume
change -0.3% vs. -0.8%
(p=0.004) after 12
months, -0.7% vs. -0.6%
(p=0.664) between 12
and 24 months, and -0.9%
vs. -1.2% (p=0.372) after
24 months
24 months
Lublin et al., Ann
Neurol 2013
(CombiRx study)
RRMS
(n=1008)
IFN beta-1a 30mcg
SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
36 months
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20mg SC/day: percent
volume change -2.60% vs.
-2.99% vs. -5.16% (ns; ns)
after 36 months
White matter O'Connor et al., New
Eng J Med 2011;
Wolinsky et al., Mult
Scler 2013
(TEMSO study)
RMS
(n=1088)
Teriflunomide 14mg and
7mg vs. Placebo, mean
volume difference from
Placebo -6.146mL
(p=0.0002) and -3.106mL
(p=0.0609) after 108
weeks
108 weeks
Filippi et al., J Neurol
Neurosurg
Psychiatry. 2013
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
median percent volume
change -0.0% vs. -0.4%
(p=0.004) after 12
months, -0.2% vs. -0.2%
(p=0.857) between 12
and 24 months, and -0.3%
vs. -0.5% (p=0.327) after
24 months
24 months
Lublin et al., Ann
Neurol 2013
(CombiRx study)
RRMS
(n=1008)
IFN beta-1a 30mcg
SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: volume
change  −1.73mL (SD 
22.63) vs.  −0.71mL 
(17.01) −1.72mL (15.66); 
differences were not
statistically significant
36 months
CSF Lublin et al., Ann
Neurol 2013
(CombiRx study)
RRMS
(n=1008)
IFN beta-1a 30mcg
SC/week + GA 20mg
SC/day vs IFN beta-1a
30mcg SC/week vs GA
20mg SC/day: percent
volume change 0.60% vs.
0.51% vs. 0.57% (ns; ns)
after 36 months
36 months
Thalamus Filippi et al., J Neurol
Neurosurg
Psychiatry. 2013
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
median percent volume
change -0.6% vs. -1.0%
(p=0.005) after 12
months, -0.7% vs. -0.9%
(p=0.233) between 12
and 24 months, and -1.3%
vs. -1.8% (p=0.003)
24 months
MTR Whole brain Gold et al., NEJM
2012; Arnold et al., J
Neurol 2014
(DEFINE study)
RRMS
(n=1234, but
MRI cohort:
n=540)
Dimethyl fumarate BID vs.
TID vs. placebo: percent
change:
BID: 0.129%, p (vs.
placebo) 0.0027;
TID: 0.096%, p (vs.
placebo) 0.0051;
Placebo: -0.386%
(reduction) after 24
months
24 months
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Calabresi et al.,
Lancet Neurol 2014;
Arnold et al., BMC
Neurol 2014
(ADVANCE study)
RRMS
(n=1512)
Peginterferon beta-1a
every 4 vs. 2 weeks vs.
Placebo, percent change
-0.432% (p=0.6873), and -
0.129% (p=0.0438), vs. -
0.382% after 1 year
24 months
Filippi et al., J Neurol
Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
signal change 0.31 vs. -
0.09 (p=0.013) after 12
months, -0.08 vs. -0.18
(p=0.642) between 12
and 24 months, and 0.23
vs. -0.27 (p=0.015) after
24 months
24 months
Miller et al.,
Neurology 2015
(CONFIRM study)
RRMS
(n=681)
Dimethyl Fumarate
240mg BID and TID vs.
Glatiramer Acetate vs.
Placebo, percent change:
-0.167 (ns), -0.008 (ns),
and 0.010 (ns) vs. -0.419
after 2 years
24 months
White matter Filippi et al., J Neurol
Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
signal change 0.32 vs. -
0.09 (p=0.013) after 12
months, -0.05 vs. -0.18
(p=0.486) between 12
and 24 months, and 0.27
vs. -0.27 (p=0.011) after
24 months
24 months
Grey matter Filippi et al., J Neurol
Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
signal change 0.30 vs. -
0.11 (p=0.014) after 12
months, -0.16 vs. -0.22
(p=0.787) between 12
and 24 months, and 0.14
vs. -0.33 (p=0.034) after
24 months
24 months
T2 lesions Filippi et al., J Neurol
Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
signal change 0.39 vs.
0.02 (p=0.239) after 12
months, 0.07 vs. -0.08
(p=0.651) between 12
and 24 months, and 0.46
vs. -0.07 (p=0.168) after
24 months
24 months
Proton MR
Spectroscopy
NAA/Cr value Filippi et al., J Neurol
Neurosurg
Psychiatry. 2014
(ALLEGRO study)
RRMS
(n=1106)
Laquinimod vs. Placebo,
signal change 0.047 vs. -
0.176 (p=0.179) after 24
months
24 months
Abbreviations: Gd: gadolinium; MTR: magnetisation transfer ratio; NAA/Cr: N-acetyl aspartate-
creatine ratio; RRMS: relapsing-remitting MS.
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Table 5: Brain MRI outcome measures in phase III trials in CIS
Brain MRI
Inclusion criteria: controlled phase III clinical trials
Exclusion criteria: incomplete data presentation (e.g. missing values); descriptive findings in absence
of any statistical analysis; secondary analyses of clinical trials and extension studies evaluating the
same clinical endpoints of the main trial in population subgroups or during longer observation time.
Original
neuroimaging
outcome
Derived
outcome
measures
Trial Condition
(no. of
patients
randomised)
Drug, effect
(vs. placebo/ another
active arm)
Duration of
the trial
T2 lesions Number of
new lesions
Kappos et
al.
Neurology
2006;
Barkhof et
al. Ann
Neurol
2007
(BENEFIT
study)
CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 2.9 vs.
4.4 up to the conversion to
MS (p<0.0001), 2.2 vs. 4.6
after 2 years (p<0.001)
24 months
Comi et al.
Lancet
2009
(PRECISE
study)
CIS (n=481) Glatiramer Acetate vs.
Placebo, number of lesions
4.2 vs. 9.8 (p<0.0001) after
2.32 years
36 months
Number of
new or
enlarging
lesions
Jacobs et
al. New
Eng J Med
2000,
Phase III
(CHAMPS
study)
CIS (n=383) Interferon beta-1a 30μg vs. 
Placebo, number of lesions
1.5 vs. 2.8 after 6 months
(p=0.01), 2.1 vs. 4.0 after
12 months (p<0.001), 2.1
vs. 5.0 after 18 months
(p<0.001)
Early
termination
due to
obvious
superiority
of IFN over
placebo
(initially
planned: 36
months)
Comi et al.
Lancet
2001,
phase III
(ETOMS
study)
CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, median number
of lesions per patient per
scan 2.0 vs. 3.0 after 2
years (p<0.001)
24 months
Leist et al.
Lancet
Neurol
2014
(ORACLE
MS study)
CIS (n=616) Cladribine 5.25 mg/Kg or
3.5 mg/Kg, vs. Placebo,
median cumulative number
of lesions 0.0 or 0.0 vs. 2.0
after 96 weeks (p<0.001)
96 weeks
Lesion
volume
Miller et
al. Lancet
Neurol
2014
CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, volume
change -0.028mL
(p=0.0374) vs. 0.023mL
108 weeks
79
(TOPIC
study)
(p=0.7789) vs. 0.044mL
after 108 weeks
Volume of T2
lesions
Jacobs et
al. New
Eng J Med
2000
(CHAMPS
study)
CIS (n=383) Interferon beta-1a 30μg vs. 
Placebo, median volume
change -123mm3 vs.
40mm3 after 6 months
(p<0.001), 102mm3 vs.
214mm3 after 12 months
(p=0.004), 28mm3 vs.
313mm3 after 18 months
(p<0.001)
Early
termination:
obvious
superiority
of IFN over
placebo
(initially
planned: 36
months)
Comi et al.
Lancet
2001
(ETOMS
study)
CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, median volume
change -487mm3 vs. -
299mm3 after 2 years
(p=0.002); median percent
volume change -13.0% vs.
8.8% after 2 years
(p=0.002)
24 months
Kappos et
al.
Neurology
2006;
Barkhof et
al. Ann
Neurol
2007
(BENEFIT
study)
CIS (n=487) Interferon beta-1b vs.
Placebo, volume change -
888.5mm3 vs. -431.6mm3
up to the conversion to MS
(p<0.05), -1.0cm3 vs. -
0.3cm3 after 2 years
(p=0.02)
24 months
Miller et
al. Lancet
Neurol
2014
(TOPIC
study)
CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, volume
change -0.029mL
(p=0.0503) vs. 0.022mL
(p=0.7360) vs. 0.045mL
after 108 weeks
108 weeks
Gd-
enhancing
lesions
Number of
Gd-
enhancing
lesions
Jacobs et
al. New
Eng J Med
2000
(CHAMPS
study)
CIS (n=383) Interferon beta-1a 30μg vs. 
Placebo, number of lesions
0.9 vs. 1.5 after 6 months
(p=0.03), 0.7 vs. 1.6 after
12 months (p=0.02), 0.4 vs.
1.4 after 18 months
(p<0.001)
Early
termination:
obvious
superiority
of IFN over
placebo
(initially
planned: 36
months)
Comi et al.
Lancet
2001
(ETOMS
study)
CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, median number
of lesions per patient per
scan 0.5 vs. 0.0 after 2
years (p=0.809)
24 months
Kappos et
al.
Neurology
2006;
Barkhof et
al. Ann
Neurol
CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 1.9 vs.
4.3 up to conversion to MS
(p<0.0001), 2.2 vs. 4.6 after
2 years (p<0.001); new
lesions per scan 0.4 vs. 1.0
24 months
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2007
(BENEFIT
study)
after 2 years (p<0.001)
Leist et al.
Lancet
Neurol
2014
(ORACLE
MS study)
CIS (n=616) Cladribine 5.25 mg/Kg or
3.5 mg/Kg, vs. Placebo,
median cumulative number
of lesions 0.0 or 0.0 vs. 2.0
after 96 weeks (p<0.001)
96 weeks
Miller et
al. Lancet
Neurol
2014
(TOPIC
study)
CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, number
of lesions per scan 0.395
(p=0.0008) vs. 0.749
(p=0.4436) vs. 0.953 after
108 weeks
108 weeks
Volume of
Gd-
enhancing
lesions
Kappos et
al.
Neurology
2006;
Barkhof et
al. Ann
Neurol
2007
(BENEFIT
study)
CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
volume of lesions
203.5mm3 vs. 520.6mm3
up to conversion to MS
(p<0.0001), 0.2cm3 vs.
0.5cm3 after 2 years
(p<0.001); volume of
lesions per scan 0.1cm3 vs.
0.1cm3 after 2 years
(p<0.001)
24 months
Miller et
al. Lancet
Neurol
2014
(TOPIC
study)
CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, volume
change 0.034mL(p<0.0001)
vs. 0.058mL (p=0.0077) vs.
0.079mL after 108 weeks
108 weeks
T1 lesions New T1
lesions
Kappos et
al.
Neurology
2006;
Barkhof et
al. Ann
Neurol
2007
(BENEFIT
study)
CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 0.2 vs.
0.3 after 2 years (p<0.001)
24 months
Comi et al.
Lancet
2009,
phase III10
(PRECISE
study)
CIS (n=481) Glatiramer Acetate vs.
Placebo, cumulative
number of lesions 1.7 vs.
3.6 (p<0.0001) after 2.32
years
36 months
Volume of T1
lesions
Miller et
al. Lancet
Neurol
2014
(TOPIC
study)
CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, volume
change -0.016mL
(p=0.0120) vs. 0.015mL
(p=0.9100) vs. 0.014mL
after 108 weeks
108 weeks
Kappos et
al.
CIS (n=487) Interferon beta-1b vs.
Placebo, change in volume
24 months
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Neurology
2006;
Barkhof et
al. Ann
Neurol
2007
(BENEFIT
study)
of lesions -0.0cm3 vs. -
0.1cm3 after 2 years
(p=0.29)
Combined
measures
Combined
unique
lesions
Comi et al.
Lancet
2001
(ETOMS
study)
CIS (n=309) Interferon beta-1a 22μg vs. 
Placebo, proportion of
patients without lesions
16% vs. 6% after 2 years
(p=0.005)
24 months
Kappos et
al.
Neurology
2006;
Barkhof et
al. Ann
Neurol
2007
(BENEFIT
study)
CIS (n=487) Interferon beta-1b vs.
Placebo, cumulative
number of lesions 3.7 vs.
8.5 up to the conversion to
MS (p<0.001), 5.7 vs. 10.3
after 2 years (p<0.001)
24 months
Comi et al.
Lancet
Neurol
2012
(REFLEX
study)
CIS (n=517) Interferon beta-1a three
times a week vs. once a
week vs. Placebo, number
of lesions per patient per
scan 0.60 vs. 1.23 vs. 2.70
(p<0.0001; p<0.0001;
p=0.0015) after 2 years
108 weeks
Leist et al.
Lancet
Neurol
2014
(ORACLE
MS study)
CIS (n=616) Cladribine 5.25 mg/Kg or
3.5 mg/Kg, vs. Placebo,
median cumulative number
of lesions 1.0 or 1.0 vs. 4.0
after 96 weeks (p<0.001)
96 weeks
Brain atrophy Brain
parenchymal
fraction
Comi et al.
Lancet
2009
(PRECISE
study)
CIS (n=481) Glatiramer Acetate vs.
Placebo, percent volume
change -0.33% vs. -0.38%
(ns)
36 months
Miller et
al. Lancet
Neurol
2014
(TOPIC
study)
CIS (n=618) Teriflunomide 14mg vs.
7mg vs. Placebo, volume
change -0.008mL
(p=0.4495) vs. -0.002mL
(p=0.4462) vs. -0.003mL
after 108 weeks
108 weeks
Abbreviations: Gd: gadolinium; CIS: clinically isolated syndrome.
82
Table 6: Brain MRI outcome measures in phase III trials in progressive MS
Brain MRI
Inclusion criteria: controlled phase III clinical trials
Exclusion criteria: incomplete data presentation (e.g. missing values); descriptive findings in absence
of any statistical analysis; secondary analyses of clinical trials and extension studies evaluating the
same clinical endpoints of the main trial in population subgroups or during longer observation time.
Original
neuroimaging
outcome
Derived outcome
measures
Trial Condition (no. of
patients
randomised)
Drug, effect
(vs. placebo/
another active
arm)
Duration of the
trial
T2 lesions Number of new
or enlarging
lesions
Secondary
Progressive
Efficacy Clinical
Trial of
Recombinant
Interferon-beta-
1a in MS
(SPECTRIMS)
Study Group; Li et
al., Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a 44µg
vs. IFN beta-1a
22µg vs. placebo:
median number
lesions per
patient per scan:
0.17, 0.20 and
0.67, respectively,
p < 0.0001 (all
comparisons with
placebo)
36 months
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo: mean
number of lesions
was reduced
45.6% in the IFN-
1a group relative
to the placebo
group at month
24
24 months
Hommes et al.,
Lancet Neurol
2004; Fazekas et
al., Mult Scler
2005 (ESIMS
study)
SPMS (n=612) Intravenous
Immunoglobulin
vs. Placebo,
number of lesions
2.67 vs. 3.44 after
1 year (ns), 2.45
vs. 3.01 after 2
years (ns), 4.94
vs. 6.44 overall
(p=0.06)
24 months
Freedman et al.,
Neurology 2011
(MAESTRO study)
SPMS (n=612) MBP8298 vs.
Placebo,
cumulative
number of lesions
among DR2+ or
DR4+ 1.9 vs. 1.8
after 12 months
(p=0.034), among
DR2-/DR4- 1.7 vs.
2.0 after 12
24 months
83
months (p=0.828)
Zajicek et al.,
Lancet Neurol
2013 (CUPID
study)
PPMS (n=191),
SPMS (n=302)
(received
treatment: n=493;
randomised:
n=498)
Dronabinol vs.
Placebo,
proportion of
patients with
lesions 37% vs.
40% after 3 years
(p=0.70)
36 months
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
vs. Placebo, lesion
number per year
0.13 vs. 0.50%
(p<0.001);
number of
patients free of
lesions 80% vs.
60% (p<0.001)
after 36 months
36 months
Volume of T2
lesions
European Study
Group on
Interferon beta-
1b in Secondary
Progressive MS,
Lancet 1998
(EUSPMS study)
SPMS (n=718) Interferon beta-
1b vs. Placebo,
percent lesion
volume change -
5% vs. 8%
(p<0.0001) after 3
years
Early termination:
obvious
superiority of IFN
vs. placebo
(initially planned:
39 months)
Secondary
Progressive
Efficacy Clinical
Trial of
Recombinant
Interferon-beta-
1a in MS
(SPECTRIMS)
Study Group; Li et
al., Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a 44µg
vs. IFN beta-1a
22µg vs. placebo:
Median change in
burden of disease
(in mm2, i.e. sum
of lesional area
per patient and
scan, as an
indirect measure
of T2 lesion
volume): -32 vs. -
4 vs. +263,
respectively,
p<0.0001 for
comparisons of
both doses vs.
placebo
36 months
Cohen et al.,
Neurology 2002
(IMPACT study)
SPMS (n=436) IFN beta-1a
60mcg/week IM
vs. placebo:
Median change in
total T2-
hyperintense
lesion volume
(from baseline)
was reduced in
the IFNb-1a group
compared to the
24 months
84
placebo group by
69.1% at month
24 (p<0.001)
Hommes et al.,
Lancet Neurol
2004; Fazekas et
al., Mult Scler
2005 (ESIMS
study)
SPMS (n=318) Intravenous
Immunoglobulin
vs. Placebo, lesion
volume 25.44cm3
vs. 24.98cm3 after
1 year (ns),
25.17cm3 vs.
23.66cm3 after 2
years (ns)
24 months
The North
American Study
Group on
Interferon beta-
1b in Secondary
Progressive MS
Neurology 2004
(NASPMS study)
SPMS (n=939) Interferon beta-
1b 250μg or 
160μg vs. 
Placebo, median
percent change in
annual lesion area
0.4% (p<0.001),
0.8% (p<0.001),
vs. 10.9% after 3
years
Early termination
for futility
(initially planned:
36 months)
Wolinsky et al.,
Ann Neurol 2007
(PROMISE study)
PPMS (n=943) Glatiramer
acetate vs.
Placebo, percent
volume change -
39% after 1 year
(p=0.1716), -71%
after 2 years
(p=0.0026), and -
58% after 3 years
(p=0.1344)
36 months
Hawker et al., Ann
Neurol 2009
(OLYMPUS study)
PPMS (n=439) Rituximab vs.
Placebo, volume
change 2205mm3
vs. 1507mm3
(p<0.001) after 96
weeks
96 weeks
Freedman et al.,
Neurology 2011
(MAESTRO study)
SPMS (n=612) MBP8298 vs.
Placebo, median
volume change
among DR2+ or
DR4+ 417.5mm3
vs. 491.5mm3
after 24 months
(p=0.802), among
DR2-/DR4-
684.8mm3 vs.
738.0mm3 after
24 months
(p=0.873)
24 months
Montalban et al.,
N Engl J Med.
PPMS (n=732) Ocrelizumab
600mg (300mg
120 weeks
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2016 (ORATORIO
study)
x2) /24 weeks IV
vs. placebo:
percent volume
change: -3.4% vs.
+7.4% (p<0.0001)
Gd-enhancing
lesions
Number of Gd-
enhancing lesions
Hommes et al.,
Lancet Neurol
2004; Fazekas et
al., MSJ 2005
(ESIMS study)
SPMS (=318) Intravenous
Immunoglobulin
vs. Placebo,
number of lesions
1.62 vs. 1.47 after
1 year (ns), 1.14
vs. 0.86 after 2
years (ns), 2.47
vs. 2.32 overall
(ns); percent of
enhancing scans
35.2% vs. 45.3%
after 1 year (ns),
32.1% vs. 28.3%
after 2 years (ns)
24 months
The North
American Study
Group on
Interferon beta-
1b in Secondary
Progressive MS
Neurology 2004
(NASPMS study)
SPMS (n=939) Interferon beta-
1b 250μg or 
160μg vs. 
Placebo, annual
new active lesion
rate 6.4
(p<0.001), 4.5
(p<0.001), vs. 18.7
after 3 years
Early termination
for futility
(initially planned:
36 months)
Wolinsky et al.,
Ann Neurol 2007
(PROMISE study)
PPMS (n=943) Glatiramer
acetate vs.
Placebo, percent
change -89% after
1 year (p=0.0022),
-47% after 2 years
(p=0.0702), and -
6% after 3 years
(p=0=8387)
36 months
Freedman et al.,
Neurology 2011
(MAESTRO study)
SPMS (n=612) MBP8298 vs.
Placebo, lesion
change among
DR2+ or DR4+ 1.1
vs. 0.8 after 12
months
(p=0.427), among
DR2-/DR4- 0.9 vs.
1.0 after 12
months (p=0.765)
24 months
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
vs. Placebo, lesion
number per scan
0.05 vs. 0.21
(p<0.001) after 36
months
36 months
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Number of
patients with Gd-
enhancing lesions
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
vs. Placebo,
percentage of
patients free of
lesions 87% vs.
78% (p=0.006)
after 36 months
36 months
T1 lesions New T1 lesions Zajicek et al.,
Lancet Neurol
2013 (CUPID
study)
PPMS (n=191),
SPMS (n=302)
(randomised:
n=498)
Dronabinol vs.
Placebo,
percentage of
patients with
lesions 34% vs.
33% after 3 years
(p=0.87)
36 months
New non-
enhancing T1
lesions
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
vs. Placebo, lesion
number per year
0.09 vs. 0.24
(p<0.001);
number of
patients free of
lesions 82% vs.
72% (p=0.003)
after 36 months
36 months
Volume of T1
lesions
Hommes et al.,
Lancet Neurol
2004; Fazekas et
al., MSJ 2005
(ESIMS study)
SPMS (n=318) Intravenous
Immunoglobulin
vs. Placebo, lesion
volume 3.78mm3
vs. 3.68mm3 after
1 year (ns),
3.58mm3 vs.
3.59mm3 after 2
years (ns)
24 months
T1/T2 lesion
volume ratio
Hommes et al.,
Lancet Neurol
2004; Fazekas et
al., MSJ 2005
(ESIMS study)
SPMS (n=318) Intravenous
Immunoglobulin
vs. Placebo, ratio
0.136 vs. 0.131
after 1 year (ns),
0.123 vs. 0.136
after 2 years (ns)
24 months
Combined
measures
Combined unique
active lesions
Secondary
Progressive
Efficacy Clinical
Trial of
Recombinant
Interferon-beta-
1a in MS
(SPECTRIMS)
Study Group; Li et
al., Neurology
2001 (SPECTRIMS
study)
SPMS (n=618) IFN beta-1a 44µg
vs. IFN beta-1a
22µg vs. placebo:
Median numbers
of combined
unique lesions:
0.11, 0.22 and
1.0, respectively,
p = 0.005 (IFN
beta-1a 22µg vs.
placebo);
p<0.0001 (IFN
beta-1a 44µg vs.
placebo).
36 months
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Brain atrophy Brain
parenchymal
fraction
Hawker et al., Ann
Neurol 2009
(OLYMPUS study)
PPMS (n=439) Rituximab vs.
Placebo, volume
change -9.9cm3
vs. -10.8cm3
(p=0.62) after 96
weeks
96 weeks
Percent change Hommes et al.,
Lancet Neurol
2004; Fazekas et
al., MSJ 2005
(ESIMS study)
SPMS (n=318) Intravenous
Immunoglobulin
vs. Placebo,
percent change -
0.30% vs. -0.13%
after 1 year (ns), -
0.11% vs. -0.06%
after 2 years (ns)
24 months
Freedman et al.,
Neurology 2011
(MAESTRO study)
SPMS (n=612) MBP8298 vs.
Placebo, percent
change among
DR2+ or DR4+ -
1.21% vs. -0.78%
after 24 months
(p=0.440), among
DR2-/DR4- -1.23%
vs. -0.62% after
24 months
(p=0.942)
24 months
Zajicek et al.,
Lancet Neurol
2013 (CUPID
study)
PPMS (n=191),
SPMS (n=302)
(randomised:
n=498)
Dronabinol vs.
Placebo, yearly
percent change -
0.68% vs. -0.66%
after 3 years
(p=0.94)
36 months
Lublin et al.,
Lancet 2016
(INFORMS study)
PPMS (n=970) Fingolimod 0.5mg
vs. Placebo,
percent change -
1.49% vs. -1.53%
(p=0.673) after 36
months
36 months
Montalban et al.,
N Engl J Med.
2016 (ORATORIO
study)
PPMS (n=732) Ocrelizumab
600mg (300mg
x2) /24 weeks IV
vs. placebo: rate
of brain volume
loss: -0.9% vs. -
1.1% (p=0.0206)
120 weeks
Abbreviations: Gd: gadolinium; PPMS: primary progressive multiple sclerosis; SPMS: secondary
progressive multiple sclerosis.
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Table 7: Phase II and 3 trials which used spinal cord MRI outcomes
Original
neuroimaging
outcome
Trials Condition (no.
of patients
randomised)
Drug, effect
(vs. placebo/ another active arm)
Duration of
the trial
Cervical cord
area
Montalban et
al. Mult Scler
2009, phase II
PPMS (n=49),
transitional
progressive MS
(n=24)
Interferon beta-1b (250μg on 
alternate days) vs. Placebo, percent
change in cord area -1.6% vs. -1.3%
after 12 months (ns), -0.9% vs. -
1.6% after 24 months (ns)
24 months
Leary et al.
Neurology
2003, phase II
PPMS (n=50) Interferon beta-1a (30μg vs. 60μg 
per week) vs. Placebo, percent
change in cord area -0.5% vs. -1.0%
vs. 0.3% after 12 months (ns), -
3.7% vs. 1.5% vs. -1.3% after 24
months (ns)
24 months
Lin et al. J
Neurol
Neurosurg
Psychiatry
2003, phase II
RRMS (n=20),
SPMS (n=18)
Interferon beta-1a (44μg three 
times per week), percent change in
cord area -1.0% vs. -1.7% after 6
months (ns), -1.5% vs. -2.8% after
12 months (ns), -1.8% vs. -2.9%
after 18 months (ns), -4.5% vs. -
5.7% after 48 months (ns)
48 months
Frank et al.
Mult Scler
2002, phase II
SPMS (n=6),
RRMS (n=1)
RhIGF-1 (0.05 mg/kg twice a day),
not reported (ns)
24 weeks
Kapoor et al.
Lancet Neurol
2010, phase II
SPMS (n=120) Lamotrigine vs. Placebo, percent
change in cord area -1.60% vs. -
1.26% after 24 months (ns)
24 months
Kalkers et al.
Mult Scler
2002, phase II
PPMS (n=16) Placebo for 12 months vs. Riluzole
for following 12 months (2x50mg
per day), percent change in cord
area -2.0% vs. -0.2% (not reported)
24 months
Yaldizli et al.
ECTRIMS 2015,
phase III
(INFORMS
study)
PPMS (n=823) Fingolimod vs. Placebo, % change
from baseline: percent change in
cord area -2.04% vs. -2.44% after
24 months (ns)
24 months
Abbreviations: ns: not significant; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-
remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis
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Table 8: Past and ongoing phase II and III trials which use OCT-related measures
Optical Coherence Tomography
Original OCT
outcome
Trial Condition
(number of
patients
randomised)
Drug, effect Duration of the
trial
Retinal nerve
fibre layer
thickness
Dorr et al. Trials
2012, phase II
RRMS and CIS
(n=80)
Vitamin D (20400 IU every
other day) vs. Vitamin D (400
IU every other day), ongoing
24 months
Horton et al.
Neurology 2013,
phase II
>6 months after
ON in RRMS
(n=22)
4-aminopyridine vs. Placebo
(crossover), percent change -
1.89% vs. 1.45% after 5 weeks
for RNFL 60-80μm (p=0.01) 
10 weeks
Cambron et al.
Trials 2014,
phase II
PPMS and
SPMS (n=120,
expected)
Fluoxetine (40mg per day) vs.
Placebo, ongoing
108 weeks
Llufriu et al. PloS
ONE 2014, phase
II
RRMS (n=9) Autologous Mesenchymal
Stem Cells vs. Placebo,
change in thickness OD -
0.2μm vs. 0.0μm (ns) and OS -
0.33μm vs. -0.22μm (ns) after 
6, and OD -0.02μm vs. -
0.02μm (ns) and OS -0.4μm 
vs. 0.0μm (ns) after 12 
months
12 months
Diem et al. BMJ
Open 2015,
phase II
Acute ON in CIS
(n=100,
expected)
Erythropoietin (33000 IU per
day for 3 consecutive days)
vs. Placebo, ongoing
6 months
McKee et al. BMJ
Open 2015,
phase II
Acute ON in CIS
or in RRMS
(n=46,
expected)
Amiloride vs. Placebo,
ongoing
12 months
Rice et al. Trials
2015, phase II
PPMS (n=20),
SPMS (n=20)
(expected)
Autologous bone marrow
infusion, ongoing
12 months
Salari et al. J Res
Med Sci 2015,
phase II
Acute ON in CIS
(n=52)
Vitamin D (50000 IU per
week) vs. Placebo, change in
thickness -19.9μm vs. -
17.6μm (ns) 
6 months
Sergott et al. J
Neurol Sci 2015,
phase II
Acute ON in CIS
(n=34)
Atacicept vs. Placebo, change
in thickness -8.6μm vs. -
17.3μm (p=0.07) 
36 weeks
Raftopoulos et
al. Lancet Neurol
2016, phase II
Acute ON in CIS
and RRMS
(n=86)
Phenytoin vs. Placebo, 30%
reduction in thickness in the
extent of layer loss with
Phenytoin (p=0.021)
6 months
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Ganglion cell
layer thickness
McKee et al. BMJ
Open 2015,
phase II
ON in CIS or in
RRMS (n=46)
Amiloride vs. Placebo,
ongoing
12 months
Macular
volume
Dorr et al. Trials
2012, phase II
RRMS and CIS
(n=80)
Vitamin D (20400 IU every
other day) vs. Vitamin D (400
IU every other day), ongoing
24 months
Zarbin et al
Ophthalmlogy
2013, phase II
and phase III
(pooled data
analysis)
RRMS (n=2615) Fingolimod, macular oedema
detection
5 years
Cambron et al.
Trials 2014,
phase II
PPMS and
SPMS (n=120,
expected)
Fluoxetine (40mg per day) vs.
Placebo, ongoing
108 weeks
Llufriu et al. PloS
ONE 2014, phase
II
RRMS (n=9) Autologous Mesenchymal
Stem Cells vs. Placebo,
volume change OD -0.02mm3
vs. 0.0mm3 (ns) and OS -
0.02mm3 vs. -0.02mm3 (ns)
after 6, and OD -0.02mm3 vs.
0.0mm3 (ns) and OS -0.01mm3
vs. 0.01mm3 (ns) after 12
months
12 months
Diem et al. BMJ
Open 2015,
phase II
Acute ON in CIS
(n=100,
expected)
Erythropoietin (33000 IU per
day for 3 consecutive days)
vs. Placebo, ongoing
6 months
McKee et al. BMJ
Open 2015,
phase II
ON in CIS or in
RRMS (n=46,
expected)
Amiloride vs. Placebo,
ongoing
12 months
Rice et al. Trials
2015, phase II
PPMS (n=20),
SPMS (n=20)
(expected)
Autologous bone marrow
infusion, ongoing
12 months
Raftopoulos et
al. Lancet Neurol
2016, phase II
Acute ON in CIS
and RRMS
(n=86)
Phenytoin vs. Placebo, 34%
volume reduction in the
extent of volume loss with
Phenytoin (p=0.005)
6 months
Macular
thickness
McKee et al. BMJ
Open 2015,
phase II
ON in CIS or in
RRMS (n=46,
expected)
Amiloride vs. Placebo,
ongoing
12 months
Salari et al. J Res
Med Sci 2015,
phase II
Acute ON in CIS
(n=52)
Vitamin D (50000 IU per
week) vs. Placebo, thickness
change -0.8μm vs. -3.1μm (ns)
6 months
Abbreviations: CIS: clinically isolated syndrome; ns: not significant; ON: optic neuritis; PPMS: primary
progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary
progressive multiple sclerosis.




